WO2021214204A1 - Rna constructs and uses thereof - Google Patents
Rna constructs and uses thereof Download PDFInfo
- Publication number
- WO2021214204A1 WO2021214204A1 PCT/EP2021/060508 EP2021060508W WO2021214204A1 WO 2021214204 A1 WO2021214204 A1 WO 2021214204A1 EP 2021060508 W EP2021060508 W EP 2021060508W WO 2021214204 A1 WO2021214204 A1 WO 2021214204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- sequence
- rna
- rna polynucleotide
- medical preparation
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 695
- 239000000203 mixture Substances 0.000 claims abstract description 251
- 238000002360 preparation method Methods 0.000 claims abstract description 176
- 238000000034 method Methods 0.000 claims abstract description 132
- 108020003589 5' Untranslated Regions Proteins 0.000 claims abstract description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 258
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 254
- 229920001184 polypeptide Polymers 0.000 claims description 253
- 239000002773 nucleotide Substances 0.000 claims description 227
- 125000003729 nucleotide group Chemical group 0.000 claims description 227
- 150000002632 lipids Chemical class 0.000 claims description 199
- 150000007523 nucleic acids Chemical class 0.000 claims description 155
- 102000039446 nucleic acids Human genes 0.000 claims description 150
- 108020004707 nucleic acids Proteins 0.000 claims description 150
- 239000002245 particle Substances 0.000 claims description 128
- 230000000890 antigenic effect Effects 0.000 claims description 114
- 108090000623 proteins and genes Proteins 0.000 claims description 96
- -1 cationic lipid Chemical class 0.000 claims description 93
- 239000008194 pharmaceutical composition Substances 0.000 claims description 85
- 102000004169 proteins and genes Human genes 0.000 claims description 81
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 76
- 239000000427 antigen Substances 0.000 claims description 75
- 108091007433 antigens Proteins 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 72
- 239000002479 lipoplex Substances 0.000 claims description 60
- 239000012634 fragment Substances 0.000 claims description 59
- 239000003795 chemical substances by application Substances 0.000 claims description 56
- 230000002163 immunogen Effects 0.000 claims description 54
- 238000013519 translation Methods 0.000 claims description 53
- 230000001965 increasing effect Effects 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 43
- 239000002105 nanoparticle Substances 0.000 claims description 42
- 238000013518 transcription Methods 0.000 claims description 42
- 230000035897 transcription Effects 0.000 claims description 42
- 239000002777 nucleoside Substances 0.000 claims description 38
- 108020004414 DNA Proteins 0.000 claims description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 36
- 108020004999 messenger RNA Proteins 0.000 claims description 36
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 35
- 230000028993 immune response Effects 0.000 claims description 34
- 238000000338 in vitro Methods 0.000 claims description 34
- 208000035475 disorder Diseases 0.000 claims description 33
- 230000007935 neutral effect Effects 0.000 claims description 33
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 27
- 230000003612 virological effect Effects 0.000 claims description 25
- 230000000295 complement effect Effects 0.000 claims description 22
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 229940045145 uridine Drugs 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 235000012000 cholesterol Nutrition 0.000 claims description 18
- 238000007918 intramuscular administration Methods 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 17
- 230000006872 improvement Effects 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 230000011987 methylation Effects 0.000 claims description 15
- 238000007069 methylation reaction Methods 0.000 claims description 15
- 150000003431 steroids Chemical class 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 239000002502 liposome Substances 0.000 claims description 14
- 150000003904 phospholipids Chemical class 0.000 claims description 14
- 238000002255 vaccination Methods 0.000 claims description 14
- 229930185560 Pseudouridine Natural products 0.000 claims description 13
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 13
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 13
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 230000003993 interaction Effects 0.000 claims description 12
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 11
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 10
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 7
- 229930182558 Sterol Natural products 0.000 claims description 7
- 230000001594 aberrant effect Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 235000003702 sterols Nutrition 0.000 claims description 7
- JMOLZNNXZPAGBH-UHFFFAOYSA-M 2-hexyldecanoate Chemical compound CCCCCCCCC(C([O-])=O)CCCCCC JMOLZNNXZPAGBH-UHFFFAOYSA-M 0.000 claims description 6
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 6
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 6
- 241000711573 Coronaviridae Species 0.000 claims description 6
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 6
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 6
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 5
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 230000003248 secreting effect Effects 0.000 claims description 5
- 150000003432 sterols Chemical class 0.000 claims description 5
- 241000282836 Camelus dromedarius Species 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 claims description 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 3
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 3
- 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 claims description 3
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 claims description 3
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 108060000903 Beta-catenin Proteins 0.000 claims description 3
- 102000015735 Beta-catenin Human genes 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 3
- 101150108242 CDC27 gene Proteins 0.000 claims description 3
- 101710156847 CTD small phosphatase-like protein Proteins 0.000 claims description 3
- 102100027674 CTD small phosphatase-like protein Human genes 0.000 claims description 3
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims description 3
- 101710134395 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Proteins 0.000 claims description 3
- 102100027668 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Human genes 0.000 claims description 3
- 101710134389 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Proteins 0.000 claims description 3
- 102100027667 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Human genes 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 102100026548 Caspase-8 Human genes 0.000 claims description 3
- 108090000538 Caspase-8 Proteins 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 3
- 102100039518 Claudin-12 Human genes 0.000 claims description 3
- 101710197000 Claudin-12 Proteins 0.000 claims description 3
- 108090000229 Claudin-6 Proteins 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 3
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 claims description 3
- 108050001049 Extracellular proteins Proteins 0.000 claims description 3
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 3
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 3
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 claims description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 3
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 claims description 3
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 claims description 3
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 3
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 claims description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 3
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims description 3
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims description 3
- 101000679365 Homo sapiens Putative tyrosine-protein phosphatase TPTE Proteins 0.000 claims description 3
- 101001109419 Homo sapiens RNA-binding protein NOB1 Proteins 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 101000821981 Homo sapiens Sarcoma antigen 1 Proteins 0.000 claims description 3
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 claims description 3
- 101000739178 Homo sapiens Secretoglobin family 3A member 2 Proteins 0.000 claims description 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 3
- 108050002021 Integrator complex subunit 2 Proteins 0.000 claims description 3
- 108010047761 Interferon-alpha Proteins 0.000 claims description 3
- 102000006992 Interferon-alpha Human genes 0.000 claims description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 3
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 claims description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 3
- 208000024556 Mendelian disease Diseases 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 102000003505 Myosin Human genes 0.000 claims description 3
- 108060008487 Myosin Proteins 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 102000036673 PRAME Human genes 0.000 claims description 3
- 108060006580 PRAME Proteins 0.000 claims description 3
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 3
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102100037686 Protein SSX2 Human genes 0.000 claims description 3
- 102100022578 Putative tyrosine-protein phosphatase TPTE Human genes 0.000 claims description 3
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 claims description 3
- 206010037742 Rabies Diseases 0.000 claims description 3
- 101150066717 Rara gene Proteins 0.000 claims description 3
- 208000035977 Rare disease Diseases 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 102100021466 Sarcoma antigen 1 Human genes 0.000 claims description 3
- 102100038689 Scm-like with four MBT domains protein 1 Human genes 0.000 claims description 3
- 102100037269 Secretoglobin family 3A member 2 Human genes 0.000 claims description 3
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 108700019889 TEL-AML1 fusion Proteins 0.000 claims description 3
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 claims description 3
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 3
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 3
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 claims description 3
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 238000010362 genome editing Methods 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 claims description 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000002688 persistence Effects 0.000 claims description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 235000019833 protease Nutrition 0.000 claims description 3
- 230000001172 regenerating effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 235000002020 sage Nutrition 0.000 claims description 3
- 108091005703 transmembrane proteins Proteins 0.000 claims description 3
- 102000035160 transmembrane proteins Human genes 0.000 claims description 3
- 108091029810 SaRNA Proteins 0.000 claims description 2
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims description 2
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims description 2
- 241000907316 Zika virus Species 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 229940078677 sarna Drugs 0.000 claims description 2
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims 2
- 101150077194 CAP1 gene Proteins 0.000 claims 2
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims 2
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims 2
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 claims 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 1
- 102100038449 Claudin-6 Human genes 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 1
- 102100028721 Hermansky-Pudlak syndrome 5 protein Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 74
- 239000000463 material Substances 0.000 description 67
- 102200114227 rs199588390 Human genes 0.000 description 67
- 230000014616 translation Effects 0.000 description 52
- 150000001413 amino acids Chemical class 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 45
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 38
- 108091034057 RNA (poly(A)) Proteins 0.000 description 34
- 125000002091 cationic group Chemical group 0.000 description 34
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 32
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 30
- 239000000126 substance Substances 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 28
- 230000027455 binding Effects 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 229920000642 polymer Polymers 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 23
- 241001678559 COVID-19 virus Species 0.000 description 22
- 230000003053 immunization Effects 0.000 description 22
- 238000002649 immunization Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 230000005847 immunogenicity Effects 0.000 description 21
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 19
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 19
- 229940029575 guanosine Drugs 0.000 description 19
- 229940027941 immunoglobulin g Drugs 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 16
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 125000003835 nucleoside group Chemical group 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 108700026244 Open Reading Frames Proteins 0.000 description 13
- 229940096437 Protein S Drugs 0.000 description 12
- 101710198474 Spike protein Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 241001112090 Pseudovirus Species 0.000 description 9
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 229920002873 Polyethylenimine Polymers 0.000 description 8
- 102000007327 Protamines Human genes 0.000 description 8
- 108010007568 Protamines Proteins 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 229920006317 cationic polymer Polymers 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 229940048914 protamine Drugs 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000011725 BALB/c mouse Methods 0.000 description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 7
- 108010004073 cysteinylcysteine Proteins 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000001226 triphosphate Substances 0.000 description 7
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 6
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 6
- 102100027304 Eukaryotic translation initiation factor 4E Human genes 0.000 description 6
- 101710091918 Eukaryotic translation initiation factor 4E Proteins 0.000 description 6
- 108091023045 Untranslated Region Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N pentofuranose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 6
- 239000001294 propane Substances 0.000 description 6
- 235000013849 propane Nutrition 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- QGWBEETXHOVFQS-UHFFFAOYSA-N 6-[6-(2-hexyldecanoyloxy)hexyl-(4-hydroxybutyl)amino]hexyl 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCO)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC QGWBEETXHOVFQS-UHFFFAOYSA-N 0.000 description 5
- 108091033380 Coding strand Proteins 0.000 description 5
- 102100031673 Corneodesmosin Human genes 0.000 description 5
- 101710139375 Corneodesmosin Proteins 0.000 description 5
- BCWIFCLVCRAIQK-ZLUOBGJFSA-N Cys-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O BCWIFCLVCRAIQK-ZLUOBGJFSA-N 0.000 description 5
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 5
- 150000002327 glycerophospholipids Chemical class 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
- HXVKEKIORVUWDR-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methylaminomethyl)-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HXVKEKIORVUWDR-FDDDBJFASA-N 0.000 description 4
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 4
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 4
- VSCNRXVDHRNJOA-PNHWDRBUSA-N 5-(carboxymethylaminomethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 VSCNRXVDHRNJOA-PNHWDRBUSA-N 0.000 description 4
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 4
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 4
- QXDXBKZJFLRLCM-UAKXSSHOSA-N 5-hydroxyuridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(O)=C1 QXDXBKZJFLRLCM-UAKXSSHOSA-N 0.000 description 4
- HLZXTFWTDIBXDF-PNHWDRBUSA-N 5-methoxycarbonylmethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HLZXTFWTDIBXDF-PNHWDRBUSA-N 0.000 description 4
- YIZYCHKPHCPKHZ-PNHWDRBUSA-N 5-methoxycarbonylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YIZYCHKPHCPKHZ-PNHWDRBUSA-N 0.000 description 4
- SNNBPMAXGYBMHM-JXOAFFINSA-N 5-methyl-2-thiouridine Chemical compound S=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SNNBPMAXGYBMHM-JXOAFFINSA-N 0.000 description 4
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 4
- XMIAMUXIMWREBJ-HERUPUMHSA-N Ala-Trp-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XMIAMUXIMWREBJ-HERUPUMHSA-N 0.000 description 4
- 102100027211 Albumin Human genes 0.000 description 4
- 101150014715 CAP2 gene Proteins 0.000 description 4
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 description 4
- BGNVBNJYBVCBJH-UHFFFAOYSA-N SM-102 Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCC(OCCCCCCCCCCC)=O BGNVBNJYBVCBJH-UHFFFAOYSA-N 0.000 description 4
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 241000723792 Tobacco etch virus Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 4
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 150000002313 glycerolipids Chemical class 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 150000003313 saccharo lipids Chemical class 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 3
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 3
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 3
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 3
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 description 3
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 3
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 3
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 3
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 3
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- CZUHPNLXLWMYMG-UBHSHLNASA-N Arg-Phe-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 CZUHPNLXLWMYMG-UBHSHLNASA-N 0.000 description 3
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 3
- CZIXHXIJJZLYRJ-SRVKXCTJSA-N Asn-Cys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CZIXHXIJJZLYRJ-SRVKXCTJSA-N 0.000 description 3
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 3
- HBUJSDCLZCXXCW-YDHLFZDLSA-N Asn-Val-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HBUJSDCLZCXXCW-YDHLFZDLSA-N 0.000 description 3
- WYZLWZNAWQNLGQ-FXQIFTODSA-N Cys-Cys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N WYZLWZNAWQNLGQ-FXQIFTODSA-N 0.000 description 3
- SKSJPIBFNFPTJB-NKWVEPMBSA-N Cys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CS)N)C(=O)O SKSJPIBFNFPTJB-NKWVEPMBSA-N 0.000 description 3
- QQOWCDCBFFBRQH-IXOXFDKPSA-N Cys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N)O QQOWCDCBFFBRQH-IXOXFDKPSA-N 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101710189104 Fibritin Proteins 0.000 description 3
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 3
- FVGOGEGGQLNZGH-DZKIICNBSA-N Glu-Val-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FVGOGEGGQLNZGH-DZKIICNBSA-N 0.000 description 3
- IBYOLNARKHMLBG-WHOFXGATSA-N Gly-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IBYOLNARKHMLBG-WHOFXGATSA-N 0.000 description 3
- LBDXVCBAJJNJNN-WHFBIAKZSA-N Gly-Ser-Cys Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O LBDXVCBAJJNJNN-WHFBIAKZSA-N 0.000 description 3
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 3
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 3
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 3
- HTZKFIYQMHJWSQ-INTQDDNPSA-N His-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HTZKFIYQMHJWSQ-INTQDDNPSA-N 0.000 description 3
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 3
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 3
- DZQYZKPINJLLEN-KKUMJFAQSA-N Lys-Cys-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)O DZQYZKPINJLLEN-KKUMJFAQSA-N 0.000 description 3
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 101000987583 Mus musculus Eosinophil peroxidase Proteins 0.000 description 3
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 3
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 3
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 3
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 3
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 3
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 3
- AJBQTGZIZQXBLT-STQMWFEESA-N Pro-Phe-Gly Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 AJBQTGZIZQXBLT-STQMWFEESA-N 0.000 description 3
- ZYJMLBCDFPIGNL-JYJNAYRXSA-N Pro-Tyr-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O ZYJMLBCDFPIGNL-JYJNAYRXSA-N 0.000 description 3
- UCXDHBORXLVBNC-ZLUOBGJFSA-N Ser-Asn-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O UCXDHBORXLVBNC-ZLUOBGJFSA-N 0.000 description 3
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 3
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 3
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- DNCUODYZAMHLCV-XGEHTFHBSA-N Thr-Pro-Cys Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N)O DNCUODYZAMHLCV-XGEHTFHBSA-N 0.000 description 3
- NBIIPOKZPUGATB-BWBBJGPYSA-N Thr-Ser-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O NBIIPOKZPUGATB-BWBBJGPYSA-N 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- WSFXJLFSJSXGMQ-MGHWNKPDSA-N Tyr-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N WSFXJLFSJSXGMQ-MGHWNKPDSA-N 0.000 description 3
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 3
- TYFLVOUZHQUBGM-IHRRRGAJSA-N Tyr-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 TYFLVOUZHQUBGM-IHRRRGAJSA-N 0.000 description 3
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 3
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 description 3
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 3
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- XOTXNXXJZCFUOA-UGKPPGOTSA-N methyl 2-[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]acetate Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(=O)OC)=C1 XOTXNXXJZCFUOA-UGKPPGOTSA-N 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 229930001119 polyketide Natural products 0.000 description 3
- 125000000830 polyketide group Chemical group 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 150000003410 sphingosines Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 3
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- VGHXKGWSRNEDEP-OJKLQORTSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidine-5-carboxylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)N1C(=O)NC(=O)C(C(O)=O)=C1 VGHXKGWSRNEDEP-OJKLQORTSA-N 0.000 description 2
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 description 2
- XIJAZGMFHRTBFY-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-$l^{1}-selanyl-5-(methylaminomethyl)pyrimidin-4-one Chemical compound [Se]C1=NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XIJAZGMFHRTBFY-FDDDBJFASA-N 0.000 description 2
- UTQUILVPBZEHTK-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-methylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UTQUILVPBZEHTK-ZOQUXTDFSA-N 0.000 description 2
- KJLRIEFCMSGNSI-HKUMRIAESA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(3-methylbut-3-enylamino)methyl]-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(CNCCC(=C)C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 KJLRIEFCMSGNSI-HKUMRIAESA-N 0.000 description 2
- HLBIEOQUEHEDCR-HKUMRIAESA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(3-methylbut-3-enylamino)methyl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(CNCCC(=C)C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HLBIEOQUEHEDCR-HKUMRIAESA-N 0.000 description 2
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 2
- BTFXIEGOSDSOGN-KWCDMSRLSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,3-diazinane-2,4-dione Chemical compound O=C1NC(=O)C(C)CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BTFXIEGOSDSOGN-KWCDMSRLSA-N 0.000 description 2
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 2
- QPHRQMAYYMYWFW-FJGDRVTGSA-N 1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QPHRQMAYYMYWFW-FJGDRVTGSA-N 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 description 2
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 description 2
- NUBJGTNGKODGGX-YYNOVJQHSA-N 2-[5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-1-yl]acetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN(CC(O)=O)C(=O)NC1=O NUBJGTNGKODGGX-YYNOVJQHSA-N 0.000 description 2
- VJKJOPUEUOTEBX-TURQNECASA-N 2-[[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methylamino]ethanesulfonic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCCS(O)(=O)=O)=C1 VJKJOPUEUOTEBX-TURQNECASA-N 0.000 description 2
- DQVAZKGVGKHQDS-UHFFFAOYSA-N 2-[[1-[2-[(2-amino-4-methylpentanoyl)amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid Chemical compound CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(O)=O DQVAZKGVGKHQDS-UHFFFAOYSA-N 0.000 description 2
- LCKIHCRZXREOJU-KYXWUPHJSA-N 2-[[5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-1-yl]methylamino]ethanesulfonic acid Chemical compound C(NCCS(=O)(=O)O)N1C=C([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(NC1=O)=O LCKIHCRZXREOJU-KYXWUPHJSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- XQYRNBOPIUSUMU-UHFFFAOYSA-M 2-aminoethyl-[2,3-di(tetradecoxy)propyl]-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCN)OCCCCCCCCCCCCCC XQYRNBOPIUSUMU-UHFFFAOYSA-M 0.000 description 2
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 description 2
- RLZMYTZDQAVNIN-ZOQUXTDFSA-N 2-methoxy-4-thio-uridine Chemical compound COC1=NC(=S)C=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O RLZMYTZDQAVNIN-ZOQUXTDFSA-N 0.000 description 2
- WBVPJIKOWUQTSD-ZOQUXTDFSA-N 2-methoxyuridine Chemical compound COC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WBVPJIKOWUQTSD-ZOQUXTDFSA-N 0.000 description 2
- JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 description 2
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 description 2
- YXNIEZJFCGTDKV-JANFQQFMSA-N 3-(3-amino-3-carboxypropyl)uridine Chemical compound O=C1N(CCC(N)C(O)=O)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YXNIEZJFCGTDKV-JANFQQFMSA-N 0.000 description 2
- UTQUILVPBZEHTK-UHFFFAOYSA-N 3-Methyluridine Natural products O=C1N(C)C(=O)C=CN1C1C(O)C(O)C(CO)O1 UTQUILVPBZEHTK-UHFFFAOYSA-N 0.000 description 2
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 description 2
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 description 2
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 2
- NYZTVPYNKWYMIW-WRBBJXAJSA-N 4-[[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-dimethylazaniumyl]methyl]benzoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)CC1=CC=C(C=C1)C([O-])=O)OC(=O)CCCCCCC\C=C/CCCCCCCC NYZTVPYNKWYMIW-WRBBJXAJSA-N 0.000 description 2
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 2
- FAWQJBLSWXIJLA-VPCXQMTMSA-N 5-(carboxymethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(O)=O)=C1 FAWQJBLSWXIJLA-VPCXQMTMSA-N 0.000 description 2
- ZYEWPVTXYBLWRT-UHFFFAOYSA-N 5-Uridinacetamid Natural products O=C1NC(=O)C(CC(=O)N)=CN1C1C(O)C(O)C(CO)O1 ZYEWPVTXYBLWRT-UHFFFAOYSA-N 0.000 description 2
- AMMRPAYSYYGRKP-BGZDPUMWSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-ethylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AMMRPAYSYYGRKP-BGZDPUMWSA-N 0.000 description 2
- ITGWEVGJUSMCEA-KYXWUPHJSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(C#CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ITGWEVGJUSMCEA-KYXWUPHJSA-N 0.000 description 2
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 description 2
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 description 2
- LOEDKMLIGFMQKR-JXOAFFINSA-N 5-aminomethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CN)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LOEDKMLIGFMQKR-JXOAFFINSA-N 0.000 description 2
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 2
- ZYEWPVTXYBLWRT-VPCXQMTMSA-N 5-carbamoylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZYEWPVTXYBLWRT-VPCXQMTMSA-N 0.000 description 2
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 2
- HXVKEKIORVUWDR-UHFFFAOYSA-N 5-methylaminomethyl-2-thiouridine Natural products S=C1NC(=O)C(CNC)=CN1C1C(O)C(O)C(CO)O1 HXVKEKIORVUWDR-UHFFFAOYSA-N 0.000 description 2
- ZXQHKBUIXRFZBV-FDDDBJFASA-N 5-methylaminomethyluridine Chemical compound O=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXQHKBUIXRFZBV-FDDDBJFASA-N 0.000 description 2
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 2
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 2
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 2
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 2
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 2
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 2
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 2
- UHGUKCOQUNPSKK-CIUDSAMLSA-N Asn-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N UHGUKCOQUNPSKK-CIUDSAMLSA-N 0.000 description 2
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 2
- VNXQRBXEQXLERQ-CIUDSAMLSA-N Asp-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N VNXQRBXEQXLERQ-CIUDSAMLSA-N 0.000 description 2
- NJLLRXWFPQQPHV-SRVKXCTJSA-N Asp-Tyr-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJLLRXWFPQQPHV-SRVKXCTJSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102000003859 Claudin-6 Human genes 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- OELDIVRKHTYFNG-WDSKDSINSA-N Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CS OELDIVRKHTYFNG-WDSKDSINSA-N 0.000 description 2
- NGOIQDYZMIKCOK-NAKRPEOUSA-N Cys-Val-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NGOIQDYZMIKCOK-NAKRPEOUSA-N 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 description 2
- 102100037070 Doublecortin domain-containing protein 2 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 2
- QSTLUOIOYLYLLF-WDSKDSINSA-N Gly-Asp-Glu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QSTLUOIOYLYLLF-WDSKDSINSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 2
- QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 description 2
- WSSGUVAKYCQSCT-XUXIUFHCSA-N Ile-Met-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)O)N WSSGUVAKYCQSCT-XUXIUFHCSA-N 0.000 description 2
- RTSQPLLOYSGMKM-DSYPUSFNSA-N Ile-Trp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)O)N RTSQPLLOYSGMKM-DSYPUSFNSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 2
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 2
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 2
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 2
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 2
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 2
- HUURTRNKPBHHKZ-JYJNAYRXSA-N Met-Phe-Val Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 HUURTRNKPBHHKZ-JYJNAYRXSA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 102000007530 Neurofibromin 1 Human genes 0.000 description 2
- 108010085793 Neurofibromin 1 Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- XMIFBEZRFMTGRL-TURQNECASA-N OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(CNCCS(O)(=O)=O)c(=O)[nH]c1=S Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(CNCCS(O)(=O)=O)c(=O)[nH]c1=S XMIFBEZRFMTGRL-TURQNECASA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 2
- INHMISZWLJZQGH-ULQDDVLXSA-N Phe-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 INHMISZWLJZQGH-ULQDDVLXSA-N 0.000 description 2
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 2
- WVXQQUWOKUZIEG-VEVYYDQMSA-N Pro-Thr-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O WVXQQUWOKUZIEG-VEVYYDQMSA-N 0.000 description 2
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 2
- 108010003201 RGH 0205 Proteins 0.000 description 2
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 2
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 2
- JGLXHHQUSIULAK-OYDLWJJNSA-N Trp-Pro-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 JGLXHHQUSIULAK-OYDLWJJNSA-N 0.000 description 2
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 2
- BVWPHWLFGRCECJ-JSGCOSHPSA-N Val-Gly-Tyr Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N BVWPHWLFGRCECJ-JSGCOSHPSA-N 0.000 description 2
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 2
- MJFSRZZJQWZHFQ-SRVKXCTJSA-N Val-Met-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)O)N MJFSRZZJQWZHFQ-SRVKXCTJSA-N 0.000 description 2
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 2
- YXNIEZJFCGTDKV-UHFFFAOYSA-N X-Nucleosid Natural products O=C1N(CCC(N)C(O)=O)C(=O)C=CN1C1C(O)C(O)C(CO)O1 YXNIEZJFCGTDKV-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108091005434 innate immune receptors Proteins 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HLZXTFWTDIBXDF-UHFFFAOYSA-N mcm5sU Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=S)[nH]c1=O HLZXTFWTDIBXDF-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- WZRYXYRWFAPPBJ-PNHWDRBUSA-N methyl uridin-5-yloxyacetate Chemical compound O=C1NC(=O)C(OCC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WZRYXYRWFAPPBJ-PNHWDRBUSA-N 0.000 description 2
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108010064486 phenylalanyl-leucyl-valine Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- RVCNQQGZJWVLIP-VPCXQMTMSA-N uridin-5-yloxyacetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(OCC(O)=O)=C1 RVCNQQGZJWVLIP-VPCXQMTMSA-N 0.000 description 2
- YIZYCHKPHCPKHZ-UHFFFAOYSA-N uridine-5-acetic acid methyl ester Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=O)[nH]c1=O YIZYCHKPHCPKHZ-UHFFFAOYSA-N 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- LNGVIFNWQLYISS-KWXKLSQISA-N (12z,15z)-3-[(dimethylamino)methyl]-2-[(9z,12z)-octadeca-9,12-dienoyl]-4-oxohenicosa-12,15-dienamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)C(CN(C)C)C(C(N)=O)C(=O)CCCCCCC\C=C/C\C=C/CCCCC LNGVIFNWQLYISS-KWXKLSQISA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 1
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- OYTVCAGSWWRUII-DWJKKKFUSA-N 1-Methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O OYTVCAGSWWRUII-DWJKKKFUSA-N 0.000 description 1
- NKHPSESDXTWSQB-WRBBJXAJSA-N 1-[3,4-bis[(z)-octadec-9-enoxy]phenyl]-n,n-dimethylmethanamine Chemical compound CCCCCCCC\C=C/CCCCCCCCOC1=CC=C(CN(C)C)C=C1OCCCCCCCC\C=C/CCCCCCCC NKHPSESDXTWSQB-WRBBJXAJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UZLHBUQJHDTDRD-UHFFFAOYSA-N 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium Chemical compound CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC UZLHBUQJHDTDRD-UHFFFAOYSA-N 0.000 description 1
- IUAUYSMYFCQVNW-UHFFFAOYSA-N 2,3-didodecoxy-n,n-dimethylpropan-1-amine Chemical compound CCCCCCCCCCCCOCC(CN(C)C)OCCCCCCCCCCCC IUAUYSMYFCQVNW-UHFFFAOYSA-N 0.000 description 1
- LJARBVLDSOWRJT-UHFFFAOYSA-O 2-[2,3-di(pentadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCC LJARBVLDSOWRJT-UHFFFAOYSA-O 0.000 description 1
- PGYFLJKHWJVRMC-ZXRZDOCRSA-N 2-[4-[[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]butoxy]-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCCCOC(CN(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC)C1 PGYFLJKHWJVRMC-ZXRZDOCRSA-N 0.000 description 1
- GIEAGSSLJOPATR-TWCFUXPBSA-N 2-[8-[[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]octoxy]-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCCCCCCCOC(CN(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC)C1 GIEAGSSLJOPATR-TWCFUXPBSA-N 0.000 description 1
- KYQCXUMVJGMDNG-UHFFFAOYSA-N 3-Desoxy-D-manno-octulosonsaeure Natural products OCC(O)C(O)C(O)C(O)CC(=O)C(O)=O KYQCXUMVJGMDNG-UHFFFAOYSA-N 0.000 description 1
- DXEJZRDJXRVUPN-XUTVFYLZSA-N 3-Methylpseudouridine Chemical compound O=C1N(C)C(=O)NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DXEJZRDJXRVUPN-XUTVFYLZSA-N 0.000 description 1
- HXVVOLDXHIMZJZ-UHFFFAOYSA-N 3-[2-[2-[2-[bis[3-(dodecylamino)-3-oxopropyl]amino]ethyl-[3-(dodecylamino)-3-oxopropyl]amino]ethylamino]ethyl-[3-(dodecylamino)-3-oxopropyl]amino]-n-dodecylpropanamide Chemical compound CCCCCCCCCCCCNC(=O)CCN(CCC(=O)NCCCCCCCCCCCC)CCN(CCC(=O)NCCCCCCCCCCCC)CCNCCN(CCC(=O)NCCCCCCCCCCCC)CCC(=O)NCCCCCCCCCCCC HXVVOLDXHIMZJZ-UHFFFAOYSA-N 0.000 description 1
- ZLCFGDAOIYFIPN-MJBGKLQRSA-M 3-aminopropyl-[2,3-bis[(z)-tetradec-9-enoxy]propyl]-dimethylazanium;bromide Chemical compound [Br-].CCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC\C=C/CCCC ZLCFGDAOIYFIPN-MJBGKLQRSA-M 0.000 description 1
- QNEMTSQNLVZHQO-UHFFFAOYSA-M 3-aminopropyl-[2,3-di(tetradecoxy)propyl]-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCCCCCCCC QNEMTSQNLVZHQO-UHFFFAOYSA-M 0.000 description 1
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- PESKGJQREUXSRR-UXIWKSIVSA-N 5alpha-cholestan-3-one Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 PESKGJQREUXSRR-UXIWKSIVSA-N 0.000 description 1
- PESKGJQREUXSRR-UHFFFAOYSA-N 5beta-cholestanone Natural products C1CC2CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 PESKGJQREUXSRR-UHFFFAOYSA-N 0.000 description 1
- CBCCCLMNOBLBSC-XVYDVKMFSA-N Ala-His-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O CBCCCLMNOBLBSC-XVYDVKMFSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- YEBZNKPPOHFZJM-BPNCWPANSA-N Ala-Tyr-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O YEBZNKPPOHFZJM-BPNCWPANSA-N 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- FHETWELNCBMRMG-HJGDQZAQSA-N Asn-Leu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FHETWELNCBMRMG-HJGDQZAQSA-N 0.000 description 1
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
- VIRHEUMYXXLCBF-WDSKDSINSA-N Asp-Gly-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O VIRHEUMYXXLCBF-WDSKDSINSA-N 0.000 description 1
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 1
- 101100326791 Caenorhabditis elegans cap-2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- ATPDEYTYWVMINF-ZLUOBGJFSA-N Cys-Cys-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ATPDEYTYWVMINF-ZLUOBGJFSA-N 0.000 description 1
- NLDWTJBJFVWBDQ-KKUMJFAQSA-N Cys-Lys-Phe Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 NLDWTJBJFVWBDQ-KKUMJFAQSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DIXKFOPPGWKZLY-CIUDSAMLSA-N Glu-Arg-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O DIXKFOPPGWKZLY-CIUDSAMLSA-N 0.000 description 1
- KRRFFAHEAOCBCQ-SIUGBPQLSA-N Glu-Ile-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KRRFFAHEAOCBCQ-SIUGBPQLSA-N 0.000 description 1
- JNGJGFMFXREJNF-KBPBESRZSA-N Gly-Glu-Trp Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JNGJGFMFXREJNF-KBPBESRZSA-N 0.000 description 1
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 1
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000812663 Homo sapiens Endoplasmin Proteins 0.000 description 1
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 150000000963 Kdo2-lipid A derivatives Chemical class 0.000 description 1
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- HMDDEJADNKQTBR-BZSNNMDCSA-N Leu-His-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HMDDEJADNKQTBR-BZSNNMDCSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- DKTNGXVSCZULPO-YUMQZZPRSA-N Lys-Gly-Cys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O DKTNGXVSCZULPO-YUMQZZPRSA-N 0.000 description 1
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- MNNKPHGAPRUKMW-BPUTZDHNSA-N Met-Asp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(O)=O)=CNC2=C1 MNNKPHGAPRUKMW-BPUTZDHNSA-N 0.000 description 1
- IIHMNTBFPMRJCN-RCWTZXSCSA-N Met-Val-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IIHMNTBFPMRJCN-RCWTZXSCSA-N 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 101000920670 Mus musculus Erythropoietin Proteins 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
- 101710152005 Non-structural polyprotein Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101710114167 Polyprotein P1234 Proteins 0.000 description 1
- 101710124590 Polyprotein nsP1234 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XWYXZPHPYKRYPA-GMOBBJLQSA-N Pro-Asn-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XWYXZPHPYKRYPA-GMOBBJLQSA-N 0.000 description 1
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 1
- DIDLUFMLRUJLFB-FKBYEOEOSA-N Pro-Trp-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O DIDLUFMLRUJLFB-FKBYEOEOSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 1
- LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 description 1
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 1
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Natural products NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- LCCSEJSPBWKBNT-OSUNSFLBSA-N Thr-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N LCCSEJSPBWKBNT-OSUNSFLBSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 101000956368 Trittame loki CRISP/Allergen/PR-1 Proteins 0.000 description 1
- NXAPHBHZCMQORW-FDARSICLSA-N Trp-Arg-Ile Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NXAPHBHZCMQORW-FDARSICLSA-N 0.000 description 1
- IBBBOLAPFHRDHW-BPUTZDHNSA-N Trp-Asn-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N IBBBOLAPFHRDHW-BPUTZDHNSA-N 0.000 description 1
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 1
- NMOIRIIIUVELLY-WDSOQIARSA-N Trp-Val-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)C(C)C)=CNC2=C1 NMOIRIIIUVELLY-WDSOQIARSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- NSTPFWRAIDTNGH-BZSNNMDCSA-N Tyr-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NSTPFWRAIDTNGH-BZSNNMDCSA-N 0.000 description 1
- LQGDFDYGDQEMGA-PXDAIIFMSA-N Tyr-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N LQGDFDYGDQEMGA-PXDAIIFMSA-N 0.000 description 1
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 1
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 1
- IVXJODPZRWHCCR-JYJNAYRXSA-N Val-Arg-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N IVXJODPZRWHCCR-JYJNAYRXSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241001441550 Zeiformes Species 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- NJFCSWSRXWCWHV-USYZEHPZSA-N [(2R)-2,3-bis(octadec-1-enoxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCC=COC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC=CCCCCCCCCCCCCCCCC NJFCSWSRXWCWHV-USYZEHPZSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- HCAJCMUKLZSPFT-KWXKLSQISA-N [3-(dimethylamino)-2-[(9z,12z)-octadeca-9,12-dienoyl]oxypropyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC HCAJCMUKLZSPFT-KWXKLSQISA-N 0.000 description 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- VEWJOCYCKIZKKV-GBNDHIKLSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-GBNDHIKLSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 1
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 125000005724 cycloalkenylene group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 238000000375 direct analysis in real time Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- XSWSEQPWKOWORN-UHFFFAOYSA-N dodecan-2-ol Chemical compound CCCCCCCCCCC(C)O XSWSEQPWKOWORN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000012063 dual-affinity re-targeting Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 108010073628 glutamyl-valyl-phenylalanine Proteins 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- NRLNQCOGCKAESA-UHFFFAOYSA-N heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate Chemical compound CCCCCC=CCC=CCCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCCC=CCC=CCCCCC NRLNQCOGCKAESA-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000004249 ion pair reversed phase high performance liquid chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VLBPIWYTPAXCFJ-XMMPIXPASA-N lysophosphatidylcholine O-16:0/0:0 Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VLBPIWYTPAXCFJ-XMMPIXPASA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108091063742 miR-2255 stem-loop Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- OZBZDYGIYDRTBV-RSLAUBRISA-N n,n-dimethyl-1,2-bis[(9z,12z,15z)-octadeca-9,12,15-trienoxy]propan-1-amine Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/C\C=C/CC OZBZDYGIYDRTBV-RSLAUBRISA-N 0.000 description 1
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 description 1
- ZVJAPVDDCYWINZ-UHFFFAOYSA-N n,n-dimethyl-2,3-di(tetradecoxy)propan-1-amine Chemical compound CCCCCCCCCCCCCCOCC(CN(C)C)OCCCCCCCCCCCCCC ZVJAPVDDCYWINZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 150000003019 phosphosphingolipids Chemical class 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229930000756 phytoceramide Natural products 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003135 prenol lipids Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 150000003290 ribose derivatives Chemical class 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 125000002657 sphingoid group Chemical group 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 241000114864 ssRNA viruses Species 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000012749 thinning agent Substances 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/18011—Comoviridae
- C12N2770/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/18011—Comoviridae
- C12N2770/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/18011—Comoviridae
- C12N2770/18071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- RNA polynucleotides as therapeutics is a new and emerging field.
- the present disclosure identifies certain challenges that can be associated with RNA therapeutics.
- the present disclosure identifies the source of certain problems that can be encountered with expression of polypeptides encoded by RNA therapeutics.
- the present disclosure provides technologies for improving translation efficiency of an RNA encoding a payload, and/or expression of a polypeptide payload encoded by an RNA.
- translation efficiency and/or expression of an RNA-encoded payload can be improved with an RNA polynucleotide comprising: a Capl structure (e.g., a m2 7 ’ 3 °Gppp(mi 2 °)ApG cap); a 5’ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload.
- eukaryotic translation initiation factor 4E eukaryotic translation initiation factor 4E
- IFIT1 IFN-induced protein with tetratricopeptide repeats-1
- eIF4E may compete with IFIT1 for binding to an RNA polynucleotide based on a 5’ cap structure.
- the present disclosure provides certain technologies that may favor eIF4E binding, at least relative to IFIT1 binding, and/or may otherwise enhance translation.
- identity of particular sequence(s) proximal to a 5’ cap e.g., a 5’ Capl structure
- the present disclosure proposes that eIF4E competes with IFIT1 for binding to an RNA polynucleotide based on the identity of one or more nucleotides downstream of a 5’ cap, e.g., a cap proximal sequence as disclosed herein.
- the present disclosure demonstrates that an AGAAU or an AGCAC sequence downstream of a 5’ cap (e.g., a 5’ Cap 1 structure) can improve translation.
- the present disclosure proposes that presence of such sequence (e.g., AGAAU or an AGCAC can increase eIF4E binding, at least relative to IFIT1.
- the present disclosure documents certain advantages of avoiding (e.g., ensuring that absence of) a self-hybridizing sequence (which may, in some instances, be referred to as a self-complementary sequence) in an RNA polynucleotide encoding a payload,
- a self-hybridizing sequence which may, in some instances, be referred to as a self-complementary sequence
- the present disclosure demonstrates that such absence can improve, and/or be required for, translation (e.g., translation efficiency) of an associated (e.g., RNA- encoded) payload, and/or otherwise for expression of a polypeptide encoded thereby.
- a self-hybridizing sequence (and in particular a sequence that hybridizes with sequences within or comprising one or more of a Kozak sequence, a 5’ UTR element, and/or a 3’ UTR element) interfere with one or more aspects of translation.
- a self-hybridizing sequence may inhibit binding of transcription and/or translation factors to an RNA polynucleotide by self-hybridizing to a complementary sequence in said RNA polynucleotide.
- the present disclosure defines particular lipid components, and/or ratios thereof, that may be especially useful or effective in delivering nucleic acids, and in particular RNAs (e.g., therapeutic RNAs or other RNAs encoding a polypeptide) upon administration (e.g., by injection, such as by intramuscular injection or by intravenous injection) to a subject.
- RNAs e.g., therapeutic RNAs or other RNAs encoding a polypeptide
- the present disclosure demonstrates that lipid ALC-0315 is unusually and particularly useful for delivery as described herein.
- composition or medical preparation comprising an RNA polynucleotide, comprising: (i) a 5’ cap that is or comprises a capl structure, e.g., as disclosed herein; (ii) a 5’ UTR sequence comprising a cap proximal sequence, e.g., as disclosed herein; and (iii) a sequence encoding a payload. Also disclosed herein are methods of making and using the same to, e.g., induce an immune response in a subject.
- composition or medical preparation comprising an RNA polynucleotide comprising: a 5’ cap comprising a Capl structure; a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of the RNA polynucleotide; and a sequence encoding a payload, wherein:
- the Capl structure comprises m7G(5')ppp(5')(2'OMeNi)pN 2 , wherein Ni is position +1 of the RNA polynucleotide, and N2 is position +2 of the RNA polynucleotide, and wherein Ni and N2 are each independently chosen from: A, C, G, or U; and
- the cap proximal sequence comprises Ni and N2 of the Capl structure, and:
- A3A4X5 SEQ ID NO: 1
- C3A4X5 SEQ ID NO: 2
- A3C4A5 SEQ ID NO: 3
- A3U4G5 SEQ ID NO: 4
- a sequence comprising: X3Y4X5 (SEQ ID NO: 7); wherein X3 (nucleotide X at position +3 in SEQ ID NO: 7) or X5 (nucleotide X at position +5 in SEQ ID NO: 1 or SEQ ID NO: 2) is each independently chosen from A, G, C, or U; and wherein Y4 (nucleotide Y at position +4 in SEQ ID NO: 7) is not C.
- composition or medical preparation comprising an RNA polynucleotide comprising: a 5’ cap; a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of an RNA polynucleotide; and a sequence encoding a payload, wherein:
- the 5’ cap comprises a Capl structure comprising G*ppp(mi 2 °)NipN2, wherein:
- NI is position +1 of the RNA polynucleotide
- N2 is position +2 of the RNA polynucleotide
- Ni and N2 are each independently chosen from: A,
- G* comprises the following structure:
- the cap proximal sequence comprises Ni and N2 of the Capl structure, and: (a) a sequence selected from the group consisting of: A3A4X5 (SEQ ID NO: 1);
- C3A4X5 (SEQ ID NO: 2); A3C4A5 (SEQ ID NO: 3) and A3U4G5 (SEQ ID NO: 4); or (b) a sequence comprising: X3Y4X5 (SEQ ID NO: 7); wherein X3 (nucleotide X at position +3 in SEQ ID NO: 7) or X5 (nucleotide X at position +5 in SEQ ID NO: 1 or SEQ ID NO: 2) is each independently chosen from A, G, C, or U; and wherein Y4 (nucleotide Y at position +4 in SEQ ID NO: 7) is not C.
- composition or medical preparation comprising an RNA polynucleotide comprising: a 5’ cap comprising a Capl structure; a cap proximal sequence comprising positions +1,
- RNA polynucleotide +2, +3, +4, and +5 of the RNA polynucleotide; and a sequence encoding a payload, wherein:
- the Capl structure comprises m7(3’OMeG)(5')ppp(5')(2'OMeAi)pG 2 , wherein Ai is position +1 of the RNA polynucleotide, and G2 is position +2 of the RNA polynucleotide; and (ii) the cap proximal sequence comprises A1 and G2 of the Capl structure, and a sequence comprising: A3A4U5 at positions +3, +4 and +5 respectively of the RNA polynucleotide.
- composition or medical preparation comprising a capped RNA polynucleotide encoding a gene product, which RNA polynucleotide comprises the formula:
- R 1 is CH3, R 2 is OH or O-CH3, and R 3 is O-CH3
- Bi is any nucleobase, preferably A
- B2 is any nucleobase, preferably G
- B3 is any nucleobase, preferably A or C
- B4 is any nucleobase
- B5 is any nucleobase
- a pharmaceutical composition comprising an RNA polynucleotide disclosed herein.
- a pharmaceutical composition comprises a composition or a medical preparation disclosed herein.
- a pharmaceutical composition e.g., comprising an RNA polynucleotide disclosed herein, by combining an RNA polynucleotide with lipids to form lipid nanoparticles that encapsulate said RNA.
- a nucleic acid template suitable to produce a cap 1 -capped RNA, in which the first five nucleotides transcribed from the template strand of the nucleic acid template comprise the sequence NipN2pN 3 pN4pN5, wherein Ni is any nucleotide, preferably T; N2 is any nucleotide, preferably C; N3 is any nucleotide, preferably T or G; N4 is any nucleotide; and N5 is any nucleotide.
- a DNA template comprises: a 5’ UTR, a sequence encoding a payload, a 3’ UTR and a polyA sequence.
- an vitro transcription reaction comprising:
- a template DNA comprising a polynucleotide sequence complementary to an RNA polynucleotide sequence disclosed herein;
- RNA polynucleotide isolated from an in vitro transcription reaction provided.
- This disclosure provides, a method for producing a capped RNA comprising, transcribing a nucleic acid template in the presence of a cap structure, wherein the cap structure comprises G*ppp(mi 2' -°)NipN2, wherein Ni is complementary to position +1 of the nucleic acid template and N2 is complementary to position +2 of the nucleic acid template, and Ni and N2 are independently chosen from A, C, G or U, wherein position +3 of the nucleic acid template is any nucleotide, preferably T or G; position +4 of the nucleic acid template is any nucleotide; and position +5 of the nucleic acid template is any nucleotide, wherein G* comprises the following structure: wherein L LL represents the bond by which G* is bound to the first phosphor atom of the ppp group, R 1 is CFb, R 2 is OH or O-CH3, and R 3 is O-CH3.
- composition comprising a DNA polynucleotide comprising a sequence complementary to an RNA polynucleotide sequence provided.
- a DNA polynucleotide disclosed herein can be used to transcribe an RNA polynucleotide disclosed herein.
- This disclosure provides, a method comprising: administering to a subject, a pharmaceutical composition comprising an RNA polynucleotide disclosed herein formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle, e.g., as disclosed herein.
- a pharmaceutical composition comprising an RNA polynucleotide disclosed herein formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle, e.g., as disclosed herein.
- Also provided herein is a method of inducing an immune response in a subject comprising administering to a subject, a pharmaceutical composition comprising an RNA polynucleotide disclosed herein formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle, e.g., as disclosed herein
- a pharmaceutical composition comprising an RNA polynucleotide disclosed herein formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle, e.g., as disclosed herein
- RNA polynucleotide disclosed herein formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle, e.g., as disclosed herein.
- LNP lipid nanoparticle
- LPX lipoplex
- This disclosure provides, a method of decreasing interaction with IFIT1 of an RNA polynucleotide that comprises a 5’ cap and a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of the RNA polynucleotide, the method comprising a step of: providing a variant of an RNA polynucleotide that differs from a parental RNA polynucleotide by substitution of one or more residues within a cap proximal sequence, and determining that interaction of a variant with IFIT1 is decreased relative to that of a parental RNA polynucleotide.
- RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence that comprises positions +1, +2, +3, +4, and +5 of the RNA polynucleotide, and a sequence encoding a payload; wherein an RNA polynucleotide is characterized in that when assessed in an organism administered an RNA polynucleotide or a composition comprising the same, elevated expression and/or increased duration of expression of a payload is observed relative to an appropriate reference comparator.
- RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence that comprises positions +1, +2, +3, +4, and +5 of the RNA polynucleotide and a sequence encoding a payload
- the method comprising a step of: providing a variant of an RNA polynucleotide that differs from a parental RNA polynucleotide by substitution of one or more residues within a cap proximal sequence; and determining that expression of a variant is increased relative to that of a parental RNA polynucleotide.
- a therapeutic RNA comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload, the improvement that comprises: including one or more of the following residues in a cap proximal sequence: X at position +1 of an RNA polynucleotide, X at position +2 of an RNA polynucleotide, A at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and X at position +5 of an RNA polynucleotide, demonstrated to increase expression of an RNA when administered to a subject in an LNP formulation.
- X is chosen from A, C, G or U.
- a therapeutic RNA comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload, the improvement that comprises: including one or more of the following residues in a cap proximal sequence: X at position +1 of an RNA polynucleotide, X at position +2 of an RNA polynucleotide, C at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and X at position +5 of an RNA polynucleotide, demonstrated to increase expression of an RNA when administered to a subject in an LNP formulation.
- X is chosen from A, C, G or U.
- RNA comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload
- the improvement that comprises :inc hiding one or more of the following residues in a cap proximal sequence: A at position +1 of an RNA polynucleotide, G at position +2 of an RNA polynucleotide, A at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and U at position +5 of an RNA polynucleotide, demonstrated to increase expression of an RNA when administered to a subject in an LNP formulation.
- This discosure provides, a method of increasing translation of an RNA polynucleotide comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload, the improvement that comprises: including one or more of the following residues in a cap proximal sequence: X at position +1 of an RNA polynucleotide, X at position +2 of an RNA polynucleotide, A at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and X at position +5 of an RNA polynucleotide.
- X is chosen from A, C, G or U.
- RNA polynucleotide comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload
- the improvement that comprises: including one or more of the following residues in a cap proximal sequence: X at position +1 of an RNA polynucleotide, X at position +2 of an RNA polynucleotide, C at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and X at position +5 of an RNA polynucleotide.
- X is chosen from A, C, G or U.
- Also provided herein is a method of increasing translation of an RNA polynucleotide comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload, the improvement that comprises: including one or more of the following residues in a cap proximal sequence: A at position +1 of an RNA polynucleotide, G at position +2 of an RNA polynucleotide, A at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and U at position +5 of an RNA polynucleotide.
- Also provided herein is a method of providing a framework for an RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence, and a payload sequence, the method comprising a step of: assessing at least two variants of an RNA polynucleotide, wherein: each variant includes a same 5’ cap and payload sequence; and the variants differ from one another at one or more specific residues of a cap proximal sequence; wherein the assessing comprises determining expression levels and/or duration of expression of a payload sequence; and selecting at least one combination of 5’ cap and a cap proximal sequence that displays elevated expression relative to at least one other combination.
- Figure 1 demonstrates plasma levels of EPO at 6, 24, 48 and 72 hours after intravenous administration of mice with murine EPO (mEPO) mRNA constructs with or without a Lig3 presence in the 3’UTR sequence. Blood was collected 6, 24, 48 and 72 hours after administration and samples were analyzed for mEPO levels via ELISA.
- mEPO murine EPO
- FIGS. 2A-2C are schematics of a Lig3 sequence self-hybridizing to a 5’ UTR (FIG. 2A-2B) or a 3’ UTR (FIG. 2C )/
- Figures 3A-3I are structures of 5’ caps that can be incorporated into mRNAs.
- Figure 4 demonstrates plasma levels of mEPO at 6, 24, 48 and 72 hours after intravenous administration of mice with mEPO mRNA constructs having different nucleotides at the +3, +4 or +5 positions. Blood was collected 6, 24, 48 and 72 hours after administration and samples were analyzed for mEPO levels via ELISA.
- Figure 5 demonstrates an anti-S protein IgG response 7, 14, 21 and 28 d after immunization with BNT162al.
- BALB/c mice were immunized IM once with 1, 5 or 10 pg of LNP-formulated RBL063.3.
- animals were bled and the serum samples were analyzed for total amount of anti-S 1 (left) and anti-RBD (right) antigen- specific immunoglobulin G (IgG) measured via ELISA.
- IgG immunoglobulin G
- Figure 6 demonstrates Anti-S protein IgG response 7, 14, 21 and 28 d after immunization with BNT162bl.
- BALB/c mice were immunized IM once with 0.2, 1 or 5pg of LNP-formulated RBP020.3.
- animals were bled and the serum samples were analyzed for total amount of anti-S 1 (left) and anti-RBD (right) antigen- specific immunoglobulin G (IgG) measured via ELISA.
- IgG immunoglobulin G
- Figure 7 demonstrates neutralization of SARS-CoV-2 pseudovirus 14, 21 and 28 d after immunization with BNT162bl.
- B ALB/c mice were immunized IM once with 0.2, 1 or 5 pg of LNP-formulated RBP020.3.
- Graphs depict pVN50 serum dilutions (50% reduction of infectious events, compared to positive controls without serum).
- Mean + SEM is shown by horizontal bars with whiskers for each group.
- LLOQ lower limit of quantification.
- ULOQ upper limit of quantification.
- Figure 8 demonstrates Anti-S protein IgG response 7, 14 and 21 d after immunization with BNT162cl.
- BALB/c mice were immunized IM once with 0.2, 1 or 5pg of LNP-formulated RBS004.3.
- animals were bled and the serum samples were analyzed for total amount of anti-Sl (left) and anti-RBD (right) antigen- specific immunoglobulin G (IgG) measured via ELISA.
- IgG immunoglobulin G
- Figure 9 demonstrates neutralization of SARS-CoV-2 pseudovirus 14 and 21 d after immunization with BNT162cl.
- BALB/c mice were immunized IM once with 0.2, 1 or 5 pg of LNP-formulated RBS004.3.
- animals were bled and the sera were tested for SARS-CoV-2 pseudovirus neutralization
- Graphs depict pVN50 serum dilutions (50% reduction of infectious events, compared to positive controls without serum).
- Mean + SEM is shown by horizontal bars with whiskers for each group.
- LLOQ lower limit of quantification.
- ULOQ upper limit of quantification.
- Figure 10 demonstrates anti-S protein IgG response 7, 14, 21 and 28 d after immunization with LNP-formulated RBL063.1.
- BALB/c mice were immunized IM once with 1,
- Figure 11 shows neutralization of SARS-CoV-2 pseudovims 14, 21 and 28 d after immunization with LNP-formulated RBL063.E B ALB/c mice were immunized IM once with 1,
- FIG 12 shows Anti-S protein IgG response 7, 14 and 21 d after immunization with BNT162b2 (LNP-formulated RBP020.1).
- B ALB/c mice were immunized IM once with 0.2, 1 or 5 pg of LNP-formulated RBP020.1.
- animals were bled and the serum samples were analyzed for total amount of anti-Sl (left) and anti-RBD (right) antigen- specific immunoglobulin G (IgG) measured via ELISA.
- IgG immunoglobulin G
- Figure 13 demonstrates neutralization of SARS-CoV-2 pseudovirus 14 and 21 after immunization with BNT162b2 (LNP-formulated RBP020.1).
- B ALB/c mice were immunized IM once with 0.2, 1 or 5 pg of LNP-formulated RBP020.1.
- animals were bled and the sera were tested for SARS-CoV-2 pseudovirus neutralization.
- LLOQ lower limit of quantification.
- ULOQ upper limit of quantification.
- Figure 14 shows anti-S protein IgG response 7, 14 and 21 d after immunization with LNP-formulated RBS004.2.
- BALB/c mice were immunized IM once with 0.2, 1 or 5 pg of LNP- formulated RBS004.2.
- animals were bled and the serum samples were analyzed for total amount of anti-Sl (left) and anti-RBD (right) antigen- specific immunoglobulin G (IgG) measured via ELISA.
- IgG immunoglobulin G
- Figure 15 demonstrates neutralization of SARS-CoV-2 pseudovirus 14 and 21 after immunization with LNP-formulated RBS004.2.
- BALB/c mice were immunized IM once with 0.2, 1 or 5 pg of LNP-formulated RBS004.2.
- On 14, and 21 d after immunization animals were bled, and the sera were tested for SARS-CoV-2 pseudovirus neutralization.
- LLOQ lower limit of quantification.
- ULOQ upper limit of quantification.
- Figure 16 depicts ALC-0315 activity in the screening process.
- Figure 17 demonstrates luciferase expression was monitored on the right (site of injection), dorsal (site of injection) and ventral (drainage to the liver) sides of the animal after intramuscular administration in wild-type (WT) or ApoE knockout C57B1/6 mice in the presence or absence of ApoE3. Luciferase expression was detected using Xenolight D-Luciferin Rediject at 4, 24, 72 and 96 hours post administration.
- Figure 18 shows luciferase activity after intravenous (IV) and intramuscular (IM) administration in wild-type (WT) or ApoE knockout C57B1/6 mice in the presence (KO+) or absence (KO) of ApoE3. Luciferase expression was detected using Xenolight D-Luciferin Rediject at 4 hours post administration.
- the term “comprising” is used in the context of the present document to indicate that further members may optionally be present in addition to the members of the list introduced by “comprising”. It is, however, contemplated as a specific embodiment of the present disclosure that the term “comprising” encompasses the possibility of no further members being present, i.e., for the purpose of this embodiment "comprising” is to be understood as having the meaning of “consisting of” or “consisting essentially of”.
- agent may refer to a physical entity or phenomenon.
- an agent may be characterized by a particular feature and/or effect.
- an agent may be a compound, molecule, or entity of any chemical class including, for example, a small molecule, polypeptide, nucleic acid, saccharide, lipid, metal, or a combination or complex thereof.
- the term “agent” may refer to a compound, molecule, or entity that comprises a polymer.
- the term may refer to a compound or entity that comprises one or more polymeric moieties.
- the term “agent” may refer to a compound, molecule, or entity that is substantially free of a particular polymer or polymeric moiety. In some embodiments, the term may refer to a compound, molecule, or entity that lacks or is substantially free of any polymer or polymeric moiety.
- amino acid in its broadest sense, as used herein, the term “amino acid” refers to a compound and/or substance that can be, is, or has been incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds.
- an amino acid has the general structure H2N-C(H)(R)-COOH.
- an amino acid is a naturally-occurring amino acid.
- an amino acid is a non-natural amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L- amino acid.
- Standard amino acid refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides.
- Nonstandard amino acid refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source.
- an amino acid, including a carboxy- and/or amino-terminal amino acid in a polypeptide can contain a structural modification as compared with the general structure above.
- an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and/or substitution (e.g., of the amino group, the carboxylic acid group, one or more protons, and/or the hydroxyl group) as compared with the general structure.
- such modification may, for example, alter the circulating half-life of a polypeptide containing the modified amino acid as compared with one containing an otherwise identical unmodified amino acid.
- such modification does not significantly alter a relevant activity of a polypeptide containing the modified amino acid, as compared with one containing an otherwise identical unmodified amino acid.
- the term “amino acid” may be used to refer to a free amino acid; in some embodiments it may be used to refer to an amino acid residue of a polypeptide.
- an analog refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an “analog” shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways.
- an analog is a substance that can be generated from the reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance.
- an analog is or can be generated through performance of a synthetic process different from that used to generate the reference substance.
- Antibody agent' refers to an agent that specifically binds to a particular antigen. In some embodiments, the term encompasses a polypeptide or polypeptide complex that includes immunoglobulin structural elements sufficient to confer specific binding.
- an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as a complementarity determining region (CDR); in some embodiments an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and/or at least one light chain CDR) that is substantially identical to one found in a reference antibody. In some embodiments an included CDR is substantially identical to a reference CDR in that it is either identical in sequence or contains between 1-5 amino acid substitutions as compared with the reference CDR.
- CDR complementarity determining region
- an included CDR is substantially identical to a reference CDR in that it shows at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR.
- an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR.
- an antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art as an immunoglobulin variable domain.
- an antibody agent is a polypeptide protein having a binding domain which is homologous or largely homologous to an immunoglobulin-binding domain.
- an antibody agent may be or comprise a polyclonal antibody preparation.
- an antibody agent may be or comprise a monoclonal antibody preparation.
- an antibody agent may include one or more constant region sequences that are characteristic of a particular organism, such as a camel, human, mouse, primate, rabbit, rat; in many embodiments, an antibody agent may include one or more constant region sequences that are characteristic of a human. In some embodiments, an antibody agent may include one or more sequence elements that would be recognized by one skilled in the art as a humanized sequence, a primatized sequence, a chimeric sequence, etc. In some embodiments, an antibody agent may be a canonical antibody (e.g., may comprise two heavy chains and two light chains).
- an antibody agent may be in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multi- specific antibodies (e.g., Zybodies®, etc); antibody fragments such as Fab fragments, Fab’ fragments, F(ab’)2 fragments, Fd’ fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide- Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); cameloid antibodies; masked antibodies (e.g., Probodies®); Small Modular ImmunoPharmaceuticals (“SMIPsTM ); single chain or Tandem diabodies (TandAb®); VHHs; Anticalins®; Nanobodies® minibodies; BiTE®s; ankyrin repeat proteins or DARPINs®; Avimers®; DARTs; TCR-like antibodies;, Adnectins®;
- an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally.
- an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload [e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc], or other pendant group [e.g., poly-ethylene glycol, etc.].
- Associated Two events or entities are “associated” with one another, as that term is used herein, if the presence, level, degree, type and/or form of one is correlated with that of the other.
- a particular entity e.g., polypeptide, genetic signature, metabolite, microbe, etc
- a particular disease, disorder, or condition if its presence, level and/or form correlates with incidence of, susceptibility to, severity of, stage of, etc the disease, disorder, or condition (e.g., across a relevant population).
- two or more entities are physically “associated” with one another if they interact, directly or indirectly, so that they are and/or remain in physical proximity with one another.
- two or more entities that are physically associated with one another are covalently linked to one another; in some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another but are non-covalently associated, for example by means of hydrogen bonds, van der Waals interaction, hydrophobic interactions, magnetism, and combinations thereof.
- Binding typically refers to a non- covalent association between or among two or more entities. “Direct” binding involves physical contact between entities or moieties; indirect binding involves physical interaction by way of physical contact with one or more intermediate entities. Binding between two or more entities can typically be assessed in any of a variety of contexts - including where interacting entities or moieties are studied in isolation or in the context of more complex systems (e.g., while covalently or otherwise associated with a carrier entity and/or in a biological system or cell). Binding between two entities may be considered “specific” if, under the conditions assessed, the relevant entities are more likely to associate with one another than with other available binding partners.
- biological sample typically refers to a sample obtained or derived from a biological source (e.g., a tissue or organism or cell culture) of interest, as described herein.
- a source of interest comprises an organism, such as an animal or human.
- a biological sample is or comprises biological tissue or fluid.
- a biological sample may be or comprise bone marrow; blood; blood cells; ascites; tissue or fine needle biopsy samples; cell-containing body fluids; free floating nucleic acids; sputum; saliva; urine; cerebrospinal fluid, peritoneal fluid; pleural fluid; feces; lymph; gynecological fluids; skin swabs; vaginal swabs; oral swabs; nasal swabs; washings or lavages such as a ductal lavages or broncheoalveolar lavages; aspirates; scrapings; bone marrow specimens; tissue biopsy specimens; surgical specimens; feces, other body fluids, secretions, and/or excretions; and/or cells therefrom, etc.
- a biological sample is or comprises cells obtained from an individual.
- obtained cells are or include cells from an individual from whom the sample is obtained.
- a sample is a “primary sample” obtained directly from a source of interest by any appropriate means.
- a primary biological sample is obtained by methods selected from the group consisting of biopsy (e.g ., fine needle aspiration or tissue biopsy), surgery, collection of body fluid (e.g., blood, lymph, feces etc.), etc.
- sample refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane.
- processing e.g., by removing one or more components of and/or by adding one or more agents to
- a primary sample For example, filtering using a semi-permeable membrane.
- Such a “processed sample” may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and/or purification of certain components, etc.
- Combination therapy refers to those situations in which a subject is simultaneously exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents).
- the two or more regimens may be administered simultaneously; in some embodiments, such regimens may be administered sequentially (e.g., all “doses” of a first regimen are administered prior to administration of any doses of a second regimen); in some embodiments, such agents are administered in overlapping dosing regimens.
- “administration” of combination therapy may involve administration of one or more agent(s) or modality(ies) to a subject receiving the other agent(s) or modality(ies) in the combination.
- combination therapy does not require that individual agents be administered together in a single composition (or even necessarily at the same time), although in some embodiments, two or more agents, or active moieties thereof, may be administered together in a combination composition, or even in a combination compound (e.g., as part of a single chemical complex or covalent entity).
- Comparable refers to two or more agents, entities, situations, sets of conditions, etc., that may not be identical to one another but that are sufficiently similar to permit comparison there between so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed.
- comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features.
- the term “corresponding to” refers to a relationship between two or more entities.
- the term “corresponding to” may be used to designate the position/identity of a structural element in a compound or composition relative to another compound or composition (e.g., to an appropriate reference compound or composition).
- a monomeric residue in a polymer e.g., an amino acid residue in a polypeptide or a nucleic acid residue in a polynucleotide
- a residue in an appropriate reference polymer may be identified as “corresponding to” a residue in an appropriate reference polymer.
- residues in a polypeptide are often designated using a canonical numbering system based on a reference related polypeptide, so that an amino acid "corresponding to" a residue at position 190, for example, need not actually be the 190 th amino acid in a particular amino acid chain but rather corresponds to the residue found at 190 in the reference polypeptide; those of ordinary skill in the art readily appreciate how to identify "corresponding" amino acids.
- sequence alignment strategies including software programs such as, for example, BLAST, CS- BLAST, CUSASW++, DIAMOND, FASTA, GGSEARCH/GLSEARCH, Genoogle, HMMER, HHpred/HHsearch, IDF, Infernal, KLAST, USEARCH, parasail, PSI-BLAST, PSI-Search, ScalaBLAST, Sequilab, SAM, SSEARCH, SWAPHI, SWAPHI-LS, SWIMM, or SWIPE that can be utilized, for example, to identify “corresponding” residues in polypeptides and/or nucleic acids in accordance with the present disclosure.
- software programs such as, for example, BLAST, CS- BLAST, CUSASW++, DIAMOND, FASTA, GGSEARCH/GLSEARCH, Genoogle, HMMER, HHpred/HHsearch, IDF, Infernal, KLAST, USEARCH, parasail, PSI-BLAST, PSI-Search,
- corresponding to may be used to describe an event or entity that shares a relevant similarity with another event or entity (e.g., an appropriate reference event or entity).
- a gene or protein in one organism may be described as “corresponding to” a gene or protein from another organism in order to indicate, in some embodiments, that it plays an analogous role or performs an analogous function and/or that it shows a particular degree of sequence identity or homology, or shares a particular characteristic sequence element.
- the term “designed” refers to an agent (i) whose structure is or was selected by the hand of man; (ii) that is produced by a process requiring the hand of man; and/or (iii) that is distinct from natural substances and other known agents.
- Dosing regimen may be used to refer to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time.
- a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses.
- a dosing regimen comprises a plurality of doses each of which is separated in time from other doses.
- individual doses are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses.
- all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).
- Engineered refers to the aspect of having been manipulated by the hand of man.
- a polynucleotide is considered to be “engineered” when two or more sequences that are not linked together in that order in nature are manipulated by the hand of man to be directly linked to one another in the engineered polynucleotide and/or when a particular residue in a polynucleotide is non-naturally occurring and/or is caused through action of the hand of man to be linked with an entity or moiety with which it is not linked in nature.
- epitope refers to a moiety that is specifically recognized by an immunoglobulin (e.g., antibody or receptor) binding component.
- an epitope is comprised of a plurality of chemical atoms or groups on an antigen.
- such chemical atoms or groups are surface-exposed when the antigen adopts a relevant three-dimensional conformation.
- such chemical atoms or groups are physically near to each other in space when the antigen adopts such a conformation.
- at least some such chemical atoms are groups are physically separated from one another when the antigen adopts an alternative conformation (e.g., is linearized).
- a gene product can be a transcript.
- a gene product can be a polypeptide.
- expression of a nucleic acid sequence involves one or more of the following: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, etc); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
- composition refers to an active agent, formulated together with one or more pharmaceutically acceptable carriers.
- active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population.
- pharmaceutical compositions may be specially formulated for parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation.
- Polypeptide As used herein refers to a polymeric chain of amino acids.
- a polypeptide has an amino acid sequence that occurs in nature.
- a polypeptide has an amino acid sequence that does not occur in nature.
- a polypeptide has an amino acid sequence that is engineered in that it is designed and/or produced through action of the hand of man.
- a polypeptide may comprise or consist of natural amino acids, non-natural amino acids, or both.
- a polypeptide may comprise or consist of only natural amino acids or only non-natural amino acids.
- a polypeptide may comprise D-amino acids, L-amino acids, or both.
- a polypeptide may comprise only D-amino acids. In some embodiments, a polypeptide may comprise only L-amino acids. In some embodiments, a polypeptide may include one or more pendant groups or other modifications, e.g., modifying or attached to one or more amino acid side chains, at the polypeptide’s N-terminus, at the polypeptide’s C-terminus, or any combination thereof. In some embodiments, such pendant groups or modifications may be selected from the group consisting of acetylation, amidation, lipidation, methylation, pegylation, etc., including combinations thereof. In some embodiments, a polypeptide may be cyclic, and/or may comprise a cyclic portion.
- a polypeptide is not cyclic and/or does not comprise any cyclic portion.
- a polypeptide is linear.
- a polypeptide may be or comprise a stapled polypeptide.
- the term “polypeptide” may be appended to a name of a reference polypeptide, activity, or structure; in such instances it is used herein to refer to polypeptides that share the relevant activity or structure and thus can be considered to be members of the same class or family of polypeptides.
- exemplary polypeptides within the class whose amino acid sequences and/or functions are known; in some embodiments, such exemplary polypeptides are reference polypeptides for the polypeptide class or family.
- a member of a polypeptide class or family shows significant sequence homology or identity with, shares a common sequence motif (e.g., a characteristic sequence element) with, and/or shares a common activity (in some embodiments at a comparable level or within a designated range) with a reference polypeptide of the class; in some embodiments with all polypeptides within the class).
- a member polypeptide shows an overall degree of sequence homology or identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more and/or includes at least one region (e.g., a conserved region that may in some embodiments be or comprise a characteristic sequence element) that shows very high sequence identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99%.
- a conserved region that may in some embodiments be or comprise a characteristic sequence element
- Such a conserved region usually encompasses at least 3-4 and often up to 20 or more amino acids; in some embodiments, a conserved region encompasses at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids.
- a relevant polypeptide may comprise or consist of a fragment of a parent polypeptide.
- Prevent or prevention refers to reducing the risk of developing the disease, disorder and/or condition and/or to delaying onset of one or more characteristics or symptoms of the disease, disorder or condition. Prevention may be considered complete when onset of a disease, disorder or condition has been delayed for a predefined period of time.
- Reference As used herein describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and/or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and/or comparison to a particular possible reference or control.
- risk of a disease, disorder, and/or condition refers to a likelihood that a particular individual will develop the disease, disorder, and/or condition. In some embodiments, risk is expressed as a percentage. In some embodiments, risk is from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 up to 100%. In some embodiments risk is expressed as a risk relative to a risk associated with a reference sample or group of reference samples. In some embodiments, a reference sample or group of reference samples have a known risk of a disease, disorder, condition and/or event. In some embodiments a reference sample or group of reference samples are from individuals comparable to a particular individual.
- relative risk is 0,1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.
- risk may reflect one or more genetic attributes, e.g., which may predispose an individual toward development (or not) of a particular disease, disorder and/or condition.
- risk may reflect one or more epigenetic events or attributes and/or one or more lifestyle or environmental events or attributes.
- Susceptible to An individual who is “susceptible to” a disease, disorder, and/or condition is one who has a higher risk of developing the disease, disorder, and/or condition than does a member of the general public.
- an individual who is susceptible to a disease, disorder and/or condition may not have been diagnosed with the disease, disorder, and/or condition.
- an individual who is susceptible to a disease, disorder, and/or condition may exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may not exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.
- Vaccination refers to the administration of a composition intended to generate an immune response, for example to a disease-associated (e.g., disease- causing) agent.
- vaccination can be administered before, during, and/or after exposure to a disease-associated agent, and in certain embodiments, before, during, and/or shortly after exposure to the agent.
- vaccination includes multiple administrations, appropriately spaced in time, of a vaccine composition.
- vaccination generates an immune response to an infectious agent.
- vaccination generates an immune response to a tumor; in some such embodiments, vaccination is “personalized” in that it is partly or wholly directed to epitope(s) (e.g., which may be or include one or more neoepitopes) determined to be present in a particular individual’s tumors.
- epitope(s) e.g., which may be or include one or more neoepitopes
- Variant As used herein in the context of molecules, e.g., nucleic acids, proteins, or small molecules, the term “variant” refers to a molecule that shows significant structural identity with a reference molecule but differs structurally from the reference molecule, e.g., in the presence or absence or in the level of one or more chemical moieties as compared to the reference entity. In some embodiments, a variant also differs functionally from its reference molecule. In general, whether a particular molecule is properly considered to be a “variant” of a reference molecule is based on its degree of structural identity with the reference molecule. As will be appreciated by those skilled in the art, any biological or chemical reference molecule has certain characteristic structural elements.
- a variant by definition, is a distinct molecule that shares one or more such characteristic structural elements but differs in at least one aspect from the reference molecule.
- a variant polypeptide or nucleic acid may differ from a reference polypeptide or nucleic acid as a result of one or more differences in amino acid or nucleotide sequence and/or one or more differences in chemical moieties (e.g ., carbohydrates, lipids, phosphate groups) that are covalently components of the polypeptide or nucleic acid (e.g., that are attached to the polypeptide or nucleic acid backbone).
- moieties e.g ., carbohydrates, lipids, phosphate groups
- a variant polypeptide or nucleic acid shows an overall sequence identity with a reference polypeptide or nucleic acid that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99%.
- a variant polypeptide or nucleic acid does not share at least one characteristic sequence element with a reference polypeptide or nucleic acid.
- a reference polypeptide or nucleic acid has one or more biological activities.
- a variant polypeptide or nucleic acid shares one or more of the biological activities of the reference polypeptide or nucleic acid.
- a variant polypeptide or nucleic acid lacks one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid shows a reduced level of one or more biological activities as compared to the reference polypeptide or nucleic acid. In some embodiments, a polypeptide or nucleic acid of interest is considered to be a “variant” of a reference polypeptide or nucleic acid if it has an amino acid or nucleotide sequence that is identical to that of the reference but for a small number of sequence alterations at particular positions.
- a variant polypeptide or nucleic acid comprises about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 substituted residues as compared to a reference.
- a variant polypeptide or nucleic acid comprises a very small number (e.g., fewer than about 5, about 4, about 3, about 2, or about 1) number of substituted, inserted, or deleted, functional residues (i.e., residues that participate in a particular biological activity) relative to the reference.
- a variant polypeptide or nucleic acid comprises not more than about 5, about 4, about 3, about 2, or about 1 addition or deletion, and, in some embodiments, comprises no additions or deletions, as compared to the reference.
- a variant polypeptide or nucleic acid comprises fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly fewer than about 5, about 4, about 3, or about 2 additions or deletions as compared to the reference.
- a reference polypeptide or nucleic acid is one found in nature.
- RNA polynucleotide comprising (i) a 5’ cap that is or comprises a capl structure, e.g., as disclosed herein; (ii) a 5’ UTR sequence comprising a cap proximal sequence, e.g., as disclosed herein; and (iii) a sequence encoding a payload.
- compositions and medical preparations comprising the same, as well as methods of making and using the same.
- translation efficiency of an RNA encoding a payload, and/or expression of a payload encoded by an RNA can be improved with an RNA polynucleotide comprising a 5’ cap comprising a Capl structure disclosed herein, e.g., r 7,3 °Gppp(mi 2 °)ApG cap; a 5’ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload.
- absence of a self-hybridizing sequence in an RNA polynucleotide encoding a payload can further improve translation efficiency of an RNA encoding a payload, and/or expression of a payload encoded by an RNA payload.
- polynucleotide refers to DNA and RNA such as genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules.
- a nucleic acid may be single- stranded or double-stranded.
- RNA includes in vitro transcribed RNA (IVT RNA) or synthetic RNA. According to the invention, a polynucleotide is preferably isolated.
- nucleic acids may be comprised in a vector.
- vector includes any vectors known to the skilled person including plasmid vectors, cosmid vectors, phage vectors such as lambda phage, viral vectors such as retroviral, adenoviral or baculoviral vectors, or artificial chromosome vectors such as bacterial artificial chromosomes (BAC), yeast artificial chromosomes (YAC), or PI artificial chromosomes (PAC).
- a vector may be an expression vector; alternatively or additionally, in some embodiments, a vector may be a cloning vector.
- an expression vector may be, for example, a plasmid; alternatively or additionally, in some embodiments, an expression vector may be a viral vector.
- an expression vector will contain a desired coding sequence and appropriate other sequences necessary for the expression of the operably linked coding sequence in a particular host organism (e.g., bacteria, yeast, plant, insect, or mammal) or in in vitro expression systems.
- Cloning vectors are generally used to engineer and amplify a certain desired fragment (typically a DNA fragment), and may lack functional sequences needed for expression of the desired fragment(s).
- a nucleic acid as described and/or utilized herein may be or comprise recombinant and/or isolated molecules.
- RNA typically refers to a nucleic acid molecule which includes ribonucleotide residues.
- an RNA contains all or a majority of ribonucleotide residues.
- ribonucleotide refers to a nucleotide with a hydroxyl group at the 2'-position of a b-D- ribofuranosyl group.
- an RNA may be partly or fully double stranded RNA; in some embodiments, an RNA may comprise two or more distinct nucleic acid strands (e.g., separate molecules) that are partly or fully hybridized with one another.
- an RNA is a single strand, which may in some embodiments, self-hybridize or otherwise fold into secondary and/or tertiary structures. In some embodiments, an RNA as described and/or utilized herein does not self-hybridize, at least with respect to certain sequences as described herein.
- an RNA may be an isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, and/or a modified RNA (where the term “modified” is understood to indicate that one or more residues or other structural elements of the RNA differs from naturally occurring RNA; for example, in some embodiments, a modified RNA differs by the addition, deletion, substitution and/or alteration of one or more nucleotides and/or by one or more moieties or characteristics of a nucleotide- e.g., of a nucleoside or of a backbone structure or linkage).
- a modification may be or comprise addition of non-nucleotide material to internal RNA nucleotides or to the end(s) of RNA. It is also contemplated herein that nucleotides in RNA (e.g., in a modified RNA) may be non-standard nucleotides, such as chemically synthesized nucleotides or deoxynucleotides. For the present disclosure, these altered RNAs are considered analogs of naturally-occurring RNA.
- an RNA is or comprises messenger RNA (mRNA) that relates to an RNA transcript which encodes a polypeptide.
- mRNA messenger RNA
- an RNA disclosed herein comprises: a 5’ cap comprising a 5’ cap disclosed herein; a 5' untranslated region comprising a cap proximal sequence (5'-UTR), a sequence encoding a payload (e.g., a polypeptide); a 3' untranslated region (3'-UTR); and/or a polyadenylate (Poly A) sequence.
- an RNA disclosed herein comprises the following components in 5’ to 3’ orientation: a 5’ cap comprising a 5’ cap disclosed herein; a 5' untranslated region comprising a cap proximal sequence (5'-UTR), a sequence encoding a payload (e.g., a polypeptide); a 3' untranslated region (3'-UTR); and a PolyA sequence.
- an RNA is produced by in vitro transcription or chemical synthesis.
- an mRNA is produced by in vitro transcription using a DNA template where DNA refers to a nucleic acid that contains deoxyribonucleotides.
- an RNA disclosed herein is in vitro transcribed RNA (IVT-RNA) and may be obtained by in vitro transcription of an appropriate DNA template.
- the promoter for controlling transcription can be any promoter for any RNA polymerase.
- a DNA template for in vitro transcription may be obtained by cloning of a nucleic acid, in particular cDNA, and introducing it into an appropriate vector for in vitro transcription.
- the cDNA may be obtained by reverse transcription of RNA.
- an RNA is "replicon RNA” or simply a “replicon”, in particular "self-replicating RNA” or “self-amplifying RNA”.
- a replicon or self- replicating RNA is derived from or comprises elements derived from a ssRNA virus, in particular a positive- stranded ssRNA vims such as an alphavirus.
- Alphavimses are typical representatives of positive-stranded RNA viruses. Alphavimses replicate in the cytoplasm of infected cells (for review of the alphaviral life cycle see Jose et al., Future Microbiol., 2009, vol. 4, pp. 837-856).
- the total genome length of many alphavimses typically ranges between 11,000 and 12,000 nucleotides, and the genomic RNA typically has a 5’-cap, and a 3’ poly(A) tail.
- the genome of alphavimses encodes non-stmctural proteins (involved in transcription, modification and replication of viral RNA and in protein modification) and structural proteins (forming the vims particle). There are typically two open reading frames (ORFs) in the genome.
- the four non-stmctural proteins are typically encoded together by a first ORF beginning near the 5' terminus of the genome, while alphavims stmctural proteins are encoded together by a second ORF which is found downstream of the first ORF and extends near the 3’ terminus of the genome.
- the first ORF is larger than the second ORF, the ratio being roughly 2:1.
- RNA polynucleotide that resembles eukaryotic messenger RNA (mRNA; Gould et al., 2010, Antiviral Res., vol. 87 pp. 111-124).
- mRNA eukaryotic messenger RNA
- the (+) stranded genomic RNA directly acts like a messenger RNA for the translation of the open reading frame encoding the non- structural poly-protein (nsP1234).
- Alphavims-derived vectors have been proposed for delivery of foreign genetic information into target cells or target organisms.
- the open reading frame encoding alphaviral structural proteins is replaced by an open reading frame encoding a protein of interest.
- Alphavims-based trans-replication systems rely on alphavirus nucleotide sequence elements on two separate nucleic acid molecules: one nucleic acid molecule encodes a viral replicase, and the other nucleic acid molecule is capable of being replicated by said replicase in trans (hence the designation trans-replication system).
- Trans-replication requires the presence of both these nucleic acid molecules in a given host cell.
- the nucleic acid molecule capable of being replicated by the replicase in trans must comprise certain alphaviral sequence elements to allow recognition and RNA synthesis by the alphaviral replicase.
- an RNA described herein may have modified nucleosides.
- an RNA comprises a modified nucleoside in place of at least one (e.g., every) uridine.
- uracil describes one of the nucleobases that can occur in the nucleic acid of RNA.
- the structure of uracil is:
- uridine describes one of the nucleosides that can occur in RNA.
- the structure of uridine is:
- UTP (uridine 5 ’-triphosphate) has the following structure:
- Pseudo-UTP (pseudouridine-5 ’-triphosphate) has the following structure:
- Pseudouridine is one example of a modified nucleoside that is an isomer of uridine, where the uracil is attached to the pentose ring via a carbon-carbon bond instead of a nitrogen-carbon glycosidic bond.
- Nl-methylpseudouridine (m 1 Y), which has the structure:
- Nl-methylpseudouridine-5’ -triphosphate (in 1 YTR) has the following structure:
- m5U 5-methyluridine
- one or more uridine in an RNA described herein is replaced by a modified nucleoside.
- a modified nucleoside is a modified uridine.
- an RNA comprises a modified nucleoside in place of at least one uridine. In some embodiments, an RNA comprises a modified nucleoside in place of each uridine.
- a modified nucleoside is independently selected from pseudouridine (Y), Nl-methylpseudouridine (m 1 Y), and 5-methyluridine (m5U).
- a modified nucleoside comprises pseudouridine (Y).
- a modified nucleoside comprises N1 -methyl-pseudouridine ( 1 Y).
- a modified nucleoside comprises 5-methyluridine (m5U).
- an RNA may comprise more than one type of modified nucleoside, and a modified nucleosides are independently selected from pseudouridine (Y), Nl-methylpseudouridine (ihIY), and 5- methyluridine (m5U).
- a modified nucleosides comprise pseudouridine (Y) and Nl-methylpseudouridine (ihIY). In some embodiments, a modified nucleosides comprise pseudouridine (Y) and 5-methyluridine (m5U). In some embodiments, a modified nucleosides comprise Nl-methylpseudouridine (ihIY) and 5-methyluridine (m5U). In some embodiments, a modified nucleosides comprise pseudouridine (Y), Nl-methylpseudouridine (ihIY), and 5-methyluridine (m5U).
- a modified nucleoside replacing one or more, e.g., all, uridine in the RNA may be any one or more of 3 -methyl-uridine (m 3 U), 5-methoxy-uridine (mo 5 U), 5-aza- uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s 2 U), 4-thio-uridine (s 4 U), 4-thio- pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho 5 U), 5-aminoallyl-uridine, 5-halo- uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), uridine 5-oxyacetic acid (cmo 5 U), uridine 5- oxyacetic acid methyl ester (mcmo 5 U), 5-carboxymethyl-uridine (cm 5 U), 1-carboxymethyl- pseudouridine, 5-carboxy hydroxymethyl-uridine (chm 5 U).
- an RNA comprises other modified nucleosides or comprises further modified nucleosides, e.g., modified cytidine.
- modified cytidine e.g., in an RNA 5- methylcytidine is substituted partially or completely, preferably completely, for cytidine.
- an RNA comprises 5-methylcytidine and one or more selected from pseudouridine (y), N1 -methyl-pseudouridine (ih ⁇ y), and 5-methyl-uridine (m5U).
- an RNA comprises 5-methylcytidine and N1 -methyl-pseudouridine (ih ⁇ y).
- the RNA comprises 5-methylcytidine in place of each cytidine and N1 -methyl-pseudouridine (ml ⁇
- an RNA encoding a payload is expressed in cells of a subject treated to provide a payload, e.g., vaccine antigen.
- the RNA is transiently expressed in cells of the subject.
- the RNA is in vitro transcribed RNA.
- expression of a payload, e.g., a vaccine antigen is at the cell surface.
- a payload, e.g., a vaccine antigen is expressed and presented in the context of MHC.
- expression of a payload, e.g., a vaccine antigen is into the extracellular space, i.e., the vaccine antigen is secreted.
- transcription relates to a process, wherein the genetic code in a DNA sequence is transcribed into RNA. Subsequently, the RNA may be translated into peptide or protein.
- the term “transcription” comprises “in vitro transcription”, wherein the term “in vitro transcription” relates to a process wherein RNA, in particular mRNA, is in vitro synthesized in a cell-free system, preferably using appropriate cell extracts.
- cloning vectors are applied for the generation of transcripts. These cloning vectors are generally designated as transcription vectors and are according to the present invention encompassed by the term "vector”.
- the RNA used in the present invention preferably is in vitro transcribed RNA (IVT-RNA) and may be obtained by in vitro transcription of an appropriate DNA template.
- the promoter for controlling transcription can be any promoter for any RNA polymerase.
- RNA polymerases are the T7, T3, and SP6 RNA polymerases.
- the in vitro transcription according to the invention is controlled by a T7 or SP6 promoter.
- a DNA template for in vitro transcription may be obtained by cloning of a nucleic acid, in particular cDNA, and introducing it into an appropriate vector for in vitro transcription.
- the cDNA may be obtained by reverse transcription of RNA.
- RNA With respect to RNA, the term "expression” or “translation” relates to the process in the ribosomes of a cell by which a strand of mRNA directs the assembly of a sequence of amino acids to make a peptide or protein.
- RNA is delivered to a target cell.
- at least a portion of the RNA is delivered to the cytosol of the target cell.
- the RNA is translated by the target cell to produce the peptide or protein it encodes.
- the target cell is a spleen cell.
- the target cell is an antigen presenting cell such as a professional antigen presenting cell in the spleen.
- the target cell is a dendritic cell or macrophage.
- RNA particles such as RNA lipid particles described herein may be used for delivering RNA to such target cell. Accordingly, the present disclosure also relates to a method for delivering RNA to a target cell in a subject comprising the administration of the RNA particles described herein to the subject.
- the RNA is delivered to the cytosol of the target cell.
- the RNA is translated by the target cell to produce the peptide or protein encoded by the RNA.
- Encoding refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
- a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
- Both the coding strand the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
- nucleic acid compositions described herein are characterized by (e.g., when administered to a subject) sustained expression of an encoded polypeptide.
- compositions are characterized in that, when administered to a human, they achieve detectable polypeptide expression in a biological sample (e.g., serum) from such human and, in some embodiments, such expression persists for a period of time that is at least at least 36 hours or longer, including, e.g., at least 48 hours, at least 60 hours, at least 72 hours, at least 96 hours, at least 120 hours, at least 148 hours, or longer.
- the RNA encoding vaccine antigen to be administered according to the invention is non-immunogenic.
- RNA encoding immunostimulant may be administered according to the invention to provide an adjuvant effect.
- the RNA encoding immunostimulant may be standard RNA or non-immunogenic RNA.
- non-immunogenic RNA refers to RNA that does not induce a response by the immune system upon administration, e.g., to a mammal, or induces a weaker response than would have been induced by the same RNA that differs only in that it has not been subjected to the modifications and treatments that render the non-immunogenic RNA non- immunogenic, i.e., than would have been induced by standard RNA (stdRNA).
- stdRNA standard RNA
- non-immunogenic RNA which is also termed modified RNA (modRNA) herein, is rendered non-immunogenic by incorporating modified nucleosides suppressing RNA-mediated activation of innate immune receptors into the RNA and removing double-stranded RNA (dsRNA).
- modified RNA dsRNA
- any modified nucleoside may be used as long as it lowers or suppresses immunogenicity of the RNA.
- Particularly preferred are modified nucleosides that suppress RNA- mediated activation of innate immune receptors.
- the modified nucleosides comprises a replacement of one or more uridines with a nucleoside comprising a modified nucleobase.
- the modified nucleobase is a modified uracil.
- the nucleoside comprising a modified nucleobase is selected from the group consisting of 3 -methyl-uridine (m 3 U), 5-methoxy-uridine (mo 5 U), 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s 2 U), 4-thio-uridine (s 4 U), 4-thio-pseudouridine, 2-thio- pseudouridine, 5-hydroxy-uridine (ho 5 U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo- uridine or 5-bromo-uridine), uridine 5-oxyacetic acid (cmo 5 U), uridine 5-oxyacetic acid methyl ester (mcmo 5 U), 5-carboxy methyl-uridine (cm 5 U), 1-carboxymethyl-pseudouridine, 5- carboxyhydroxymethyl-uridine (chm 5 U), 5-carboxyhydroxymethyl-uridine
- the nucleoside comprising a modified nucleobase is pseudouridine (y), N1 -methyl- pseudouridine (ih ⁇ y) or 5 -methyl-uridine (m5U), in particular N1 -methyl-pseudouridine.
- the replacement of one or more uridines with a nucleoside comprising a modified nucleobase comprises a replacement of at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the uridines.
- IVTT in vitro transcription
- dsRNA double- stranded RNA
- dsRNA induces inflammatory cytokines and activates effector enzymes leading to protein synthesis inhibition.
- dsRNA can be removed from RNA such as IVT RNA, for example, by ion-pair reversed phase HPLC using a non-porous or porous C-18 polystyrene-divinylbenzene (PS-DVB) matrix.
- PS-DVB polystyrene-divinylbenzene
- an enzymatic based method using E. coli RNaselll that specifically hydrolyzes dsRNA but not ssRNA, thereby eliminating dsRNA contaminants from IVT RNA preparations can be used.
- dsRNA can be separated from ssRNA by using a cellulose material.
- an RNA preparation is contacted with a cellulose material and the ssRNA is separated from the cellulose material under conditions which allow binding of dsRNA to the cellulose material and do not allow binding of ssRNA to the cellulose material.
- remove or “removal” refers to the characteristic of a population of first substances, such as non-immunogenic RNA, being separated from the proximity of a population of second substances, such as dsRNA, wherein the population of first substances is not necessarily devoid of the second substance, and the population of second substances is not necessarily devoid of the first substance.
- a population of first substances characterized by the removal of a population of second substances has a measurably lower content of second substances as compared to the non-separated mixture of first and second substances.
- the removal of dsRNA from non-immunogenic RNA comprises a removal of dsRNA such that less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.3%, or less than 0.1% of the RNA in the non- immunogenic RNA composition is dsRNA.
- the non-immunogenic RNA is free or essentially free of dsRNA.
- the non-immunogenic RNA composition comprises a purified preparation of single- stranded nucleoside modified RNA.
- the purified preparation of single- stranded nucleoside modified RNA is substantially free of double stranded RNA (dsRNA).
- the purified preparation is at least 90%, at least 91%, at least 92%, at least 93 %, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% single stranded nucleoside modified RNA, relative to all other nucleic acid molecules (DNA, dsRNA, etc.).
- the non-immunogenic RNA is translated in a cell more efficiently than standard RNA with the same sequence.
- translation is enhanced by a factor of 2-fold relative to its unmodified counterpart.
- translation is enhanced by a 3 -fold factor.
- translation is enhanced by a 4-fold factor.
- translation is enhanced by a 5-fold factor.
- translation is enhanced by a 6-fold factor.
- translation is enhanced by a 7-fold factor.
- translation is enhanced by an 8-fold factor.
- translation is enhanced by a 9-fold factor.
- translation is enhanced by a 10- fold factor.
- translation is enhanced by a 15-fold factor. In some embodiments, translation is enhanced by a 20-fold factor. In some embodiments, translation is enhanced by a 50-fold factor. In some embodiments, translation is enhanced by a 100-fold factor. In some embodiments, translation is enhanced by a 200-fold factor. In some embodiments, translation is enhanced by a 500-fold factor. In some embodiments, translation is enhanced by a 1000-fold factor. In some embodiments, translation is enhanced by a 2000-fold factor. In some embodiments, the factor is 10- 1000-fold. In some embodiments, the factor is 10- 100-fold. In some embodiments, the factor is 10-200-fold. In some embodiments, the factor is 10-300-fold.
- the factor is 10-500-fold. In some embodiments, the factor is 20- 1000-fold. In some embodiments, the factor is 30- 1000-fold. In some embodiments, the factor is 50- 1000- fold. In some embodiments, the factor is 100- 1000-fold. In some embodiments, the factor is 200- 1000-fold. In some embodiments, translation is enhanced by any other significant amount or range of amounts.
- the non-immunogenic RNA exhibits significantly less innate immunogenicity than standard RNA with the same sequence. In some embodiments, the non- immunogenic RNA exhibits an innate immune response that is 2-fold less than its unmodified counterpart. In some embodiments, innate immunogenicity is reduced by a 3-fold factor. In some embodiments, innate immunogenicity is reduced by a 4-fold factor. In some embodiments, innate immunogenicity is reduced by a 5-fold factor. In some embodiments, innate immunogenicity is reduced by a 6-fold factor. In some embodiments, innate immunogenicity is reduced by a 7-fold factor. In some embodiments, innate immunogenicity is reduced by a 8-fold factor.
- innate immunogenicity is reduced by a 9-fold factor. In some embodiments, innate immunogenicity is reduced by a 10-fold factor. In some embodiments, innate immunogenicity is reduced by a 15-fold factor. In some embodiments, innate immunogenicity is reduced by a 20- fold factor. In some embodiments, innate immunogenicity is reduced by a 50-fold factor. In some embodiments, innate immunogenicity is reduced by a 100-fold factor. In some embodiments, innate immunogenicity is reduced by a 200-fold factor. In some embodiments, innate immunogenicity is reduced by a 500-fold factor. In some embodiments, innate immunogenicity is reduced by a 1000-fold factor. In some embodiments, innate immunogenicity is reduced by a 2000-fold factor.
- the term "exhibits significantly less innate immunogenicity" refers to a detectable decrease in innate immunogenicity.
- the term refers to a decrease such that an effective amount of the non-immunogenic RNA can be administered without triggering a detectable innate immune response.
- the term refers to a decrease such that the non-immunogenic RNA can be repeatedly administered without eliciting an innate immune response sufficient to detectably reduce production of the protein encoded by the non- immunogenic RNA.
- the decrease is such that the non-immunogenic RNA can be repeatedly administered without eliciting an innate immune response sufficient to eliminate detectable production of the protein encoded by the non-immunogenic RNA.
- Immunogenicity is the ability of a foreign substance, such as RNA, to provoke an immune response in the body of a human or other animal.
- the innate immune system is the component of the immune system that is relatively unspecific and immediate. It is one of two main components of the vertebrate immune system, along with the adaptive immune system.
- endogenous refers to any material from or produced inside an organism, cell, tissue or system.
- exogenous refers to any material introduced from or produced outside an organism, cell, tissue or system.
- expression is defined as the transcription and/or translation of a particular nucleotide sequence.
- a payload (e.g., a polypeptide) described herein is encoded by a coding sequence which is codon-optimized and/or the G/C content of which is increased compared to wild type coding sequence.
- one or more sequence regions of the coding sequence are codon-optimized and/or increased in the G/C content compared to the corresponding sequence regions of the wild type coding sequence.
- codon- optimization and/or increased the G/C content does not change the sequence of the encoded amino acid sequence.
- coding regions are preferably codon- optimized for optimal expression in a subject to be treated using an RNA polynucleotide described herein. Codon-optimization is based on the finding that the translation efficiency is also determined by a different frequency in the occurrence of tRNAs in cells. Thus, the sequence of RNA may be modified such that codons for which frequently occurring tRNAs are available are inserted in place of "rare codons".
- guanosine/cytidine (G/C) content of a coding region (e.g., of a payload sequence) of an RNA is increased compared to the G/C content of the corresponding coding sequence of a wild type RNA encoding the payload, wherein the amino acid sequence encoded by the RNA is preferably not modified compared to the amino acid sequence encoded by the wild type RNA.
- This modification of the RNA sequence is based on the fact that the sequence of any RNA region to be translated is important for efficient translation of that mRNA. Sequences having an increased G (guanosine)/C (cytidine) content are more stable than sequences having an increased A (adenosine)/U (uridine) content.
- codons which contain A and/or U nucleosides can be modified by substituting these codons by other codons, which code for the same amino acids but contain no A and/or U or contain a lower content of A and/or U nucleosides.
- G/C content of a coding region of an RNA described herein is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 55%, or even more compared to the G/C content of a coding region of a wild type RNA. 5’ cap
- caps include a Cap-0 (also referred herein as “CapO”), a Cap-1 (also referred herein as “Capl”), or Cap-2 (also referred herein as “Cap2”). See, e.g., Figure 1 of Ramanathan A et al., and Figure 1 of Decroly E et al.
- RNA refers to a structure found on the 5'-end of an RNA, e.g., mRNA, and generally includes a guanosine nucleotide connected to an RNA, e.g., mRNA, via a 5'- to 5'-triphosphate linkage (also referred to as Gppp or G(5')ppp(5')) ⁇
- a guanosine nucleoside included in a 5’ cap may be modified, for example, by methylation at one or more positions (e.g., at the 7-position) on a base (guanine), and/or by methylation at one or more positions of a ribose.
- a guanosine nucleoside included in a 5’ cap comprises a 3 ⁇ methylation at a ribose (3’OMeG). In some embodiments, a guanosine nucleoside included in a 5’ cap comprises methylation at the 7-position of guanine (m7G). In some embodiments, a guanosine nucleoside included in a 5’ cap comprises methylation at the 7-position of guanine and a 3’ O methylation at a ribose (m7(3’OMeG)).
- providing an RNA with a 5'-cap disclosed herein or a 5'-cap analog may be achieved by in vitro transcription, in which a 5'-cap is co-transcriptionally expressed into an RNA strand, or may be attached to an RNA post-transcriptionally using capping enzymes.
- co-transcriptional capping with a cap disclosed herein e.g., with a capl or a capl analog, improves the capping efficiency of an RNA compared to co- transcriptional capping with an appropriate reference comparator.
- improving capping efficiency can increase a translation efficiency and/or translation rate of an RNA, and/or increase expression of an encoded polypeptide.
- an RNA described herein comprises a 5 ’-cap or a 5’ cap analog, e.g., a CapO, a Capl or a Cap2.
- a provided RNA does not have uncapped 5'-triphosphates.
- an RNA may be capped with a 5'- cap analog.
- an RNA described herein comprises a CapO.
- an RNA described herein comprises a Capl, e.g., as described herein.
- an RNA described herein comprises a Cap2.
- a CapO structure comprises a guanosine nucleoside methylated at the 7-position of guanine (m7G).
- a CapO structure is connected to an RNA via a 5'- to 5'-triphosphate linkage and is also referred to herein as m7Gppp or m7G(5')ppp(5') ⁇
- a Capl structure comprises a guanosine nucleoside methylated at the 7-position of guanine (m7G) and a 2 ⁇ methylated first nucleotide in an RNA (2'OMeNi).
- a Capl structure is connected to an RNA via a 5'- to 5'-triphosphate linkage and is also referred to herein as m7Gppp(2'OMeNi) or m7G(5')ppp(5')(2'OMeNi).
- Ni is chosen from A, C, G, or U.
- Ni is A.
- Ni is C.
- Ni is G.
- Ni is U.
- a m7G(5')ppp(5')(2'OMeNi) Capl structure comprises a second nucleotide, N2 which is a cap proximal nucleotide at position 2 and is chosen from A, G, C, or U (m7G(5')ppp(5')(2'OMeNi)N 2 ).
- N21S A In some embodiments, N21S C. In some embodiments, N21S G. In some embodiments, N21S U.
- a capl structure is or comprises m7G(5')ppp(5')(2'OMeAi)pG 2 wherein A is a cap proximal nucleotide at position +1 and G is a cap proximal nucleotide at position +2, and has the following structure:
- a capl structure is or comprises m7G(5')ppp(5')(2'OMeAi)pU 2 wherein A is a cap proximal nucleotide at position 1 and U is a cap proximal nucleotide at position 2, and has the following structure:
- a capl structure is or comprises m7G(5')ppp(5')(2'OMeGi)pG 2 wherein G is a cap proximal nucleotide at position 1 and G is a cap proximal nucleotide at position 2, and has the following structure:
- a Capl structure comprises a guanosine nucleoside methylated at the 7-position of guanine (m7G) and one or more additional modifications, e.g., methylation on a ribose, and a 2 ⁇ methylated first nucleotide in an RNA.
- a Capl structure comprises a guanosine nucleoside methylated at the 7-position of guanine and a 3 ⁇ methylation at a ribose (m7(3’OMeG)); and a 2 ⁇ methylated first nucleotide in an RNA (2'OMeNi).
- a Capl structure is connected to an RNA via a 5'- to 5'- triphosphate linkage and is also referred to herein as m7(3’OMeG)ppp(2'OMeNi) or m7(3’OMeG)(5')ppp(5')(2'OMeNi).
- Ni is chosen from A, C, G, or U. In some embodiments, Ni is A. In some embodiments, Ni is C. In some embodiments, Ni is G. In some embodiments, Ni is U.
- a m7(3’oMeG)(5')ppp(5')(2'OMeNi) Capl structure comprises a second nucleotide, N2 which is a cap proximal nucleotide at position 2 and is chosen from A, G, C, or U (m7(3’OMeG)(5')ppp(5')(2'OMeNi)N 2 ).
- N 21S A In some embodiments, N21S C. In some embodiments, N21S G. In some embodiments, N21S U.
- a capl structure is or comprises m7(3'OMeG)(5')ppp(5')(2'OMeAi)pG2 wherein A is a cap proximal nucleotide at position 1 and G is a cap proximal nucleotide at position 2, and has the following structure:
- a capl structure is or comprises m7(3'OMeG)(5')ppp(5')(2'OMeGi)pG2 wherein G is a cap proximal nucleotide at position 1 and G is a cap proximal nucleotide at position 2, and has the following structure:
- a second nucleotide in a Capl structure can comprise one or more modifications, e.g., methylation.
- a Capl structure comprising a second nucleotide comprising a 2 ⁇ methylation is a Cap2 structure.
- an RNA polynucleotide comprising a Capl structure has increased translation efficiency, increased translation rate and/or increased expression of an encoded payload relative to an appropriate reference comparator.
- an RNA polynucleotide comprising a capl structure having m7(3'OMeG)(5')ppp(5')(2'OMeAi)pG2 wherein A is a cap proximal nucleotide at position 1 and G is a cap proximal nucleotide at position 2, has increased transaltion efficiency relative to an RNA polynucleotide comprising a capl structure having m7(3'OMeG)(5')ppp(5')(2'OMeG1)pG2 wherein Gi is a cap proximal nucleotide at position 1 and G2 is a cap proximal nucleotide at position 2.
- increased translation effieicny is assessed upon administration of an RNA polynucleotide to a cell or an organism.
- a cap analog used in an RNA polynucleotide is m2 7 ’ 3 -O Gppp(m1 2 - O )ApG (also sometimes referred to as m2 7 ’ 3 O G(5’)ppp(5’)m 2 -O ApG or m7(3'OMeG)(5')ppp(5')(2'OMeA)pG), which has the following structure:
- an RNA polynucleotide disclosed herein comprises a Cap shown in any one of Figures 3A-3I.
- an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 3A.
- an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 3B. In some embodiments, an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 3C. In some embodiments, an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 3D. In some embodiments, an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 3E. In some embodiments, an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 3F. In some embodiments, an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 3G. In some embodiments, an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 3H. In some embodiments, an RNA polynucleotide disclosed herein comprises a Cap shown in Figure 31.
- an RNA disclosed herein comprises a 5'-UTR.
- the term "untranslated region" or “UTR” relates to a region in a DNA molecule which is transcribed but is not translated into an amino acid sequence, or to the corresponding region in an RNA polynucleotide, such as an mRNA molecule.
- An untranslated region (UTR) can be present 5' (upstream) of an open reading frame (5'-UTR) and/or 3' (downstream) of an open reading frame (3'-UTR).
- a 5'-UTR, if present, is located at the 5' end, upstream of the start codon of a protein encoding region.
- a 5'-UTR is downstream of the 5'-cap (if present), e.g. directly adjacent to the 5'-cap.
- a 5’ UTR disclosed herein comprises a cap proximal sequence, e.g., as disclosed herein.
- a cap proximal sequence comprises a sequence adjacent to a 5’ cap.
- a cap proximal sequence comprises nucleotides in positions +1, +2, +3, +4, and/or +5 of an RNA polynucleotide.
- a Cap structure comprises one or more polynucleotides of a cap proximal sequence.
- a Cap structure comprises an m7 Guanosine cap and nucleotide +1 (Ni) of an RNA polynucleotide.
- a Cap structure comprises an m7 Guanosine cap and nucleotide +2 (N2) of an RNA polynucleotide.
- a Cap structure comprises an m7 Guanosine cap and nucleotides +1 and +2 (Ni and N2) of an RNA polynucleotide.
- one or more residues of a cap proximal sequence may be included in an RNA by virtue of having been included in a cap entity that (e.g., a Capl structure, etc); alternatively, in some embodiments, at least some of the residues in a cap proximal sequence may be enzymatically added (e.g., by a polymerase such as a T7 polymerase).
- +1 and +2 are the (mi 2 °)A and G residues of the cap, and +3, +4, and +5 are added by polymerase (e.g., T7 polymerase).
- a cap proximal sequence comprises Ni and N2 of a Cap structure, wherein Ni and N2 are any nucleotide, e.g., A, C, G or U.
- Ni is A.
- Ni is C.
- Ni is G.
- Ni is U.
- N2 is A.
- N2 is C.
- N2 is G.
- N2 is U.
- Ni is A and N21S A. In some embodiments, Ni is A and N21S C. In some embodiments, Ni is A and N21S G. In some embodiments, Ni is A and N21S U.
- Ni is C and N21S A. In some embodiments, Ni is C and N21S C. In some embodiments, Ni is C and N21S G. In some embodiments, Ni is C and N21S U.
- Ni is G and N21S A. In some embodiments, Ni is G and N21S C. In some embodiments, Ni is G and N21S G. In some embodiments, Ni is G and N21S U.
- Ni is U and N21S A. In some embodiments, Ni is U and N21S C. In some embodiments, Ni is U and N21S G. In some embodiments, Ni is U and N21S U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure and N 3 , N4 and N5, wherein Ni to N5 correspond to positions +1, +2, +3, +4, and/or +5 of an RNA polynucleotide.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is A. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is C. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is A.
- N4 is G.
- N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is U. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4,or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is A.
- N4 is A.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is A.
- N4 is G.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is A.
- N4 is C.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is A.
- N4 is U.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is A. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is C. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is A.
- N4 is G.
- N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is U. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is A. In some embodiments, N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is C. In some embodiments, N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is A.
- N4 is G.
- N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is A. In some embodiments, N4 is U. In some embodiments, N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is A. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is C. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is G. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is U. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is C.
- N4 is A.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is C.
- N4 is G.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is C.
- N4 is C.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is U. In some embodiments, N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is A. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is C. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is G. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is U. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is A. In some embodiments, N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is C. In some embodiments, N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is C.
- N4 is G.
- N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is C. In some embodiments, N4 is U. In some embodiments, N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is G. In some embodiments, N4 is A. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is G. In some embodiments, N4 is C. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is G.
- N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is G. In some embodiments, N4 is U. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is A.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is G.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is C.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is G. In some embodiments, N4 is U. In some embodiments, N5 is G. In some embodiments, Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is G. In some embodiments, N4 is A. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is G. In some embodiments, N4 is C. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is G.
- N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is G. In some embodiments, N4 is U. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is A.
- N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is C.
- N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is G.
- N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is G.
- N4 is U.
- N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is A. In some embodiments, N5 is A. In some embodiments, Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is C. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is G. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is U. In some embodiments, N5 is A.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is A. In some embodiments, N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is G. In some embodiments, N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is C. In some embodiments, N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is U.
- N4 is U.
- N5 is G.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is A. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is C. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is G. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is U. In some embodiments, N5 is C.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is A. In some embodiments, N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is C. In some embodiments, N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U.
- Ni is A and N2 is G.
- N 3 is U.
- N4 is G.
- N5 is U.
- Ni, N2, N 3 , N4, or N5 are any nucleotide, e.g., A, C, G or U. In some embodiments, Ni is A and N2 is G. In some embodiments, N 3 is U. In some embodiments, N4 is U. In some embodiments, N5 is U.
- a 5’ UTR disclosed herein comprises a cap proximal sequence, e.g., as disclosed herein.
- a cap proximal sequence comprises a sequence adjacent to a 5’ cap.
- a cap proximal sequence comprises nucleotides in positions +1, +2, +3, +4, and/or +5 of an RNA polynucleotide.
- a Cap structure comprises one or more polynucleotides of a cap proximal sequence.
- a Cap structure comprises an m7 Guanosine cap and nucleotide +1 (Ni) of an RNA polynucleotide.
- a Cap structure comprises an m7 Guanosine cap and nucleotide +2 (N2) of an RNA polynucleotide.
- a Cap structure comprises an m7 Guanosine cap and nucleotides +1 and +2 (Ni and N2) of an RNA polynucleotide.
- Ni and N2 are each independently chosen from: A, C, G, or U. In some embodiments, Ni is A. In some embodiments, Ni is C. In some embodiments, Ni is G. In some embodiments, Ni is U. In some embodiments, N2 is A. In some embodiments, N2 is C. In some embodiments, N2 is G. In some embodiments, N2 is U.
- Ni and N2 are each independently chosen from: A, C, G, or U. In some embodiments, Ni is A. In some embodiments, Ni is C. In some embodiments, Ni is G. In some embodiments, Ni is U. In some embodiments, N2 is A. In some embodiments, N2 is C. In some embodiments, N2 is G. In some embodiments, N2 is U.
- Ni is A and N21S A. In some embodiments, Ni is A and N21S C. In some embodiments, Ni is A and N21S G. In some embodiments, Ni is A and N21S U.
- Ni is C and N21S A. In some embodiments, Ni is C and N21S C. In some embodiments, Ni is C and N21S G. In some embodiments, Ni is C and N21S U.
- Ni is G and N21S A. In some embodiments, Ni is G and N21S C. In some embodiments, Ni is G and N21S G. In some embodiments, Ni is G and N21S U.
- Ni is U and N21S A. In some embodiments, Ni is U and N21S C. In some embodiments, Ni is U and N21S G. In some embodiments, Ni is U and N21S U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising: A 3 A4X5 (SEQ ID NO: 1).
- Ni and N2 are each independently chosen from: A, C, G, or U.
- Ni is A and N21S G.
- X5 is chosen from A, C, G or U.
- X5 is A.
- X5 is C.
- X5 is G.
- X5 is U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising: C 3 A4X5 (SEQ ID NO: 2).
- Ni and N2 are each independently chosen from: A, C, G, or U.
- Ni is A and N21S G.
- X5 is chosen from A, C, G or U.
- X5 is A.
- X5 is C.
- X5 is G.
- X5 is U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising X 3 Y4X5 (SEQ ID NO: 7).
- Ni and N2 are each independently chosen from: A, C, G, or U.
- Ni is A and N21S G.
- X 3 and X5 is each independently chosen from A, C, G or U.
- X 3 and/or X5 is A.
- X 3 and/or X5 is C.
- X 3 and/or X5 is G.
- X 3 and/or X5 is U.
- Y4 is not C.
- Y4 is A. In some embodiments, Y4 is G. In some embodiments, Y4 is U. In some embodiments, a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising X 3 Y4X5 (SEQ ID NO: 7). In some embodiments, Ni and N2are each independently chosen from: A, C, G, or U. In some embodiments, Ni is A and N21S G. In some embodiments, X 3 and X5 is each independently chosen from A, C, G or U. In some embodiments, X 3 and/or X5 is A. In some embodiments, X 3 and/or X5 is C.
- X 3 and/or X5 is G. In some embodiments, X 3 and/or X5 is U. In some embodiments, Y4 is not G. In some embodiments, Y4 is A. In some embodiments, Y4 is C. In some embodiments, Y4 is U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising A 3 C4A5 (SEQ ID NO: 3).
- Ni and N2 are each independently chosen from: A, C, G, or U.
- Ni is A and N21S G.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising A 3 U4G5 (SEQ ID NO: 4).
- Ni and N2 are each independently chosen from: A, C, G, or U.
- Ni is A and N21S G.
- a Cap structure comprises one or more polynucleotides of a cap proximal sequence.
- a Cap structure comprises an m7 Guanosine cap and nucleotide +1 (Ni) of an RNA polynucleotide.
- a Cap structure comprises an m7 Guanosine cap and nucleotide +2 (N2) of an RNA polynucleotide.
- a Cap structure comprises an m7 Guanosine cap and nucleotides +1 and +2 (Ni and N2) of an RNA polynucleotide.
- Ni and N2 are any nucleotide, e.g., A, C, G, or U.
- Ni is A.
- Ni is C.
- Ni is G.
- Ni is U.
- N2 is A.
- N2 is C.
- N2 is G.
- N2 is U.
- Ni and N2 are any nucleotide, e.g., A, C, G, or U.
- Ni is A.
- Ni is C.
- Ni is G.
- Ni is U.
- N2 is A.
- N2 is C.
- N2 is G.
- N2 is U.
- Ni is A and N21S A. In some embodiments, Ni is A and N21S C. In some embodiments, Ni is A and N21S G. In some embodiments, Ni is A and N21S U.
- Ni is C and N21S A. In some embodiments, Ni is C and N21S C. In some embodiments, Ni is C and N21S G. In some embodiments, Ni is C and N21S U.
- Ni is G and N21S A. In some embodiments, Ni is G and N21S C. In some embodiments, Ni is G and N21S G. In some embodiments, Ni is G and N21S U.
- Ni is U and N21S A. In some embodiments, Ni is U and N21S C. In some embodiments, Ni is U and N21S G. In some embodiments, Ni is U and N21S U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising: A 3 A4X5 (SEQ ID NO: 1).
- Ni and N2 are any nucleotide, e.g., A, C, G, or U.
- Ni is A and N21S G.
- X5 is chosen from A, C, G or U.
- X5 is A.
- X5 is C.
- X5 is G.
- X5 is U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising: C 3 A4X5 (SEQ ID NO: 2).
- Ni and N2 are any nucleotide, e.g., A, C, G, or U.
- Ni is A and N21S G.
- X5 is any nucleotide, e.g., A, C, G or U.
- X5 is A.
- X5 is C.
- X5 is G.
- X5 is U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising X 3 Y4X5 (SEQ ID NO: 7).
- Ni and N2 are any nucleotide, e.g., A, C, G, or U.
- Ni is A and N21S G.
- X 3 and X5 is any nucleotide, e.g., A, C, G or U.
- X 3 and/or X5 is A.
- X 3 and/or X5 is C.
- X 3 and/or X5 is G.
- X 3 and/or X5 is U.
- Y4 is not C.
- Y4 is A.
- Y4 is G.
- Y4 is U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising X 3 Y4X5 (SEQ ID NO: 7).
- Ni and N2 are any nucleotide, e.g., A, C, G, or U.
- Ni is A and N21S G.
- X 3 and X5 is any nucleotide, e.g., A, C, G or U.
- X 3 and/or X5 is A.
- X 3 and/or X5 is C.
- X 3 and/or X5 is G.
- X 3 and/or X5 is U.
- Y4 is not G.
- Y4 is A.
- Y4 is C.
- Y4 is U.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising A3C4A5 (SEQ ID NO: 3).
- Ni and N2 are any nucleotide, e.g., A, C, G, or U.
- Ni is A and N21S G.
- a cap proximal sequence comprises Ni and N2 of a Cap structure, and a sequence comprising A3U4G5 (SEQ ID NO: 4).
- Ni and N2 are any nucleotide, e.g., A, C, G, or U.
- Ni is A and N21S G.
- Exemplary 5’ UTRs include a human alpha globin (hAg) 5’UTR or a fragment thereof, a TEV 5’ UTR or a fragment thereof, a HSP705’ UTR or a fragment thereof, or a c-Jun 5’ UTR or a fragment thereof.
- hAg human alpha globin
- an RNA disclosed herein comprises a hAg 5’ UTR or a fragment thereof. In some embodiments, an RNA disclosed herein comprises a hAg 5’ UTR having 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to a human alpha globin 5’ UTR provided in SEQ ID NO: 11. In some embodiments, an RNA disclosed herein comprises a hAg 5’ UTR provided in SEQ ID NO: 11.
- an RNA disclosed herein comprises a hAg 5’ UTR having 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to a human alpha globin 5’ UTR provided in SEQ ID NO: 12. In some embodiments, an RNA disclosed herein comprises a hAg 5’ UTR provided in SEQ ID NO: 12.
- an RNA disclosed herein comprises a 3'-UTR.
- a 3'-UTR if present, is located at the 3' end, downstream of the termination codon of a protein-encoding region, but the term "3'-UTR" does preferably not include the poly(A) sequence.
- the 3'- UTR is upstream of the poly(A) sequence (if present), e.g. directly adjacent to the poly(A) sequence.
- an RNA disclosed herein comprises a 3’ UTR comprising an F element and/or an I element.
- a 3’ UTR or a proximal sequence thereto comprises a restriction site.
- a restriction site is a BamHI site.
- a restriction site is a Xhol site.
- an RNA disclosed herein comprises a 3’ UTR having 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to a 3’ UTR provided in SEQ ID NO: 13.
- an RNA disclosed herein comprises a 3’ UTR provided in SEQ ID NO: 13.
- an RNA disclosed herein comprises a polyadenylate (PolyA) sequence, e.g., as described herein.
- a PolyA sequence is situated downstream of a 3'-UTR, e.g., adjacent to a 3'-UTR.
- poly(A) sequence or "poly-A tail” refers to an uninterrupted or interrupted sequence of adenylate residues which is typically located at the 3'-end of an RNA polynucleotide.
- Poly(A) sequences are known to those of skill in the art and may follow the 3’- UTR in the RNAs described herein.
- An uninterrupted poly(A) sequence is characterized by consecutive adenylate residues. In nature, an uninterrupted poly(A) sequence is typical.
- RNAs disclosed herein can have a poly(A) sequence attached to the free 3'-end of the RNA by a template- independent RNA polymerase after transcription or a poly(A) sequence encoded by DNA and transcribed by a template-dependent RNA polymerase.
- a poly (A) sequence of about 120 A nucleotides has a beneficial influence on the levels of RNA in transfected eukaryotic cells, as well as on the levels of protein that is translated from an open reading frame that is present upstream (5’) of the poly(A) sequence ( Holtkamp et ah, 2006, Blood, vol. 108, pp. 4009-4017).
- the poly(A) sequence may be of any length.
- a poly(A) sequence comprises, essentially consists of, or consists of at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 A nucleotides, and, in particular, about 120 A nucleotides.
- nucleotides in the poly(A) sequence typically at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% by number of nucleotides in the poly(A) sequence are A nucleotides, but permits that remaining nucleotides are nucleotides other than A nucleotides, such as U nucleotides (uridylate), G nucleotides (guanylate), or C nucleotides (cytidylate).
- consists of means that all nucleotides in the poly(A) sequence, i.e., 100% by number of nucleotides in the poly(A) sequence, are A nucleotides.
- a nucleotide or “A” refers to adenylate.
- a poly(A) sequence is attached during RNA transcription, e.g., during preparation of in vitro transcribed RNA, based on a DNA template comprising repeated dT nucleotides (deoxythymidylate) in the strand complementary to the coding strand.
- the DNA sequence encoding a poly(A) sequence (coding strand) is referred to as poly(A) cassette.
- the poly(A) cassette present in the coding strand of DNA essentially consists of dA nucleotides, but is interrupted by a random sequence of the four nucleotides (dA, dC, dG, and dT). Such random sequence may be 5 to 50, 10 to 30, or 10 to 20 nucleotides in length.
- a cassette is disclosed in WO 2016/005324 Al, hereby incorporated by reference. Any poly(A) cassette disclosed in WO 2016/005324 Al may be used in the present invention.
- a poly(A) cassette that essentially consists of dA nucleotides, but is interrupted by a random sequence having an equal distribution of the four nucleotides (dA, dC, dG, dT) and having a length of e.g., 5 to 50 nucleotides shows, on DNA level, constant propagation of plasmid DNA in E. coli and is still associated, on RNA level, with the beneficial properties with respect to supporting RNA stability and translational efficiency is encompassed.
- the poly(A) sequence contained in an RNA polynucleotide described herein essentially consists of A nucleotides, but is interrupted by a random sequence of the four nucleotides (A, C, G, U). Such random sequence may be 5 to 50, 10 to 30, or 10 to 20 nucleotides in length.
- no nucleotides other than A nucleotides flank a poly(A) sequence at its 3'-end, i.e., the poly(A) sequence is not masked or followed at its 3'-end by a nucleotide other than A.
- the poly(A) sequence may comprise at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 nucleotides. In some embodiments, the poly(A) sequence may essentially consist of at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 nucleotides. In some embodiments, the poly(A) sequence may consist of at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 nucleotides.
- the poly(A) sequence comprises at least 100 nucleotides. In some embodiments, the poly(A) sequence comprises about 150 nucleotides. In some embodiments, the poly(A) sequence comprises about 120 nucleotides. In some embodiments, an RNA disclosed herein comprises a poly(A) sequence comprising the nucleotide sequence of SEQ ID NO: 14, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 14.
- an RNA disclosed herein comprises a poly(A) sequence of SEQ ID NO: 14.
- an RNA polynucleotide disclosed herein comprises a sequence encoding a payload, e.g., as described herein.
- a sequence encoding a payload comprises a promoter sequence.
- a sequence encoding a payload comprises a sequence encoding a secretory signal peptide.
- a payload is chosen from: a protein replacement polypeptide; an antibody agent; a cytokine; an antigenic polypeptide; a gene editing component; a regenerative medicine component or combinations thereof.
- a payload is or comprises a protein replacement polypeptide.
- a protein replacement polypeptide comprises a polypeptide with aberrant expression in a disease or disorder.
- a protein replacement polypeptide comprises an intracellular protein, an extracellular protein, or a transmembrane protein.
- a protein replacement polypeptide comprises an enzyme.
- a disease or disorder with aberrant expression of a polypeptide includes but is not limited to: a rare disease, a metabolic disorder, a muscular dystrophy, a cardiovascular disease, or a monogenic disease.
- a payload is or comprises an antibody agent.
- an antibody agent binds to a polypeptide expressed on a cell.
- an antibody agent comprises a CD3 antibody, a Claudin 6 antibody, or a combination thereof.
- a payload is or comprises a cytokine or a fragment or a variant thereof.
- a cytokine comprises: IL-12 or a fragment or variant or a fusion thereof, IL-15 or a fragment or a variant or a fusion thereof, GMCSF or a fragment or a variant thereof; or IFN-alpha or a fragment or a variant thereof.
- a payload is or comprises an antigenic polypeptide or an immunogenic variant or an immunogenic fragment thereof.
- an antigenic polypeptide comprises one epitope from an antigen.
- an antigenic polypeptide comprises a plurality of distinct epitopes from an antigen.
- an antigenic polypeptide comprising a plurality of distinct epitopes from an antigen is polyepitopic.
- an antigenic polypeptide comprises: an antigenic polypeptide from an allergen, a viral antigenic polypeptide, a bacterial antigenic polypeptide, a fungal antigenic polypeptide, a parasitic antigenic polypeptide, an antigenic polypeptide from an infectious agent, an antigenic polypeptide from a pathogen, a tumor antigenic polypeptide, or a self- antigenic polypeptide.
- a viral antigenic polypeptide comprises an HIV antigenic polypeptide, an influenza antigenic polypeptide, a Coronavims antigenic polypeptide, a Rabies antigenic polypeptide, or a Zika vims antigenic polypeptide.
- a viral antigenic polypeptide is or comprises a Coronavims antigenic polypeptide.
- a Coronavims antigen is or comprises a SARS- CoV-2 protein.
- a SARS-CoV-2 protein comprises a SARS-CoV-2 Spike (S) protein, or an immunogenic variant or an immunogenic fragment thereof.
- a SARS-CoV-2 protein, or immunogenic variant or immunogenic fragment thereof comprises proline residues at positions 986 and 987.
- a SARS-CoV-2 S polypeptide has at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to a SARS-CoV-2 S polypeptide disclosed herein. In some embodiments, a SARS-CoV-2 S polypeptide has at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to SEQ ID NO: 9.
- a SARS-CoV-2 S polypeptide is encoded by an RNA having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to a SARS-CoV-2 S polynucleotide disclosed herein. In some embodiments, a SARS-CoV-2 S polypeptide is encoded by an RNA having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to SEQ ID NO: 10.
- a payload is or comprises a tumor antigenic polypeptide or an immunogenic variant or an immunogenic fragment thereof.
- a tumor antigenic polypeptide comprises a tumor specific antigen, a tumor associated antigen, a tumor neoantigen, or a combination thereof.
- a tumor antigenic polypeptide comprises p53, ART-4, BAGE, ss-catenin/m, Bcr-abL CAMEL, CAP-1, CASP-8, CDC27/m, CDK4/m, CEA, CLAUDIN-12, c-MYC, CT, Cyp-B, DAM, ELF2M, ETV6-AML1, G250, GAGE, GnT-V, Gap 100, HAGE, HER-2/neu, HPV-E7, HPV-E6, HAST-2, hTERT (or hTRT), LAGE, LDLR/FUT, MAGE- A, preferably MAGE-A1, MAGE-A2, MAGE- A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, or MAGE-A12, MAGE-B, MAGE-C, MART- 1/Melan
- a tumor antigenic polypeptide comprises a tumor antigen from a carcinoma, a sarcoma, a melanoma, a lymphoma, a leukemia, or a combination thereof.
- a tumor antigenic polypeptide comprises a melanoma tumor antigen.
- a tumor antigenic polypeptide comprises a prostate cancer antigen.
- a tumor antigenic polypeptide comprises a HPV16 positive head and neck cancer antigen.
- a tumor antigenic polypeptide comprises a breast cancer antigen.
- a tumor antigenic polypeptide comprises an ovarian cancer antigen.
- a tumor antigenic polypeptide comprises a lung cancer antigen.
- a tumor antigenic polypeptide comprises an NSCLC antigen.
- a payload is or comprises a self- antigenic polypeptide or an immunogenic variant or an immunogenic fragment thereof.
- a self- antigenic polypeptide comprises an antigen that is typically expressed on cells and is recognized as a self-antigen by an immune system.
- a self-antigenic polypeptide comprises: a multiple sclerosis antigenic polypeptide, a Rheumatoid arthritis antigenic polypeptide, a lupus antigenic polypeptide, a celiac disease antigenic polypeptide, a Sjogren’s syndrome antigenic polypeptide, or an ankylosing spondylitis antigenic polypeptide, or a combination thereof.
- an RNA polynucleotide described herein or a composition or medical preparation comprising the same comprises a nucleotide sequence disclosed herein.
- an RNA polynucleotide comprises a sequence having at least 80% identity to a nucleotide sequence disclosed herein.
- an RNA polynucleotide comprises a sequence encoding a polypeptide having at least 80% identity to a polypeptide sequence disclosed herein.
- Exemplary nucleotide and polypeptide sequences are provided e.g., in Table 1 or in this section titled “Exemplary polynucleotides” or in Example 2.
- an RNA polynucleotide described herein or a composition or medical preparation comprising the same is transcribed by a DNA template.
- a DNA template used to transcribe an RNA polynucleotide described herein comprises a sequence complementary to an RNA polynucleotide.
- a payload described herein is encoded by an RNA polynucleotide described herein comprising a nucleotide sequence disclosed herein, e.g., in Table 1 or in this section titled “Exemplary polynucleotides” or in Example 2.
- an RNA polynucleotide encodes a polypeptide payload having at least 80% identity to a polypeptide payload sequence disclosed herein.
- a payload described herein is encoded by an RNA polynucleotide transcribed by a DNA template comprising a sequence complementary to an RNA polynucleotide.
- RBL063.1 (SEQ ID NO: 28 nucleotide; SEQ ID NO: 9 amino acid)
- S1S2 protein Encoded antigen Viral spike protein (S1S2 protein) of the SARS-CoV-2 (S1S2 full-length protein, sequence variant)
- RBL063.2 (SEQ ID NO: 29 nucleotide; SEQ ID NO: 9 amino acid) Structure beta-S-ARCA(Dl)-hAg-Kozak-S 1S2-PP-FI-A30L70
- S1S2 protein Encoded antigen Viral spike protein (S1S2 protein) of the SARS-CoV-2 (S1S2 full-length protein, sequence variant)
- S protein Encoded antigen Viral spike protein (S protein) of the SARS-CoV-2 (partial sequence, Receptor Binding Domain (RBD) of S1S2 protein)
- BNT162b2; RBP020.1 SEQ ID NO: 31 nucleotide; SEQ ID NO: 9 amino acid
- S1S2 protein Encoded antigen Viral spike protein (S1S2 protein) of the SARS-CoV-2 (S1S2 full-length protein, sequence variant)
- RBP020.2 SEQ ID NO: 10 nucleotide; SEQ ID NO: 9 amino acid (see Table 1)
- S1S2 protein Encoded antigen Viral spike protein (S1S2 protein) of the SARS-CoV-2 (S1S2 full-length protein, sequence variant)
- S1S2 protein Encoded antigen Viral spike protein (S1S2 protein) of the SARS-CoV-2 (partial sequence, Receptor Binding Domain (RBD) of S1S2 protein fused to fibritin)
- SEQ ID NO: 32 agaauaaacu aguauucuuc ugguccccac agacucagag agaacccgcc accauguuug 60 uguuucuugu gcugcugccu cuugugugucuu cucagugugugu ggugagauuu ccaaauauua 120 caaaucugug uccauuugga gaaguguuua augcaacaag auuugcaucu guguaugcau 180 ggaauagaaa aagaauuucu aauugugugg cugauuauuc ugugcuguau aauagugcuu 240 cuuuuuccac auuuaaaugu uaugga
- S protein Encoded antigen Viral spike protein (S protein) of the SARS-CoV-2 (S1S2 full-length protein, sequence variant)
- S protein Encoded antigen Viral spike protein (S protein) of the SARS-CoV-2 (S1S2 full-length protein, sequence variant)
- S protein Encoded antigen Viral spike protein (S protein) of the SARS-CoV-2 (partial sequence, Receptor Binding Domain (RBD) of S1S2 protein)
- RBS004.4 (SEQ ID NO: 36; SEQ ID NO: 37)
- S protein Encoded antigen Viral spike protein (S protein) of the SARS-CoV-2 (partial sequence, Receptor Binding Domain (RBD) of S1S2 protein)
- S1S2 protein Encoded antigen Viral spike protein (S1S2 protein) of the SARS-CoV-2 (partial sequence, Receptor Binding Domain (RBD) of S1S2 protein fused to Fibritin fused to Transmembrane Domain (TM) of S1S2 protein); intrinsic S1S2 protein secretory signal peptide (aa 1-19) at the N-terminus of the antigen sequence
- Lys Arg lie Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser 50 55 60
- S1S2 protein Encoded antigen Viral spike protein (S1S2 protein) of the SARS-CoV-2 (partial sequence, Receptor Binding Domain (RBD) of S1S2 protein fused to Fibritin fused to Transmembrane Domain (TM) of S1S2 protein); immunoglobulin secretory signal peptide (aa 1-22) at the N- terminus of the antigen sequence
- Trp lie Trp Arg Ile Leu Phe Leu Val Gly Ala Ala Thr Gly 1 5 10 15 Ala His Ser Gin Met Gin Val Arg Phe Pro Asn Ile Thr Asn Leu Cys 20 25 30
- Trp Asn Arg Lys Arg lie Ser Asn Cys Val Ala Asp Tyr Ser Val Leu 50 55 60
- Nucleic acids described herein such as RNA encoding a payload may be administered formulated as particles.
- the term “particle” relates to a structured entity formed by molecules or molecule complexes.
- the term “particle” relates to a micro- or nano-sized structure, such as a micro- or nano-sized compact structure dispersed in a medium.
- a particle is a nucleic acid containing particle such as a particle comprising DNA, RNA or a mixture thereof.
- a nucleic acid particle is a nanoparticle.
- nanoparticle refers to a particle having an average diameter suitable for parenteral administration.
- a “nucleic acid particle” can be used to deliver nucleic acid to a target site of interest (e.g., cell, tissue, organ, and the like).
- a nucleic acid particle may be formed from at least one cationic or cationically ionizable lipid or lipid-like material, at least one cationic polymer such as protamine, or a mixture thereof and nucleic acid.
- Nucleic acid particles include lipid nanoparticle (LNP)-based and lipoplex (LPX)-based formulations.
- the cationic or cationically ionizable lipid or lipid-like material and/or the cationic polymer combine together with the nucleic acid to form aggregates, and this aggregation results in colloidally stable particles.
- particles described herein further comprise at least one lipid or lipid-like material other than a cationic or cationically ionizable lipid or lipid-like material, at least one polymer other than a cationic polymer, or a mixture thereof
- nucleic acid particles comprise more than one type of nucleic acid molecules, where the molecular parameters of the nucleic acid molecules may be similar or different from each other, like with respect to molar mass or fundamental structural elements such as molecular architecture, capping, coding regions or other features.
- Nucleic acid particles described herein may have an average diameter that in some embodiments ranges from about 30 nm to about 1000 nm, from about 50 nm to about 800 nm, from about 70 nm to about 600 nm, from about 90 nm to about 400 nm, or from about 100 nm to about 300 nm.
- Nucleic acid particles described herein may exhibit a polydispersity index less than about 0.5, less than about 0.4, less than about 0.3, or about 0.2 or less.
- the nucleic acid particles can exhibit a polydispersity index in a range of about 0.1 to about 0.3 or about 0.2 to about 0.3.
- the N/P ratio gives the ratio of the nitrogen groups in the lipid to the number of phosphate groups in the RNA. It is correlated to the charge ratio, as the nitrogen atoms (depending on the pH) are usually positively charged and the phosphate groups are negatively charged.
- the N/P ratio where a charge equilibrium exists, depends on the pH. Lipid formulations are frequently formed at N/P ratios larger than four up to twelve, because positively charged nanoparticles are considered favorable for transfection. In that case, RNA is considered to be completely bound to nanoparticles.
- Nucleic acid particles described herein can be prepared using a wide range of methods that may involve obtaining a colloid from at least one cationic or cationically ionizable lipid or lipid-like material and/or at least one cationic polymer and mixing the colloid with nucleic acid to obtain nucleic acid particles.
- the term "colloid” as used herein relates to a type of homogeneous mixture in which dispersed particles do not settle out.
- the insoluble particles in the mixture are microscopic, with particle sizes between 1 and 1000 nanometers.
- the mixture may be termed a colloid or a colloidal suspension. Sometimes the term “colloid” only refers to the particles in the mixture and not the entire suspension.
- colloids comprising at least one cationic or cationically ionizable lipid or lipid-like material and/or at least one cationic polymer methods are applicable herein that are conventionally used for preparing liposomal vesicles and are appropriately adapted.
- the most commonly used methods for preparing liposomal vesicles share the following fundamental stages: (i) lipids dissolution in organic solvents, (ii) drying of the resultant solution, and (iii) hydration of dried lipid (using various aqueous media).
- lipids are firstly dissolved in a suitable organic solvent, and dried down to yield a thin film at the bottom of the flask. The obtained lipid film is hydrated using an appropriate aqueous medium to produce a liposomal dispersion.
- an additional downsizing step may be included.
- Reverse phase evaporation is an alternative method to the film hydration for preparing liposomal vesicles that involves formation of a water-in-oil emulsion between an aqueous phase and an organic phase containing lipids. A brief sonication of this mixture is required for system homogenization. The removal of the organic phase under reduced pressure yields a milky gel that turns subsequently into a liposomal suspension.
- ethanol injection technique refers to a process, in which an ethanol solution comprising lipids is rapidly injected into an aqueous solution through a needle. This action disperses the lipids throughout the solution and promotes lipid structure formation, for example lipid vesicle formation such as liposome formation.
- the RNA lipoplex particles described herein are obtainable by adding RNA to a colloidal liposome dispersion. Using the ethanol injection technique, such colloidal liposome dispersion is, in some embodiments, formed as follows: an ethanol solution comprising lipids, such as cationic lipids and additional lipids, is injected into an aqueous solution under stirring.
- the RNA lipoplex particles described herein are obtainable without a step of extrusion.
- extruding refers to the creation of particles having a fixed, cross-sectional profile. In particular, it refers to the downsizing of a particle, whereby the particle is forced through filters with defined pores.
- LNPs typically comprise four components: ionizable cationic lipids, neutral lipids such as phospholipids, a steroid such as cholesterol, and a polymer conjugated lipid such as polyethylene glycol (PEG)-lipids. Each component is responsible for payload protection, and enables effective intracellular delivery.
- LNPs may be prepared by mixing lipids dissolved in ethanol rapidly with nucleic acid in an aqueous buffer.
- average diameter refers to the mean hydrodynamic diameter of particles as measured by dynamic laser light scattering (DLS) with data analysis using the so-called cumulant algorithm, which provides as results the so-called Zaverage with the dimension of a length, and the polydispersity index (PI), which is dimensionless (Koppel, D., J. Chem. Phys. 57, 1972, pp 4814-4820, ISO 13321). Ilere "average diameter", “diameter” or “size” for particles is used synonymously with this value of the Zaverage.
- the "polydispersity index” is preferably calculated based on dynamic light scattering measurements by the so-called cumulant analysis as mentioned in the definition of the "average diameter". Under certain prerequisites, it can be taken as a measure of the size distribution of an ensemble of nanoparticles.
- nucleic acid containing particles have been described previously to be suitable for delivery of nucleic acid in particulate form (e.g. Kaczmarek, J. C. et ah, 2017, Genome Medicine 9, 60).
- nanoparticle encapsulation of nucleic acid physically protects nucleic acid from degradation and, depending on the specific chemistry, can aid in cellular uptake and endosomal escape.
- the present disclosure describes particles comprising nucleic acid, at least one cationic or cationically ionizable lipid or lipid-like material, and/or at least one cationic polymer which associate with nucleic acid to form nucleic acid particles and compositions comprising such particles.
- the nucleic acid particles may comprise nucleic acid which is complexed in different forms by non-covalent interactions to the particle.
- the particles described herein are not viral particles, in particular infectious viral particles, i.e., they are not able to virally infect cells.
- Suitable cationic or cationically ionizable lipids or lipid-like materials and cationic polymers are those that form nucleic acid particles and are included by the term "particle forming components" or “particle forming agents".
- the term “particle forming components” or “particle forming agents” relates to any components which associate with nucleic acid to form nucleic acid particles. Such components include any component which can be part of nucleic acid particles.
- compositions, methods and uses involving more than one, e.g., 2, 3, 4, 5, 6 or even more nucleic acid species such as RNA species e.g., a) a nucleic acid comprising a first nucleotide sequence encoding an amino acid sequence comprising at least a fragment of a parental vims protein, wherein amino acid positions in the at least a fragment of a parental virus protein are modified to comprise amino acids found in the corresponding amino acid positions of one or more virus protein variants; and b) a nucleic acid comprising a second nucleotide sequence encoding an amino acid sequence comprising at least a fragment of a parental virus protein, wherein amino acid positions in the at least a fragment of a parental virus protein are modified to comprise amino acids found in the corresponding amino acid positions of one or more virus protein variants.
- each nucleic acid species is separately formulated as an individual particulate formulation.
- each individual particulate formulation will comprise one nucleic acid species.
- the individual particulate formulations may be present as separate entities, e.g. in separate containers.
- Such formulations are obtainable by providing each nucleic acid species separately (typically each in the form of a nucleic acid- containing solution) together with a particle-forming agent, thereby allowing the formation of particles.
- Respective particles will contain exclusively the specific nucleic acid species that is being provided when the particles are formed (individual particulate formulations).
- a composition such as a pharmaceutical composition comprises more than one individual particle formulation.
- Respective pharmaceutical compositions are referred to as mixed particulate formulations.
- Mixed particulate formulations according to the invention are obtainable by forming, separately, individual particulate formulations, as described above, followed by a step of mixing of the individual particulate formulations. By the step of mixing, a formulation comprising a mixed population of nucleic acid-containing particles is obtainable. Individual particulate populations may be together in one container, comprising a mixed population of individual particulate formulations.
- nucleic acid species are formulated together as a combined particulate formulation.
- Such formulations are obtainable by providing a combined formulation (typically combined solution) of different RNA species together with a particle forming agent, thereby allowing the formation of particles.
- a combined particulate formulation will typically comprise particles which comprise more than one RNA species.
- different RNA species are typically present together in a single particle.
- Cationic polymeric materials e.g., polymers
- polymeric materials are commonly used for nanoparticle-based delivery.
- cationic materials are used to electrostatically condense the negatively charged nucleic acid into nanoparticles.
- These positively charged groups often consist of amines that change their state of protonation in the pH range between 5.5 and 7.5, thought to lead to an ion imbalance that results in endosomal rupture.
- Polymers such as poly-L-lysine, polyamidoamine, protamine and polyethyleneimine, as well as naturally occurring polymers such as chitosan have all been applied to nucleic acid delivery and are suitable as cationic materials useful in some embodiments herein.
- some investigators have synthesized polymeric materials specifically for nucleic acid delivery. Poly(P-amino esters), in particular, have gained widespread use in nucleic acid delivery owing to their ease of synthesis and biodegradability.
- such synthetic materials may be suitable for use as cationic materials herein.
- a "polymeric material”, as used herein, is given its ordinary meaning, i.e., a molecular structure comprising one or more repeat units (monomers), connected by covalent bonds. In some embodiments, such repeat units can all be identical; alternatively, in some cases, there can be more than one type of repeat unit present within the polymeric material.
- a polymeric material is biologically derived, e.g., a biopolymer such as a protein.
- additional moieties can also be present in the polymeric material, for example targeting moieties such as those described herein.
- a polymer (or polymeric moiety) utilized in accordance with the present disclosure may be a copolymer. Repeat units forming the copolymer can be arranged in any fashion.
- repeat units can be arranged in a random order; alternatively or additionally, in some embodiments, repeat units may be arranged in an alternating order, or as a "block" copolymer, i.e., comprising one or more regions each comprising a first repeat unit (e.g., a first block), and one or more regions each comprising a second repeat unit (e.g., a second block), etc.
- Block copolymers can have two (a diblock copolymer), three (a triblock copolymer), or more numbers of distinct blocks.
- a polymeric material for use in accordance with the present disclosure is biocompatible.
- Biocompatible materials are those that typically do not result in significant cell death at moderate concentrations.
- a biocompatible material is biodegradable, i.e., is able to degrade, chemically and/or biologically, within a physiological environment, such as within the body.
- a polymeric material may be or comprise protamine or polyalkyleneimine, in particular protamine.
- protamine is often used to refer to any of various strongly basic proteins of relatively low molecular weight that are rich in arginine and are found associated especially with DNA in place of somatic histones in the sperm cells of various animals (as fish).
- protamine is often used to refer to proteins found in fish sperm that are strongly basic, are soluble in water, are not coagulated by heat, and yield chiefly arginine upon hydrolysis. In purified form, they are used in a long-acting formulation of insulin and to neutralize the anticoagulant effects of heparin.
- protamine refers to a protamine amino acid sequence obtained or derived from natural or biological sources, including fragments thereof and/or multimeric forms of said amino acid sequence or fragment thereof, as well as (synthesized) polypeptides which are artificial and specifically designed for specific purposes and cannot be isolated from native or biological sources.
- a polyalkyleneimine comprises polyethylenimine and/or polypropylenimine, preferably polyethyleneimine.
- a preferred polyalkyleneimine is polyethyleneimine (PEI).
- the average molecular weight of PEI is preferably 0.75-102 to 107 Da, preferably 1000 to 105 Da, more preferably 10000 to 40000 Da, more preferably 15000 to 30000 Da, even more preferably 20000 to 25000 Da.
- linear polyalkyleneimine such as linear polyethyleneimine (PEI).
- Cationic materials contemplated for use herein include those which are able to electrostatically bind nucleic acid.
- cationic polymeric materials contemplated for use herein include any cationic polymeric materials with which nucleic acid can be associated, e.g. by forming complexes with the nucleic acid or forming vesicles in which the nucleic acid is enclosed or encapsulated.
- particles described herein may comprise polymers other than cationic polymers, e.g., non-cationic polymeric materials and/or anionic polymeric materials. Collectively, anionic and neutral polymeric materials are referred to herein as non-cationic polymeric materials.
- Lipid and lipid-like material Lipid and lipid-like material
- lipid and "lipid-like material” are used herein to refer to molecules which comprise one or more hydrophobic moieties or groups and optionally also one or more hydrophilic moieties or groups. Molecules comprising hydrophobic moieties and hydrophilic moieties are also frequently denoted as amphiphiles. Lipids are usually poorly soluble in water.
- amphiphilic nature allows the molecules to self-assemble into organized structures and different phases.
- One of those phases consists of lipid bilayers, as they are present in vesicles, multilamellar/unilamellar liposomes, or membranes in an aqueous environment.
- Hydrophobicity can be conferred by the inclusion of apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s).
- hydrophilic groups may comprise polar and/or charged groups and include carbohydrates, phosphate, carboxylic, sulfate, amino, sulfhydryl, nitro, hydroxyl, and other like groups.
- amphiphilic refers to a molecule having both a polar portion and a non-polar portion. Often, an amphiphilic compound has a polar head attached to a long hydrophobic tail. In some embodiments, the polar portion is soluble in water, while the non-polar portion is insoluble in water. In addition, the polar portion may have either a formal positive charge, or a formal negative charge. Alternatively, the polar portion may have both a formal positive and a negative charge, and be a zwitterion or inner salt.
- the amphiphilic compound can be, but is not limited to, one or a plurality of natural or non natural lipids and lipid-like compounds.
- lipid-like material lipid-like compound or “lipid-like molecule” relates to substances that structurally and/or functionally relate to lipids but may not be considered as lipids in a strict sense.
- the term includes compounds that are able to form amphiphilic layers as they are present in vesicles, multilamellar/unilamellar liposomes, or membranes in an aqueous environment and includes surfactants, or synthesized compounds with both hydrophilic and hydrophobic moieties.
- the term refers to molecules, which comprise hydrophilic and hydrophobic moieties with different structural organization, which may or may not be similar to that of lipids.
- the term “lipid” is to be construed to cover both lipids and lipid-like materials unless otherwise indicated herein or clearly contradicted by context.
- amphiphilic compounds that may be included in an amphiphilic layer include, but are not limited to, phospholipids, aminolipids and sphingolipids.
- the amphiphilic compound is a lipid.
- lipid refers to a group of organic compounds that are characterized by being insoluble in water, but soluble in many organic solvents. Generally, lipids may be divided into eight categories: fatty acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, polyketides (derived from condensation of ketoacyl subunits), sterol lipids and prenol lipids (derived from condensation of isoprene subunits). Although the term “lipid” is sometimes used as a synonym for fats, fats are a subgroup of lipids called triglycerides. Lipids also encompass molecules such as fatty acids and their derivatives (including tri-, di-, monoglycerides, and phospholipids), as well as sterol- containing metabolites such as cholesterol.
- Fatty acids, or fatty acid residues are a diverse group of molecules made of a hydrocarbon chain that terminates with a carboxylic acid group; this arrangement confers the molecule with a polar, hydrophilic end, and a nonpolar, hydrophobic end that is insoluble in water.
- the carbon chain typically between four and 24 carbons long, may be saturated or unsaturated, and may be attached to functional groups containing oxygen, halogens, nitrogen, and sulfur. If a fatty acid contains a double bond, there is the possibility of either a cis or trans geometric isomerism, which significantly affects the molecule's configuration. Cis-double bonds cause the fatty acid chain to bend, an effect that is compounded with more double bonds in the chain.
- Other major lipid classes in the fatty acid category are the fatty esters and fatty amides.
- Glycerolipids are composed of mono-, di-, and tri- substituted glycerols, the best-known being the fatty acid triesters of glycerol, called triglycerides.
- triacylglycerol is sometimes used synonymously with "triglyceride”.
- the three hydroxyl groups of glycerol are each esterified, typically by different fatty acids.
- Additional subclasses of glycerolipids are represented by glycosylglycerols, which are characterized by the presence of one or more sugar residues attached to glycerol via a glycosidic linkage.
- the glycerophospholipids are amphipathic molecules (containing both hydrophobic and hydrophilic regions) that contain a glycerol core linked to two fatty acid-derived "tails" by ester linkages and to one "head” group by a phosphate ester linkage.
- Examples of glycerophospholipids usually referred to as phospholipids (though sphingomyelins are also classified as phospholipids) are phosphatidylcholine (also known as PC, GPCho or lecithin), phosphatidylethanolamine (PE or GPEtn) and phosphatidylserine (PS or GPSer).
- Sphingolipids are a complex family of compounds that share a common structural feature, a sphingoid base backbone.
- the major sphingoid base in mammals is commonly referred to as sphingosine.
- Ceramides N-acyl- sphingoid bases
- the fatty acids are typically saturated or mono- unsaturated with chain lengths from 16 to 26 carbon atoms.
- the major phosphosphingolipids of mammals are sphingomyelins (ceramide phosphocholines), whereas insects contain mainly ceramide phosphoethanolamines and fungi have phytoceramide phosphoinositols and mannose- containing headgroups.
- the glycosphingolipids are a diverse family of molecules composed of one or more sugar residues linked via a glycosidic bond to the sphingoid base. Examples of these are the simple and complex glycosphingolipids such as cerebrosides and gangliosides.
- Sterol lipids such as cholesterol and its derivatives, or tocopherol and its derivatives, are an important component of membrane lipids, along with the glycerophospholipids and sphingomyelins.
- Saccharolipids describe compounds in which fatty acids are linked directly to a sugar backbone, forming structures that are compatible with membrane bilayers.
- a monosaccharide substitutes for the glycerol backbone present in glycerolipids and glycerophospholipids.
- the most familiar saccharolipids are the acylated glucosamine precursors of the Lipid A component of the lipopolysaccharides in Gram-negative bacteria.
- Typical lipid A molecules are disaccharides of glucosamine, which are derivatized with as many as seven fatty- acyl chains. The minimal lipopoly saccharide required for growth in E.
- Kdo2-Lipid A a hexa-acylated disaccharide of glucosamine that is glycosylated with two 3-deoxy-D-manno- octulosonic acid (Kdo) residues.
- Polyketides are synthesized by polymerization of acetyl and propionyl subunits by classic enzymes as well as iterative and multimodular enzymes that share mechanistic features with the fatty acid synthases. They comprise a large number of secondary metabolites and natural products from animal, plant, bacterial, fungal and marine sources, and have great structural diversity. Many polyketides are cyclic molecules whose backbones are often further modified by glycosylation, methylation, hydroxylation, oxidation, or other processes.
- lipids and lipid-like materials may be cationic, anionic or neutral.
- Neutral lipids or lipid-like materials exist in an uncharged or neutral zwitterionic form at a selected pH.
- nucleic acid particles described and/or utilized in accordance with the present disclosure may comprise at least one cationic or cationically ionizable lipid or lipid like material as particle forming agent.
- Cationic or cationically ionizable lipids or lipid-like materials contemplated for use herein include any cationic or cationically ionizable lipids or lipid-like materials which are able to electrostatically bind nucleic acid.
- cationic or cationically ionizable lipids or lipid-like materials contemplated for use herein can be associated with nucleic acid, e.g. by forming complexes with the nucleic acid or forming vesicles in which the nucleic acid is enclosed or encapsulated.
- a "cationic lipid” or “cationic lipid-like material” refers to a lipid or lipid like material having a net positive charge. Cationic lipids or lipid-like materials bind negatively charged nucleic acid by electrostatic interaction. Generally, cationic lipids possess a lipophilic moiety, such as a sterol, an acyl chain, a diacyl or more acyl chains, and the head group of the lipid typically carries the positive charge.
- a cationic lipid or lipid-like material has a net positive charge only at certain pH, in particular acidic pH, while it has preferably no net positive charge, preferably has no charge, i.e., it is neutral, at a different, preferably higher pH such as physiological pH.
- This ionizable behavior is thought to enhance efficacy through helping with endosomal escape and reducing toxicity as compared with particles that remain cationic at physiological pH.
- cationic or cationically ionizable lipid or lipid-like materials are comprised by the term "cationic lipid or lipid-like material” unless contradicted by the circumstances.
- a cationic or cationically ionizable lipid or lipid-like material comprises a head group which includes at least one nitrogen atom (N) which is positive charged or capable of being protonated.
- cationic lipids include, but are not limited to: ((4- hydroxybutyl)azanediyl)bis(hexane-6,l-diyl)bis(2-hexyldecanoate); l,2-dioleoyl-3- trimethylammonium propane (DOTAP); N,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), l,2-di-0-octadecenyl-3-trimethylammonium propane (DOTMA), 3-(N — (N',N'- dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), dimethyldioctadecylammonium (DDAB); l,2-dioleoyl-3-dimethylammonium-propane (DODAP); l,2-diacyloxy-3- dimethylammonium propanes; l,2-dialkyloxy-3-di
- GAP-DLRIE ⁇ -propanaminium bromide
- GAP-DMRIE N-(2-Aminoethyl)- N,N-dimethyl-2,3-bis(tetradecyloxy)-l-propanaminium bromide
- DOBAQ N-(4- carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-l-aminium
- DOBAQ 2-( ⁇ 8-[(3b)- cholest-5-en-3-yloxy]octyl ⁇ oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-l-yloxy]propan- 1-amine
- Octyl-CLinDMA 2-( ⁇ 8-[(3b)- cholest-5-en-3-yloxy]octyl ⁇ oxy)-N,N-dimethyl-3-[(9Z,12Z)-
- a cationic lipid is or comprises heptadecan-9-yl 8-((2- hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate (SM-102).
- a cationic lipid is or comprises a cationic lipid shown in the structure below.
- a cationic lipid is or comprises ((4- hydroxybutyl)azanediyl)bis(hexane-6,l-diyl)bis(2-hexyldecanoate) which is also referred to as ALC-0315 herein.
- a cationic lipid may comprise from about 10 mol % to about 100 mol %, about 20 mol % to about 100 mol %, about 30 mol % to about 100 mol %, about 40 mol % to about 100 mol %, or about 50 mol % to about 100 mol % of the total lipid present in the particle.
- a particle for use in accordance with the present disclosure includes ALC-0315, for example in a weight percent within a range of about 40-55 mol percent of total lipids.
- particles described herein comprise (e.g., in addition to a cationic lipid such as ALC315), one or more lipids or lipid-like materials other than cationic or cationically ionizable lipids or lipid-like materials, e.g., non-cationic lipids or lipid-like materials (including non-cationically ionizable lipids or lipid-like materials).
- a cationic lipid such as ALC315
- lipids or lipid-like materials other than cationic or cationically ionizable lipids or lipid-like materials, e.g., non-cationic lipids or lipid-like materials (including non-cationically ionizable lipids or lipid-like materials).
- anionic and neutral lipids or lipid-like materials are referred to herein as non-cationic lipids or lipid-like materials.
- nucleic acid particles by addition of other hydrophobic moieties, such as cholesterol and lipids, in addition to an ionizable/cationic lipid or lipid-like material may enhance particle stability and efficacy of nucleic acid delivery.
- hydrophobic moieties such as cholesterol and lipids
- an additional lipid or lipid-like material may be incorporated which may or may not affect the overall charge of the nucleic acid particles.
- the additional lipid or lipid-like material is a non-cationic lipid or lipid-like material.
- the non-cationic lipid may comprise, e.g., one or more anionic lipids and/or neutral lipids.
- an "anionic lipid” refers to any lipid that is negatively charged at a selected pH.
- a neutral lipid refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH.
- the additional lipid comprises one of the following neutral lipid components: (1) a phospholipid, (2) cholesterol or a derivative thereof; or (3) a mixture of a phospholipid and cholesterol or a derivative thereof.
- cholesterol derivatives include, but are not limited to, cholestanol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'- hydroxybutyl ether, tocopherol and derivatives thereof, and mixtures thereof.
- Specific phospholipids that can be used include, but are not limited to, phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidic acids, phosphatidylserines or sphingomyelin.
- Such phospholipids include in particular diacylphosphatidylcholines, such as distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O- octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), l-oleo
- the additional lipid is DSPC or DSPC and cholesterol.
- the nucleic acid particles include both a cationic lipid and an additional lipid.
- particles described herein include a polymer conjugated lipid such as a pegylated lipid.
- a polymer conjugated lipid such as a pegylated lipid.
- pegylated lipid refers to a molecule comprising both a lipid portion and a polyethylene glycol portion. Pegylated lipids are known in the art.
- a pegylated lipid is ALC-0159, also referred to herein as (2- [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide).
- the amount of the at least one cationic lipid compared to the amount of the at least one additional lipid may affect important nucleic acid particle characteristics, such as charge, particle size, stability, tissue selectivity, and bioactivity of the nucleic acid. Accordingly, in some embodiments, the molar ratio of the at least one cationic lipid to the at least one additional lipid is from about 10:0 to about 1:9, about 4:1 to about 1:2, or about 3:1 to about 1:1.
- the non-cationic lipid, in particular neutral lipid, may comprise from about 0 mol % to about 90 mol %, from about 0 mol % to about 80 mol %, from about 0 mol % to about 70 mol %, from about 0 mol % to about 60 mol %, or from about 0 mol % to about 50 mol %, of the total lipid present in the particle.
- particles for use in accordance with the present disclosure may include, for example, ALC-0315, DSPC, CHOL, and ALC-0159, for example, wherein ALC- 0315 is at about 40 to 55 mol percent; DSPC is at about 5 to 15 mol percent; CHOL is at about 30 to 50 mol percent; and ALC-0159 is at about 1 to 10 mol percent.
- an RNA may be present in RNA lipoplex particles.
- RNA lipoplex particle relates to a particle that contains lipid, in particular cationic lipid, and RNA. Electrostatic interactions between positively charged liposomes and negatively charged RNA results in complexation and spontaneous formation of RNA lipoplex particles. Positively charged liposomes may be generally synthesized using a cationic lipid, such as DOTMA, and additional lipids, such as DOPE. In some embodiments, a RNA lipoplex particle is a nanoparticle.
- the RNA lipoplex particles include both a cationic lipid and an additional lipid.
- the cationic lipid is DOTMA and the additional lipid is DOPE.
- the molar ratio of the at least one cationic lipid to the at least one additional lipid is from about 10:0 to about 1:9, about 4:1 to about 1:2, or about 3:1 to about 1:1. In specific embodiments, the molar ratio may be about 3:1, about 2.75:1, about 2.5:1, about 2.25:1, about 2:1, about 1.75:1, about 1.5:1, about 1.25:1, or about 1:1. In an exemplary embodiment, the molar ratio of the at least one cationic lipid to the at least one additional lipid is about 2:1.
- RNA lipoplex particles described herein have an average diameter that in some embodiments ranges from about 200 nm to about 1000 nm, from about 200 nm to about 800 nm, from about 250 to about 700 nm, from about 400 to about 600 nm, from about 300 nm to about 500 nm, or from about 350 nm to about 400 nm.
- the RNA lipoplex particles have an average diameter of about 200 nm, about 225 nm, about 250 nm, about 275 nm, about 300 nm, about 325 nm, about 350 nm, about 375 nm, about 400 nm, about 425 nm, about 450 nm, about 475 nm, about 500 nm, about 525 nm, about 550 nm, about 575 nm, about 600 nm, about 625 nm, about 650 nm, about 700 nm, about 725 nm, about 750 nm, about 775 nm, about 800 nm, about 825 nm, about 850 nm, about 875 nm, about 900 nm, about 925 nm, about 950 nm, about 975 nm, or about 1000 nm.
- the RNA lipoplex particles have an average diameter that ranges from about 250 nm to about 700 nm. In another embodiment, the RNA lipoplex particles have an average diameter that ranges from about 300 nm to about 500 nm. In an exemplary embodiment, the RNA lipoplex particles have an average diameter of about 400 nm.
- RNA lipoplex particles andor compositions comprising RNA lipoplex particles described herein are useful for delivery of RNA to a target tissue after parenteral administration, in particular after intravenous administration.
- RNA lipoplex particles may be prepared using liposomes that may be obtained by injecting a solution of the lipids in ethanol into water or a suitable aqueous phase.
- the aqueous phase has an acidic pH.
- the aqueous phase comprises acetic acid, e.g., in an amount of about 5 mM.
- Liposomes may be used for preparing RNA lipoplex particles by mixing the liposomes with RNA.
- the liposomes and RNA lipoplex particles comprise at least one cationic lipid and at least one additional lipid.
- the at least one cationic lipid comprises l,2-di-0-octadecenyl-3- trimethylammonium propane (DOTMA) and/or l,2-dioleoyl-3-trimethylammonium-propane (DOTAP).
- DOTMA l,2-di-0-octadecenyl-3- trimethylammonium propane
- DOTAP l,2-dioleoyl-3-trimethylammonium-propane
- the at least one additional lipid comprises l,2-di-(9Z- octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol (Choi) and/or 1,2- dioleoyl-sn-glycero-3-phosphocholine (DOPC).
- the at least one cationic lipid comprises l,2-di-0-octadecenyl-3-trimethylammonium propane (DOTMA) and the at least one additional lipid comprises l,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE).
- DOPE 1,2- dioleoyl-sn-glycero-3-phosphocholine
- the liposomes and RNA lipoplex particles comprise 1,2-di-O- octadecenyl-3-trimethylammonium propane (DOTMA) and l,2-di-(9Z-octadecenoyl)-sn- glycero-3-phosphoethanolamine (DOPE).
- DOTMA 1,2-di-O- octadecenyl-3-trimethylammonium propane
- DOPE 1,2-di-(9Z-octadecenoyl)-sn- glycero-3-phosphoethanolamine
- RNA lipoplex particles having a net negative charge may be used to preferentially target spleen tissue or spleen cells such as antigen- presenting cells, in particular dendritic cells. Accordingly, following administration of the RNA lipoplex particles, RNA accumulation and/or RNA expression in the spleen occurs. Thus, RNA lipoplex particles of the disclosure may be used for expressing RNA in the spleen. In an embodiment, after administration of the RNA lipoplex particles, no or essentially no RNA accumulation and/or RNA expression in the lung and/or liver occurs.
- RNA lipoplex particles of the disclosure may be used for expressing RNA in such antigen presenting cells.
- the antigen presenting cells are dendritic cells and/or macrophages.
- Lipid nanoparticles Lipid nanoparticles
- nucleic acid such as RNA described herein is administered in the form of lipid nanoparticles (LNPs).
- LNP lipid nanoparticles
- the LNP may comprise any lipid capable of forming a particle to which the one or more nucleic acid molecules are attached, or in which the one or more nucleic acid molecules are encapsulated.
- the LNP comprises one or more cationic lipids, and one or more stabilizing lipids.
- Stabilizing lipids include neutral lipids and pegylated lipids.
- the LNP comprises a cationic lipid, a neutral lipid, a steroid, a polymer conjugated lipid; and the RNA, encapsulated within or associated with the lipid nanoparticle.
- an LNP comprises from 40 to 55 mol percent, from 40 to 50 mol percent, from 41 to 49 mol percent, from 41 to 48 mol percent, from 42 to 48 mol percent, from 43 to 48 mol percent, from 44 to 48 mol percent, from 45 to 48 mol percent, from 46 to 48 mol percent, from 47 to 48 mol percent, or from 47.2 to 47.8 mol percent of the cationic lipid.
- the LNP comprises about 47.0, 47.1, 47.2, 47.3, 47.4, 47.5, 47.6, 47.7, 47.8, 47.9 or 48.0 mol percent of the cationic lipid.
- the neutral lipid is present in a concentration ranging from 5 to 15 mol percent, from 7 to 13 mol percent, or from 9 to 11 mol percent. In some embodiments, the neutral lipid is present in a concentration of about 9.5, 10 or 10.5 mol percent. In some embodiments, the steroid is present in a concentration ranging from 30 to 50 mol percent, from 35 to 45 mol percent or from 38 to 43 mol percent. In some embodiments, the steroid is present in a concentration of about 40, 41, 42, 43, 44, 45 or 46 mol percent.
- the LNP comprises from 1 to 10 mol percent, from 1 to 5 mol percent, or from 1 to 2.5 mol percent of the polymer conjugated lipid.
- the LNP comprises from 40 to 50 mol percent a cationic lipid; from 5 to 15 mol percent of a neutral lipid; from 35 to 45 mol percent of a steroid; from 1 to 10 mol percent of a polymer conjugated lipid; and the RNA, encapsulated within or associated with the lipid nanoparticle.
- the mol percent is determined based on total mol of lipid present in the lipid nanoparticle.
- the neutral lipid is selected from the group consisting of DSPC,
- the neutral lipid is selected from the group consisting of DSPC, DPPC, DOPC, POPC, DOPE, DOPG, DPPG, POPE, DPPE, DMPE, DSPE, and SM.
- the neutral lipid is selected from the group consisting of DSPC, DPPC,
- the neutral lipid is DSPC.
- the steroid is cholesterol
- the polymer conjugated lipid is a pegylated lipid.
- the pegylated lipid has the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
- R12 and R13 are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and w has a mean value ranging from 30 to 60.
- R12 and R13 are each independently straight, saturated alkyl chains containing from 12 to 16 carbon atoms.
- w has a mean value ranging from 40 to 55.
- the average w is about 45.
- R12 and R13 are each independently a straight, saturated alkyl chain containing about 14 carbon atoms, and w has a mean value of about 45.
- the pegylated lipid is DMG-PEG 2000, e.g., having the following structure:
- the cationic lipid component of the LNPs has the structure of Formula
- G3 is C1-C24 alkylene, C1-C24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene;
- Ra is H or Cl -Cl 2 alkyl;
- R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl
- R4 is C1-C12 alkyl
- R5 is H or C1-C6 alkyl; and x is 0, 1 or 2.
- the lipid has one of the following s (IIIA) (IIIB) wherein:
- A is a 3 to 8-membered cycloalkyl or cycloalkylene ring
- R6 is, at each occurrence, independently H, OH or C1-C24 alkyl; n is an integer ranging from 1 to 15.
- the lipid has structure (IIIA), and in other embodiments, the lipid has structure (IIIB).
- the lipid has one of the following structures (IIIC) or
- the lipid has one of the following structures (HIE) or (IIIF):
- the lipid has one of the following structures (IIIG), (IIIH), (IIII), or (IIIJ):
- n is an integer ranging from 2 to 12, for example from 2 to 8 or from 2 to 4.
- n is 3, 4, 5 or 6.
- n is 3.
- n is 4.
- n is 5.
- n is 6.
- y and z are each independently an integer ranging from 2 to 10.
- y and z are each independently an integer ranging from 4 to 9 or from 4 to 6.
- R6 is H. In other of the foregoing embodiments, R6 is C1-C24 alkyl. In other embodiments, R6 is OH.
- G3 is unsubstituted. In other embodiments, G3 is substituted. In various different embodiments, G3 is linear C1-C24 alkylene or linear Cl -C24 alkenylene.
- R1 or R2, or both is C6-C24 alkenyl.
- R1 and R2 each, independently have the following structure: wherein: R7a and R7b are, at each occurrence, independently H or C1-C12 alkyl; and a is an integer from 2 to 12, wherein R7a, R7b and a are each selected such that R1 and R2 each independently comprise from 6 to 20 carbon atoms.
- a is an integer ranging from 5 to 9 or from 8 to 12.
- At least one occurrence of R7a is H.
- R7a is H at each occurrence.
- at least one occurrence of R7b is C1-C8 alkyl.
- C1-C8 alkyl is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, n- hexyl or n-octyl.
- R1 or R2, or both has one of the following structures:
- R3 is OH
- R4 is methyl or ethyl.
- the cationic lipid of Formula (III) has one of the structures set forth in the table below.
- an LNP comprises a lipid of Formula (III), RNA, a neutral lipid, a steroid and a pegylated lipid.
- a lipid of Formula (III) is compound III-3.
- a neutral lipid is DSPC.
- a steroid is cholesterol.
- a pegylated lipid is ALC-0159.
- the cationic lipid is present in the LNP in an amount from about 40 to about 50 mole percent. In some embodiments, the neutral lipid is present in the LNP in an amount from about 5 to about 15 mole percent. In some embodiments, the steroid is present in the LNP in an amount from about 35 to about 45 mole percent. In some embodiments, the pegylated lipid is present in the LNP in an amount from about 1 to about 10 mole percent.
- the LNP comprises compound III-3 in an amount from about 40 to about 50 mole percent, DSPC in an amount from about 5 to about 15 mole percent, cholesterol in an amount from about 35 to about 45 mole percent, and ALC-0159 in an amount from about 1 to about 10 mole percent. In some embodiments, the LNP comprises compound III-3 in an amount of about 47.5 mole percent, DSPC in an amount of about 10 mole percent, cholesterol in an amount of about 40.7 mole percent, and ALC-0159 in an amount of about 1.8 mole percent.
- the cationic lipid has one of the structures set forth in the table below.
- the LNP comprises a cationic lipid shown in the above table, e.g., a cationic lipid of Formula (B) or Formula (D), in particular a cationic lipid of Formula (D), RNA, a neutral lipid, a steroid and a pegylated lipid.
- the neutral lipid is DSPC.
- the steroid is cholesterol.
- the pegylated lipid is DMG-PEG 2000.
- the LNP comprises a cationic lipid that is an ionizable lipid-like material (lipidoid).
- lipidoid ionizable lipid-like material
- the cationic lipid has the following structure:
- the N/P value is preferably at least about 4. In some embodiments, the N/P value ranges from 4 to 20, 4 to 12, 4 to 10, 4 to 8, or 5 to 7. In some embodiments, the N/P value is about 6.
- LNP described herein may have an average diameter that in some embodiments ranges from about 30 nm to about 200 nm, or from about 60 nm to about 120 nm.
- a pharmaceutical composition comprises an RNA polynucleotide disclosed herein formulated as a particle.
- a particle is or comprises a lipid nanoparticle (LNP) or a lipoplex (LPX) particle.
- LNP lipid nanoparticle
- LPX lipoplex
- an RNA polynucleotide disclosed herein may be administered in a pharmaceutical composition or a medicament and may be administered in the form of any suitable pharmaceutical composition.
- a pharmaceutical composition described herein is an immunogenic composition for inducing an immune response.
- an immunogenic composition is a vaccine.
- an RNA polynucleotide disclosed herein may be administered in a pharmaceutical composition which may comprise a pharmaceutically acceptable carrier and may optionally comprise one or more adjuvants, stabilizers etc.
- a pharmaceutical composition is for therapeutic or prophylactic treatments.
- adjuvant relates to a compound which prolongs, enhances or accelerates an immune response.
- adjuvants comprise a heterogeneous group of compounds such as oil emulsions (e.g., Freund's adjuvants), mineral compounds (such as alum), bacterial products (such as Bordetella pertussis toxin), or immune- stimulating complexes.
- adjuvants include, without limitation, LPS, GP96, CpG oligodeoxynucleotides, growth factors, and cytokines, such as monokines, lymphokines, interleukins, chemokines.
- the cytokines may be IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IFNa, PTNGg, GM-CSF, LT-a.
- Further known adjuvants are aluminium hydroxide, Freund's adjuvant or oil such as Montanide® ISA51.
- Other suitable adjuvants for use in the present disclosure include lipopeptides, such as Pam3Cys.
- compositions according to the present disclosure are generally applied in a “pharmaceutically effective amount” and in “a pharmaceutically acceptable preparation”.
- pharmaceutically acceptable refers to the non-toxicity of a material which does not interact with the action of the active component of the pharmaceutical composition.
- the term "pharmaceutically effective amount” or “therapeutically effective amount” refers to the amount which achieves a desired reaction or a desired effect alone or together with further doses.
- the desired reaction preferably relates to inhibition of the course of the disease. This comprises slowing down the progress of the disease and, in particular, interrupting or reversing the progress of the disease.
- the desired reaction in a treatment of a disease may also be delay of the onset or a prevention of the onset of said disease or said condition.
- compositions described herein will depend on the condition to be treated, the severeness of the disease, the individual parameters of the patient, including age, physiological condition, size and weight, the duration of treatment, the type of an accompanying therapy (if present), the specific route of administration and similar factors. Accordingly, the doses administered of the compositions described herein may depend on various of such parameters. In the case that a reaction in a patient is insufficient with an initial dose, higher doses (or effectively higher doses achieved by a different, more localized route of administration) may be used.
- a pharmaceutical composition disclosed herein may contain salts, buffers, preservatives, and optionally other therapeutic agents.
- a pharmaceutical composition disclosed herein comprises one or more pharmaceutically acceptable carriers, diluents and/or excipients.
- Suitable preservatives for use in a pharmaceutical compositions of the present disclosure include, without limitation, benzalkonium chloride, chlorobutanol, paraben and thimerosal.
- excipient refers to a substance which may be present in a pharmaceutical composition of the present disclosure but is not an active ingredient. Examples of excipients, include without limitation, carriers, binders, diluents, lubricants, thickeners, surface active agents, preservatives, stabilizers, emulsifiers, buffers, flavoring agents, or colorants.
- diluting and/or thinning agent relates a diluting and/or thinning agent.
- the term “diluent” includes any one or more of fluid, liquid or solid suspension and/or mixing media. Examples of suitable diluents include ethanol, glycerol and water.
- carrier refers to a component which may be natural, synthetic, organic, inorganic in which the active component is combined in order to facilitate, enhance or enable administration of the pharmaceutical composition.
- a carrier as used herein may be one or more compatible solid or liquid fillers, diluents or encapsulating substances, which are suitable for administration to subject. Suitable carrier include, without limitation, sterile water, Ringer, Ringer lactate, sterile sodium chloride solution, isotonic saline, polyalkylene glycols, hydrogenated naphthalenes and, in particular, biocompatible lactide polymers, lactide/glycolide copolymers or polyoxyethylene/polyoxy-propylene copolymers.
- the pharmaceutical composition of the present disclosure includes isotonic saline.
- compositions for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R Gennaro edit. 1985).
- compositions can be selected with regard to the intended route of administration and standard pharmaceutical practice.
- a pharmaceutical composition described herein may be administered intravenously, intraarterially, subcutaneously, intradermally or intramuscularly.
- the pharmaceutical composition is formulated for local administration or systemic administration.
- Systemic administration may include enteral administration, which involves absorption through the gastrointestinal tract, or parenteral administration.
- parenteral administration refers to the administration in any manner other than through the gastrointestinal tract, such as by intravenous injection.
- the pharmaceutical composition is formulated for intramuscular administration.
- the pharmaceutical composition is formulated for systemic administration, e.g., for intravenous administration. Characterization
- an RNA polynucleotide disclosed herein is characterized in that, when assessed in an organism administered a composition or medical preparation comprising an RNA polynucleotide, elevated expression of a payload is observed relative to an appropriate reference comparator.
- an RNA polynucleotide disclosed herein is characterized in that, when assessed in an organism administered a composition or medical preparation comprising an RNA polynucleotide, increased duration of expression (e.g., prolonged expression) of a payload is observed relative to an appropriate reference comparator.
- an RNA polynucleotide disclosed herein is characterized in that, when assessed in an organism administered a composition or medical preparation comprising an RNA polynucleotide, decreased interaction with IFIT1 of an RNA polynucleotide is observed relative to an appropriate reference comparator.
- an RNA polynucleotide disclosed herein is characterized in that, when assessed in an organism administered a composition or medical preparation comprising an RNA polynucleotide, increased translation an RNA polynucleotide is observed relative to an appropriate reference comparator.
- a reference comparator comprises an organism administered an otherwise similar RNA polynucleotide without a m7(3’OMeG)(5')ppp(5')(2'OMeAi)pG 2 cap. In some embodiments, a reference comparator comprises an organism administered an otherwise similar RNA polynucleotide without a cap proximal sequence disclosed herein. In some embodiments, a reference comparator comprises an organism administered an otherwise similar RNA polynucleotide with a self-hybridizing sequence.
- an RNA polynucleotide disclosed herein is characterized in that, when assessed in an organism administered a composition or medical preparation comprising an RNA polynucleotide, elevated expression and increased duration of expression (e.g., prolonged expression) of a payload is observed relative to an appropriate reference comparator.
- elevated expression is determined at least 24 hours, at least 48 hours at least 72 hours, at least 96 hours or at least 120 hours after administration of a composition or medical preparation comprising an RNA polynucleotide. In some embodiments, elevated expression is determined at least 24 hours after administration of a composition or medical preparation comprising an RNA polynucleotide. . In some embodiments, elevated expression is determined at least 48 hours after administration of a composition or medical preparation comprising an RNA polynucleotide. . In some embodiments, elevated expression is determined at least 72 hours after administration of a composition or medical preparation comprising an RNA polynucleotide.
- elevated expression is determined at least 96 hours after administration of a composition or medical preparation comprising an RNA polynucleotide. In some embodiments, elevated expression is determined at least 120 hours after administration of a composition or medical preparation comprising an RNA polynucleotide.
- elevated expression is determined at about 24-120 hours after administration of a composition or medical preparation comprising an RNA polynucleotide. In some embodiments, elevated expression is determined at about 24-110 hours, about 24-100 hours, about 24-90 hours, about 24-80 hours, about 24-70 hours, about 24-60 hours, about 24-50 hours, about 24-40 hours, about 24-30 hours, about 30-120 hours, about 40-120 hours, about 50- 120 hours, about 60-120 hours, about 70-120 hours, about 80-120 hours, about 90-120 hours, about 100-120 hours, or about 110-120 hours after administration of a composition or medical preparation comprising an RNA polynucleotide.
- elevated expression of a payload is at least 2-fold to at least 10- fold. In some embodiments, elevated expression of a payload is at least 2-fold. In some embodiments, elevated expression of a payload is at least 3-fold. In some embodiments, elevated expression of a payload is at least 4-fold. In some embodiments, elevated expression of a payload is at least 6-fold. In some embodiments, elevated expression of a payload is at least 8- fold. In some embodiments, elevated expression of a payload is at least 10-fold.
- elevated expression of a payload is about 2-fold to about 50-fold. In some embodiments, elevated expression of a payload is about 2-fold to about 45-fold, about 2- fold to about 40-fold, about 2-fold to about 30-fold, about 2-fold to about 25-fold, about 2-fold to about 20-fold, about 2-fold to about 15-fold, about 2-fold to about 10-fold, about 2-fold to about 8-fold, about 2-fold to about 5-fold, about 5-fold to about 50-fold, about 10-fold to about 50- fold, about 15-fold to about 50-fold, about 20-fold to about 50-fold, about 25-fold to about 50- fold, about 30-fold to about 50-fold, about 40-fold to about 50-fold, or about 45-fold to about 50- fold.
- elevated expression (e.g., increased duration of expression) of a payload persists for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours after administration of a composition or a medical preparation comprising an RNA polynucleotide.
- elevated expression of a payload persists for at least 24 hours after administration.
- elevated expression of a payload persists for at least 48 hours after administration.
- elevated expression of a payload persists for at least 72 hours after administration.
- elevated expression of a payload persists for at least 96 hours after administration.
- elevated expression of a payload persists for at least 120 hours after administration of a composition or medical preparation comprising an RNA polynucleotide.
- elevated expression of a payload persists for at about 24-120 hours after administration of a composition or medical preparation comprising an RNA polynucleotide. In some embodiments, elevated expression persists for about 24-110 hours, about 24-100 hours, about 24-90 hours, about 24-80 hours, about 24-70 hours, about 24-60 hours, about 24-50 hours, about 24-40 hours, about 24-30 hours, about 30-120 hours, about 40- 120 hours, about 50-120 hours, about 60-120 hours, about 70-120 hours, about 80-120 hours, about 90-120 hours, about 100-120 hours, or about 110-120 hours after administration of a composition or medical preparation comprising an RNA polynucleotide.
- RNA polynucleotide comprising a 5’cap; a 5’ UTR comprising a cap proximal structure; and a sequence encoding a payload.
- an in vitro transcription reaction comprising:
- a template DNA comprising a polynucleotide sequence complementary to an RNA polynucleotide sequence disclosed herein; (ii) a polymerase; and (iii) an RNA polynucleotide.
- a polymerase is or comprises a T7 polymerase.
- a reaction further comprises a 5’ cap or a 5’ cap analog.
- a 5’ cap analog is or comprises a Capl structure.
- an RNA polynucleotide comprises a cap comprising a Capl structure; and a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of the RNA polynucleotide; and a sequence encoding a payload.
- a Capl structure comprises m7G(5')ppp(5')(2'OMeNl)pN2, wherein N1 is position +1 of the RNA polynucleotide, and N2 is position +2 of the RNA polynucleotide, and wherein N 1 and N2 are each independently chosen from: A, C, G, or U.
- RNA comprises: N 3 which is complementary to position +3 of the nucleic acid template and is any nucleotide, preferably A or C; N4 which is complementary to position +4 of the nucleic acid template and is a nucleotide selected from the group consisting of A, G and U, preferably T; and N5 which is complementary to position +5 of the nucleic acid template and is any nucleotide, wherein G* comprises the following structure: wherein ALLLL represents the bond by which G* is bound to the first phosphor atom of the
- RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence that comprises positions +1, +2, +3, +4, and +5 of an RNA polynucleotide, and a sequence encoding a payload; wherein an RNA polynucleotide is characterized in that when assessed in an organism administered an RNA polynucleotide or a composition comprising the same, elevated expression and/or increased duration of expression of an payload is observed relative to an appropriate reference comparator.
- a method comprising: administering to a subject, a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle disclosed herein.
- a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle disclosed herein.
- LNP lipid nanoparticle
- LPX lipoplex
- a method of inducing an immune response in a subject comprising administering to a subject, a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle disclosed herein.
- a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle disclosed herein.
- LNP lipid nanoparticle
- LPX lipoplex
- a method of vaccination of a subject comprising administering to a subject, a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle disclosed herein.
- a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle disclosed herein.
- a methood of decreasing interaction with IFIT1 of an RNA polynucleotide that comprises a 5’ cap and a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of the RNA polynucleotide
- the method comprising a step of: providing a variant of an RNA polynucleotide that differs from a parental RNA polynucleotide by substitution of one or more residues within the cap proximal sequence, and determining that interaction of a variant with IFIT1 is decreased relative to that of a parental RNA polynucleotide.
- determining comprises administering the RNA polynucleotide or a composition comprising the same to a cell or an organism.
- RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence that comprises positions +1, +2, +3, +4, and +5 of the RNA polynucleotide and a sequence encoding a payload
- the method comprising a step of: providing a variant of an RNA polynucleotide that differs from a parental RNA polynucleotide by substitution of one or more residues within a cap proximal sequence; and determining that expression of a variant is increased relative to that of a parental RNA polynucleotide.
- determining comprises administering the RNA polynucleotide or a composition comprising the same to a cell or an organism.
- increased translatability is assessed by increased expression and/or a persistence of expression of the payload.
- increased expression is determined at least 6 hours, at least 24 hours, at least 48 hours at least 72 hours, at least 96 hours or at least 120 hours after administering.
- increase in expression is at least 2-fold to 10-fold.
- increase in expression is about 2-fold to 50-fold.
- elevated expression persists for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours after administration.
- a therapeutic RNA comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload, the improvement that comprises: including one or more of the following residues in a cap proximal sequence: X at position +1 of an RNA polynucleotide, X at position +2 of an RNA polynucleotide, A at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and X at position +5 of an RNA polynucleotide, demonstrated to increase expression of the RNA when administered to a subject in an LNP formulation.
- X is chosen from A, C, G or U.
- a therapeutic RNA comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload, the improvement that comprises: including one or more of the following residues in a cap proximal sequence: A at position +1 of an RNA polynucleotide, G at position +2 of an RNA polynucleotide, A at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and U at position +5 of an RNA polynucleotide, demonstrated to increase expression of the RNA when administered to a subject in an LNP formulation.
- a therapeutic RNA comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload, the improvement that comprises: including one or more of the following residues in a cap proximal sequence: X at position +1 of an RNA polynucleotide, X at position +2 of an RNA polynucleotide, C at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and X at position +5 of an RNA polynucleotide, demonstrated to increase expression of the RNA when administered to a subject in an LNP formulation.
- X is chosen from A, C, G or U.
- RNA polynucleotide comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload
- the improvement that comprises: including one or more of the following residues in a cap proximal sequence: X at position +1 of an RNA polynucleotide, X at position +2 of an RNA polynucleotide, A at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and X at position +5 of an RNA polynucleotide.
- X is chosen from A, C, G or U.
- RNA polynucleotide comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload
- the improvement that comprises: including one or more of the following residues in a cap proximal sequence: A at position +1 of an RNA polynucleotide, G at position +2 of an RNA polynucleotide, A at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and U at position +5 of an RNA polynucleotide.
- RNA polynucleotide comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload
- the improvement that comprises: including one or more of the following residues in a cap proximal sequence: X at position +1 of an RNA polynucleotide, X at position +2 of an RNA polynucleotide, C at position +3 of an RNA polynucleotide, A at position +4 of an RNA polynucleotide, and X at position +5 of an RNA polynucleotide.
- X is chosen from A, C, G or U.
- an immune response is induced in a subject. In some embodiments of any of the methods disclosed herein, an immune response is a prophylactic immune response or a therapeutic immune response.
- a subject is a mammal.
- a subject is a human. In some embodiments of any of the methods disclosed herein, a subject has a disease or disorder disclosed herein.
- vaccination generates an immune response to an agent.
- an immune response is a prophylactic immune response.
- a subject has a disease or disorder disclosed herein.
- one dose of a pharmaceutical composition is administered.
- a plurality of doses of a pharmaceutical composition is administered.
- the method further comprises administration of one or more therapeutic agents.
- one or more therapeutic agents are administered before, after, or concurrently with administration of a pharmaceutical composition comprising an RNA polynucleotide.
- RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence, and a payload sequence
- the method comprising a step of: assessing at least two variants of an RNA polynucleotide, wherein: each variant includes a same 5’ cap and payload sequence; and the variants differ from one another at one or more specific residues of a cap proximal sequence; wherein the assessing comprises determining expression levels and/or duration of expression of a payload; and selecting at least one combination of 5’ cap and a cap proximal sequence that displays elevated expression relative to at least one other combination.
- assessing comprises administering an RNA construct or a composition comprising the same to a cell or an organism:
- elevated expression of a payload is detected at a time point at least 6 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours after administering.
- elevated expression is at least 2-fold to 10-fold. In some embodiments, elevated expression is about 2-fold to about 50-fold.
- elevated expression of a payload persists for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours after administering.
- an RNA polynucleotide comprises one or more features of an RNA polynucleotide provided herein.
- a composition comprising an RNA polynucleotide comprises a pharmaceutical composition provided herein.
- a composition or medical preparation comprising an RNA polynucleotide comprising: a 5’ cap comprising a Capl structure; a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of the RNA polynucleotide; and a sequence encoding a payload, wherein:
- the Capl structure comprises m7G(5')ppp(5')(2'OMeNi)pN 2 , wherein Ni is position +1 of the RNA polynucleotide, and N2 is position +2 of the RNA polynucleotide, and wherein Ni and N2 are each independently chosen from: A, C, G, or U; and
- the cap proximal sequence comprises Ni and N2 of the Capl structure, and:
- A3A4X5 SEQ ID NO: 1
- C3A4X5 SEQ ID NO: 2
- A3C4A5 SEQ ID NO: 3
- A3U4G5 SEQ ID NO: 4
- a sequence comprising: X3Y4X5 (SEQ ID NO: 7); wherein X3 (nucleotide X at position +3 in SEQ ID NO: 7) or X5 (nucleotide X at position +5 in SEQ ID NO: 1 or SEQ ID NO: 2) is each independently chosen from A, G, C, or U; and wherein Y4 (nucleotide Y at position +4 in SEQ ID NO: 7) is not C.
- the Ni position is A and the N2 position is U, and the Capl structure comprises m7G(5')ppp(5')(2'OMeAi)pU2; or
- the Ni position is G and the N2 position is G
- the Capl structure comprises m7G(5')ppp(5')(2'OMeGi)pG2.
- composition or medical preparation of embodiment 1 or 2, wherein a methylated Guanosine (m7G) in the Capl structure further comprises one or more modifications, e.g.,, wherein the m7G in the Capl structure comprises a methylated ribose.
- composition or medical preparation of embodiment 3, wherein the m7G in the Capl comprises a 3 ⁇ methylation (m7(3’OMeG)).
- a composition or medical preparation comprising an RNA polynucleotide comprising: a 5’ cap; a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of an RNA polynucleotide; and a sequence encoding a payload, wherein:
- the 5’ cap comprises a Capl structure comprising G*ppp(m1 2'-O )N1pN2 , wherein:
- NI is position +1 of the RNA polynucleotide
- N2 is position +2 of the RNA polynucleotide
- Ni and N2 are each independently chosen from: A, C, G, or U;
- G* comprises the following structure: wherein represents the bond by which G* is bound to the first phosphor atom of the ppp group, R 1 is CH 3 , R 2 is OH or O-CH 3 , and R 3 is O-CH 3; and (ii) a cap proximal sequence comprises Ni and N2 of the Capl structure, and:
- A3A4X5 SEQ ID NO: 1
- C3A4X5 SEQ ID NO: 2
- A3C4A5 SEQ ID NO: 3
- A3U4G5 SEQ ID NO: 4
- a sequence comprising X3Y4X5 (SEQ ID NO: 7); wherein X3 (nucleotide X at position +3 in SEQ ID NO: 7) or X5 (nucleotide X at position +5 in SEQ ID NO: 1 or SEQ ID NO: 2) is each independently chosen from A, G, C, or U; and wherein Y4 (nucleotide Y at position +4 in SEQ ID NO: 7) is not C.
- the Ni position is A and the N2 position is U, and the Capl structure comprises m7G(5')ppp(5')(2'OMeAi)pU2; or
- the Ni position is G and the N2 position is G
- the Capl structure comprises m7G(5')ppp(5')(2'OMeGi)pG2.
- cap proximal sequence comprises Ni and N2 of the Capl structure, and a sequence comprising: A3A4X5 (SEQ ID NO: 1), optionally wherein X5 is any nucleotide, e.g., A, C, G or U, preferably U.
- the cap proximal sequence comprises Ni and N2 of the Capl structure, and a sequence comprising A3U4G5 (SEQ ID NO: 4).
- composition or medical preparation comprising an RNA polynucleotide comprising: a 5’ cap comprising a Capl structure; a cap proximal sequence comprising positions +1,
- RNA polynucleotide +2, +3, +4, and +5 of the RNA polynucleotide; and a sequence encoding a payload, wherein:
- the Capl structure comprises m7(3’OMeG)(5')ppp(5')(2'OMeAi)pG2, wherein Ai is position +1 of the RNA polynucleotide, and G2 is position +2 of the RNA polynucleotide; and (ii) the cap proximal sequence comprises Ai and G2 of the Capl structure, and a sequence comprising: A3A4U5 at positions +3, +4 and +5 respectively of the RNA polynucleotide.
- composition or medical preparation comprising a capped RNA polynucleotide encoding a gene product, which RNA polynucleotide comprises the formula:
- R 1 is CH3, R 2 is OH or O-CH3, and R 3 is O-CH3
- Bi is any nucleobase, preferably A
- B2 is any nucleobase, preferably G
- B3 is any nucleobase, preferably A or C
- B4 is any nucleobase
- B5 is any nucleobase
- RNA polynucleotide comprises a 5’ UTR; and/or the RNA polynucleotide further comprises a 3’ UTR sequence; and/or a polyA sequence.
- the RNA polynucleotide does not comprise a self-hybridizing sequence, optionally wherein a self-hybridizing sequence is a sequence that can hybridize to a sequence in a 5’ UTR or 3’ UTR of the RNA polynucleotide, e.g., wherein the self-hybridizing sequence is or comprises SEQ ID NO: 8.
- a 5’ UTR comprises a human alpha globin (hAg) 5 ’UTR or a fragment thereof, a TEV 5’ UTR or a fragment thereof, a HSP705’ UTR or a fragment thereof, or a c-Jun 5’ UTR or a fragment thereof.
- composition or medical preparation of any one of the preceding embodiments wherein the RNA polynucleotide comprises a 3’ UTR or a fragment thereof, optionally wherein the 3’ UTR sequence comprises SEQ ID NO: 13, or a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity thereto.
- the 3’ UTR or a proximal sequence thereto comprises a restriction site, optionally wherein the restriction site is a BamHI site or a Xhol site.
- composition or medical preparation of any one of the preceding embodiments, wherein a PolyA sequence comprises at least 100 nucleotides, optionally wherein:
- a polyA sequence is an interrupted sequence of adenine nucleotides
- a polyA sequence comprises 30 adenine nucleotides followed by 70 adenine nucleotides, wherein the 30 adenine nucleotides and 70 adenine nucleotides are separated by a linker sequence.
- composition or medical preparation of embodiment 25, wherein a polyA sequence comprises the sequence of SEQ ID NO: 14.
- composition or medical preparation of any one of the preceding embodiments wherein an RNA polynucleotide comprises a sequence encoding a payload chosen from: a protein replacement polypeptide; an antibody agent; a cytokine; an antigenic polypeptide; a gene editing component; a regenerative medicine component or combinations thereof.
- a payload chosen from: a protein replacement polypeptide; an antibody agent; a cytokine; an antigenic polypeptide; a gene editing component; a regenerative medicine component or combinations thereof.
- 31 The composition or medical preparation of any one of the preceding embodiments, characterized in that, when assessed in an organism administered the composition or medical preparation comprising the RNA polynucleotide, elevated expression and/or increased duration of expression of the payload is observed relative to an appropriate reference comparator.
- composition or medical preparation of embodiment 32, wherein a disease or disorder with aberrant expression of a polypeptide includes but is not limited to: a rare disease, a metabolic disorder, a muscular dystrophy, a cardiovascular disease, or a monogenic disease.
- composition or medical preparation of embodiment 34, wherein an antibody agent comprises a CD3 antibody, a Claudin 6 antibody, or a combination thereof.
- composition or medical preparation of embodiment 30, wherein a payload is or comprises a cytokine or a fragment or a variant thereof, optionally wherein a cytokine comprises: IL-12 or a fragment or variant or a fusion thereof, IL-15 or a fragment or a variant or a fusion thereof, GMCSF or a fragment or a variant thereof; or IFN-alpha or a fragment or a variant thereof.
- a payload is or comprises an antigenic polypeptide or an immunogenic variant or an immunogenic fragment thereof, optionally wherein an antigenic polypeptide comprises one epitope from an antigen or a plurality of distinct epitopes from an antigen.
- composition or medical preparation of embodiment 37, wherein an antigenic polypeptide comprising a plurality of distinct epitopes from an antigen is polyepitopic.
- composition or medical preparation of embodiment 37 or 38, wherein an antigenic polypeptide comprises: an antigenic polypeptide from an allergen, a viral antigenic polypeptide, a bacterial antigenic polypeptide, a fungal antigenic polypeptide, a parasitic antigenic polypeptide, an antigenic polypeptide from an infectious agent, an antigenic polypeptide from a pathogen, a tumor antigenic polypeptide, or a self-antigenic polypeptide.
- composition or medical preparation of embodiment 39, wherein a viral antigenic polypeptide comprises an HIV antigenic polypeptide, an influenza antigenic polypeptide, a Coronavirus antigenic polypeptide, a Rabies antigenic polypeptide, or a Zika virus antigenic polypeptide, optionally wherein a viral antigenic polypeptide is or comprises a Coronavirus antigenic polypeptide.
- composition or medical preparation of embodiment 40 wherein a Coronavirus antigen is or comprises a SARS-CoV-2 protein, optionally wherein a SARS-CoV-2 protein comprises a SARS-CoV-2 Spike (S) protein, or an immunogenic variant or an immunogenic fragment thereof.
- a Coronavirus antigen is or comprises a SARS-CoV-2 protein
- a SARS-CoV-2 protein comprises a SARS-CoV-2 Spike (S) protein, or an immunogenic variant or an immunogenic fragment thereof.
- composition or medical preparation of embodiment 41, wherein the SARS-CoV-2 protein, or immunogenic variant or immunogenic fragment thereof, comprises proline residues at positions 986 and 987.
- composition or medical preparation of embodiment 41 or 42, wherein a SARS-CoV-2 S polypeptide (i) has at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to SEQ ID NO: 9; or
- (ii) is encoded by an RNA having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to SEQ ID NO: 10.
- composition or medical preparation of embodiment 43 or 44, wherein a tumor antigenic polypeptide comprises p53, ART-4, BAGE, ss-catenin/m, Bcr-abL CAMEL, CAP-1, CASP-8, CDC27/m, CDK4/m, CEA, CLAUDIN-12, c-MYC, CT, Cyp-B, DAM, ELF2M, ETV6-AML1, G250, GAGE, GnT-V, Gap 100, HAGE, HER-2/neu, HPV-E7, HPV-E6, HAST-2, hTERT (or hTRT), LAGE, LDLR/FUT, MAGE-A, preferably MAGE-A1, MAGE-A2, MAGE- A3, MAGE- A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, or MAGE-A12, MAGE-B, MAGE-
- composition or medical preparation of any one of embodiments 44-45, wherein a tumor antigenic polypeptide comprises a tumor antigen from a carcinoma, a sarcoma, a melanoma, a lymphoma, a leukemia, or a combination thereof.
- a tumor antigenic polypeptide comprises: a melanoma tumor antigen; a prostate cancer antigen; a HPV16 positive head and neck cancer antigen; a breast cancer antigen; an ovarian cancer antigen; a lung cancer antigen, e.g., an NSCLC antigen.
- a payload is or comprises a self- antigenic polypeptide or an immunogenic variant or an immunogenic fragment thereof, optionally wherein a self-antigenic polypeptide comprises an antigen that is typically expressed on cells and is recognized as a self-antigen by an immune system.
- composition or medical preparation of embodiment 48, wherein a self-antigenic polypeptide comprises: a multiple sclerosis antigenic polypeptide, a Rheumatoid arthritis antigenic polypeptide, a lupus antigenic polypeptide, a celiac disease antigenic polypeptide, a Sjogren’s syndrome antigenic polypeptide, or an ankylosing spondylitis antigenic polypeptide, or a combination thereof.
- a modified nucleoside is selected from pseudouridine (y), N1 -methyl-pseudouridine (m 1 y), and 5-methyl-uridine (m5U).
- composition or medical preparation of any one of the preceding embodiments, wherein an RNA polynucleotide is characterized in that upon administration to an organism it increases the expression level and/or duration of expression of an encoded payload, compared to administration of an otherwise similar RNA polynucleotide without a m7(3’OMeG)(5')ppp(5')(2'OMeAi)pG2 cap, without a cap proximal sequence disclosed herein, and/or with a self-hybridizing sequence, optionally wherein: (i) increased expression is determined at least 6 hours, at least 24 hours, at least 48 hours at least 72 hours, at least 96 hours or at least 120 hours after the administering, optionally wherein the increase in expression is at least 2-fold to 10-fold; or
- elevated expression persists for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours.
- composition or medical preparation of any one of the preceding embodiments wherein the RNA is formulated or is to be formulated as a liquid, a solid, or a combination thereof; wherein the RNA is formulated or is to be formulated for injection; or wherein the RNA is formulated or is to be formulated for intramuscular administration.
- a pharmaceutical composition comprising an RNA polynucleotide of any one of the preceding embodiments, formulated as a particle, optionally wherein a particle is or comprises a lipid nanoparticle (LNP) or a lipoplex (LPX) particle.
- LNP lipid nanoparticle
- LPX lipoplex
- a lipid nanoparticle comprises each of: a cationic lipid; a sterol; a neutral lipid; and a lipid conjugate.
- composition of embodiment 56 wherein the cationic lipid is or comprises ((4-hydroxybutyl)azanediyl)bis(hexane-6,l-diyl)bis(2-hexyldecanoate), the sterol is a cholesterol, the neutral lipid is or comprises a phospholipid, and the lipid conjugate is or comprises a polyethylene glycol (PEG)-lipid.
- the cationic lipid is or comprises ((4-hydroxybutyl)azanediyl)bis(hexane-6,l-diyl)bis(2-hexyldecanoate)
- the sterol is a cholesterol
- the neutral lipid is or comprises a phospholipid
- the lipid conjugate is or comprises a polyethylene glycol (PEG)-lipid.
- composition of embodiment 57, wherein the phospholipid is or comprises distearoylphosphatidylcholine (DSPC).
- DSPC distearoylphosphatidylcholine
- composition of embodiment 57, wherein the (PEG)-lipid is or comprises 2- [(polyethylene g 1 yco 1 )-2000] -N, /V-di tctradccy 1 acetamide .
- composition of any one of embodiments 56-58, wherein the lipid nanoparticle comprises each of:a. ((4-hydroxybutyl)azanediyl)bis(hexane-6,l-diyl)bis(2- hexyldecanoate); b. a cholesterol; c. distearoylphosphatidylcholine (DSPC); and d. 2- [(poly ethylene glycol)-2000] -N, /V-ditetradecylacetamide.
- a neutral lipid is present in a concentration ranging from 5 to 15 mol percent of total lipids
- a cationically ionizable lipid is present in a concentration ranging from 40 to 55 mol percent of total lipids
- a steroid is present in a concentration ranging from 30 to 50 mol percent of total lipids
- a pegylated lipid is present in a concentration ranging from 1 to 10 mol percent of total lipids.
- lipid nanoparticle comprise from 40 to 55 mol percent of a cationically ionizable lipid; from 5 to 15 mol percent of a neutral lipid; from 30 to 50 mol percent of a steroid; and from 1 to 10 mol percent of a pegylated lipid.
- RNA lipoplex particle is obtainable by mixing an RNA polynucleotide with liposomes.
- compositions 55-63 wherein a pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents and/or excipients.
- 65 The pharmaceutical composition of any one of embodiments 55-64, which is packaged as a kit, optionally wherein the kit further comprises instructions for use of said pharmaceutical composition for inducing an immune response in a subject.
- a nucleic acid template suitable to produce a cap 1 -capped RNA in which the first five nucleotides transcribed from the template strand of the nucleic acid template comprise the sequence NipN2pN 3 pN4pNs, wherein Ni is any nucleotide, preferably T; N2 is any nucleotide, preferably C; N3 is any nucleotide, preferably T or G; N4 is any nucleotide; and N5 is any nucleotide.
- nucleic acid template of embodiment 67 wherein the DNA template comprises: a 5’ UTR, a sequence encoding a payload, a 3’ UTR and a poly A sequence.
- a template DNA comprising a polynucleotide sequence complementary to an RNA polynucleotide sequence provided in any one of embodiments 1-54;
- a polymerase e.g., a T7 polymerase
- RNA polynucleotide comprises a cap comprising a Capl structure; and a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of the RNA polynucleotide; and a sequence encoding a payload, optionally wherein the Capl structure comprises m7G(5')ppp(5')(2'OMeNi)pN2, wherein Ni is position +1 of the RNA polynucleotide, and N2 is position +2 of the RNA polynucleotide, and wherein Ni and N2 are each independently chosen from: A, C, G, or U.
- RNA polynucleotide isolated from an in vitro transcription reaction provided in any one of embodiments 69-71.
- a method for producing a capped RNA comprising, transcribing a nucleic acid template in the presence of a cap structure, wherein the cap structure comprises G*ppp(m1 2'-O )N1pN2 , wherein Ni is complementary to position +1 of the nucleic acid template and N2 is complementary to position +2 of the nucleic acid template, and Ni and N2 are independently chosen from A, C, G or U, wherein position +3 of the nucleic acid template is any nucleotide, preferably T or G; position +4 of the nucleic acid template is any nucleotide; and position +5 of the nucleic acid template is any nucleotide, wherein G* comprises the following structure: wherein represents the bond by which G* is bound to the first phosphor atom of the ppp group, R 1 is CH 3 , R 2 is OH or O-CH 3 , and R 3 is O-CH 3 .
- composition comprising a DNA polynucleotide comprising a sequence complementary to an RNA polynucleotide sequence provided in any one of embodiments 1-54.
- the DNA polynucleotide composition of embodiment 74 which can be used to transcribe an RNA polynucleotide and/or, which is disposed in a vector.
- a method comprising: administering to a subject, a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle of any one of embodiments 55-64.
- a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle of any one of embodiments 55-64.
- a method of inducing an immune response in a subject comprising administering to a subject, a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle of any one of embodiments 55-64.
- a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle of any one of embodiments 55-64.
- a method of vaccination of a subject by administering a pharmaceutical composition comprising an RNA polynucleotide formulated in a lipid nanoparticle (LNP) or a lipoplex (LPX) particle of any one of embodiments 55-64.
- LNP lipid nanoparticle
- LPX lipoplex
- vaccination generates an immune response, optionally wherein an immune response is a prophylactic immune response.
- a method of decreasing interaction with IFIT1 of an RNA polynucleotide that comprises a 5’ cap and a cap proximal sequence comprising positions +1, +2, +3, +4, and +5 of the RNA polynucleotide comprising a step of: providing a variant of the RNA polynucleotide that differs from the parental RNA polynucleotide by substitution of one or more residues within the cap proximal sequence, and determining that interaction of the variant with IFIT1 is decreased relative to that of the parental RNA polynucleotide, optionally wherein the determining comprises administering the RNA polynucleotide or a composition comprising the same to a cell or an organism.
- a method of producing a polypeptide comprising a step of: providing an RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence that comprises positions +1, +2, +3, +4, and +5 of the RNA polynucleotide, and a sequence encoding a payload; wherein the RNA polynucleotide is characterized in that when assessed in an organism administered the RNA polynucleotide or a composition comprising the same, elevated expression and/or increased duration of expression of the payload is observed relative to an appropriate reference comparator.
- a method of increasing translatability of an RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence that comprises positions +1, +2, +3, +4, and +5 of the RNA polynucleotide and a sequence encoding a payload comprising a step of: providing a variant of the RNA polynucleotide that differs from a parental RNA polynucleotide by substitution of one or more residues within the cap proximal sequence; and determining that expression of the variant is increased relative to that of the parental RNA polynucleotide, optionally wherein the determining comprises administering the RNA polynucleotide or a composition comprising the same to a cell or an organism.
- increased expression is determined at least 6 hours, at least 24 hours, at least 48 hours at least 72 hours, at least 96 hours or at least 120 hours after the administering, optionally wherein the increase in expression is at least 2-fold to 10-fold; or
- elevated expression persists for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours.
- RNA comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload
- the improvement that comprises: including one or more of the following residues in a cap proximal sequence: A at position +1 of the RNA polynucleotide, G at position +2 of the RNA polynucleotide, A at position +3 of the RNA polynucleotide, A at position +4 of the RNA polynucleotide, and U at position +5 of the RNA polynucleotide, demonstrated to increase expression of the RNA when administered to a subject in an LNP formulation.
- a method of increasing translation of an RNA polynucleotide comprising a 5’ cap that includes a Capl structure, a cap proximal sequence and a sequence encoding a payload the improvement that comprises: including one or more of the following residues in a cap proximal sequence: A at position +1 of the RNA polynucleotide, G at position +2 of the RNA polynucleotide, A at position +3 of the RNA polynucleotide, A at position +4 of the RNA polynucleotide, and U at position +5 of the RNA polynucleotide.
- RNA polynucleotide that comprises a 5’ cap, a cap proximal sequence, and a payload sequence
- the method comprising a step of: assessing at least two variants of the RNA polynucleotide, wherein: each variant includes the same 5’ cap and payload sequence; and the variants differ from one another at one or more specific residues of the cap proximal sequence; wherein the assessing comprises determining expression levels and/or duration of expression of the payload sequence; and selecting at least one combination of 5’ cap and a cap proximal sequence that displays elevated expression relative to at least one other combination.
- RNA construct or a composition comprising the same comprises administering the RNA construct or a composition comprising the same to a cell or an organism:
- the elevated expression is detected at a time point at least 6 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours after the administering, optionally wherein the elevated expression is at least 2-fold to 10-fold; and/or the elevated expression persists for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours.
- RNA polynucleotide comprises one or more features of an RNA polynucleotide provided in any one of embodiments 1-54.
- the present Example describes the generation of RNA cassettes with improved expression level of an encoded payload, and/or increased duration of expression of an encoded payload in vivo.
- the methods used in this Example are described below.
- plasmids encoding codon-optimized murine erythropoietin (mEPO) were used.
- the plasmids corresponding to 5’ untranslated region sequences of tobacco etch virus 5' leader RNA (TEV) or human a-globin (hAg) mRNA were linearized with BspQI (New England Biolabs, Cat# R0712L) to generate templates.
- the MEGAscript T7 RNA polymerase kit (Thermo Fisher Scientific, Cat# AMB 1334-5) was used for transcription, and UTP was replaced with Nl- methylpseudouridine (ihIY) 5 ’-triphosphate (TriLink, Cat#N-1081).
- Capping of the mRNAs was performed co-transcriptionally using anti-reverse Capl analogue CleanCap413 (TriLink, Cat#N- 7413) at a final concentration of 3 mM.
- TriLink anti-reverse Capl analogue CleanCap413
- the initial GTP concentration in a transcription reaction was reduced from 7.5 mM to 1.5 mM and was incubated at 37°C for 30 min in a hybridization chamber.
- the initial concentration of additional nucleotides including ATP, CTP and m 1 YTR corresponded to the final 7.5 mM concentration. Adding of extra 1.5 mM GTP to the mixture was required after 30, 60, 90 and 120 minutes of incubation and incubated further at 37°C for 30 minutes.
- the mRNAs were transcribed to contain 100 nt-long 3’ poly(A) tail.
- DNA Turbo DNase Thermo Fisher Scientific, Cat#AM1907
- Thermo Fisher Scientific, Cat#AM1907 was added to the reaction mix and incubated the mixture at 37°C for 15 minutes.
- the synthesized mRNA was isolated from the reaction mix by precipitation with half reaction volume of 8 M LiCl solution (Sigma- Aldrich, Cat#L7026). After chilling at - 20°C for at least 1 hour, the RNA pellet was collected by centrifuging at 17.000 x g at 4°C for 5 minutes. After washing the RNA pellet twice with at least 200 pi ice-cold 75% Ethanol solution, it was dissolved in nuclease free water.
- the concentration and quality of in vitro transcribed mRNA were measured on a NanoDrop2000C spectrophotometer (Thermo Fisher Scientific, Cat#ND- 2000c). Aliquots of denatured IVT mRNAs were analyzed by electrophoresis in agarose gels containing 0.005% (v/v) GelRedTM nucleic acid gel stain (Masek T et ah, (2005) Anal Biochem 336: 46-50). Small aliquots of mRNA samples were stored in siliconized tubes at -20°C. All mRNAs were cellulose-purified as described (Baiersdorfer M. et al. (2019) Mol Ther Nucleic Acids 15(15):26-35).
- mice For quantification of mouse EPO levels, plasma samples were collected from mice injected with IVT mRNA encoding for murine erythropoietin complexed with TransIT mRNA (Mirusbio, Cat#MIR2255) at the indicated time points and analyzed by mouse Erythropoietin DuoSet ELISA kit (R&D Systems, Cat#DY959). Flat-bottom 96-well plates were pre-coated with 2 pg/ml rat anti mouse EPO capture antibody (100 pl/well) and incubated at room temperature (RT) overnight.
- RT room temperature
- the plates were washed three times with PBS containing 0.05% Tween-20 and incubated with 1% BSA (bovine serum albumin) (Sigma-Aldrich, Cat#2153) solution at RT for 2 hours to prevent non-specific binding of the antibody and washed again. A seven point standard curve using 2-fold serial dilutions and a high standard of 4000 pg/ml was applied. At a final volume of 50 pi plasma samples and standard diluted in 1% BSA solution were added to the appropriate wells and incubated at RT for 2 hours. After washing the plates, 100 pi of 1 mg/ml of rat biotinylated anti mouse EPO detection antibody in 1% BSA solution was distributed to each well and incubated RT for 2 hours.
- BSA bovine serum albumin
- the plates were washed and then incubated with 100 m ⁇ Streptavidin conjugated to horseradish peroxidase diluted (1:200) in 1% BSA solution at room temperature for 20 min. After washing, TMB 2-Component Microwell Peroxidase substrate solution (Medac Gmbh, Cat#50-76- 11) was added to each well (100 m ⁇ /well). Samples were incubated at room temperature for 5 min, and 2 M sulfuric acid (R&D Systems, Cat#DY994) was added (50 m ⁇ /well) to stop the reaction and absorbance was measured at 450 nm and 570 nm using an Infinite 200 Pro plate reader (Tecan).
- This Example assesses the effect of sequence elements in an RNA on the expression level and/or duration of expression of a payload encoded by the RNA.
- the first evaluation focused on assessing the impact of self-hybridization sequences in 3’ UTR sequence of an RNA polynucleotide.
- RNA constructs with or without a self-hybridization sequence termed “Lig3” were generated and injected intravenously into mice. At 6, 24, 48, and 72 h after mRNA injection, blood was collected from the animals and assessed for expression of EPO -the polypeptide encoded by the RNA constructs.
- RNA encoded payload One of the structural elements of an RNA which is required for translation and/or stability is a 5’ cap.
- the different 5’ Cap structures that can be used with an RNA are shown in FIGs. 3A-3H. It was previously shown that the IFIT1 (interferon-induced tetratricopeptidel) protein can bind to the 5 ’-end of the mRNA with very high affinity when the mRNA has a capO structure (PLoS pathogens (2013) 9, el003663).
- the affinity of IFITl’s interaction with an mRNA reduces when it has a capl structure and this allows for preferential binding by translation factors such as the elongation factor eIF4E.
- RNAs having different residues in positions +3, +4 and +5 of the RNA sequence were generated and tested. Positions +1 and +2 of the RNA sequences tested were A and G respectively. Animals were injected intravenously with the various RNA constructs shown in FIG. 4. At 6, 24, 48, and 72 h after injection, blood was collected from the animals and assessed for expression of EPO -the polypeptide encoded by the RNA constructs.
- EPO expression level at 6 hours and 24 hours after administration of RNA was comparable in all animals administered the various constructs. At 48 hours post-administration, some constructs resulted in better in vivo expression of EPO compared to others (compare AGAAU with AGACA at 48 hours). At 72 hours, the difference in in vivo EPO expression between animals dosed with the different constructs was even more significant with the AGACA construct showing more than a 10-fold reduced expression of EPO compared to several constructs including the AGAAU, AGAAC, AGCAA, AGCAC constructs.
- RNA construct having an optimized cap proximal RNA sequence with increased payload expression and/or duration of expression in vivo allows for administration of a lower dose of said RNA or a composition comprising the same to an organism relative to a comparator, e.g., an RNA sequence without an optimized cap proximal sequence.
- the present Example describes certain coronavims vaccine RNAs.
- Exemplified constructs include sequences encoding at least one epitope of a coronavims spike protein, and various other structural elements and/or features.
- documents that exemplified RNAs including, for example, a capl structure and proximal cap sequences as described herein are well expressed and strongly immunogenic.
- mice In the study, four groups of each eight female BALB/c mice were immunized once with the animal trial material at three different doses, or with buffer (control group; see Table 4). While the clinical trial material will be diluted in saline, the animal trial material was diluted in PBS including 300mM sucrose. As this is the storage buffer of the material itself, the test items are representative for the vaccine that will be used in the planned clinical trials. Immunizations were given IM using a dose volume of 20 pL.
- Plates were again washed three times with 300 pL/well lx PBS supplemented with 0.01% Tween 20 and incubated with mouse serum samples diluted in lx Casein Blocking Buffer for 1 hour at 37°C on a microplate shaker. Plates were washed three times with 300 pL/well lx PBS supplemented with 0.01% Tween 20 and subsequently incubated with Peroxidase-conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch Ltd., Cat. No. 115-036-071; diluted 1:7500 in lx Casein Blocking Buffer) for 45 minutes at 37°C on a microplate shaker.
- Peroxidase-conjugated goat anti-mouse secondary antibody Jackson ImmunoResearch Ltd., Cat. No. 115-036-071; diluted 1:7500 in lx Casein Blocking Buffer
- VSV vesicular stomatitis virus
- ORF open-reading frame
- GFP green fluorescent protein
- VSV/SARS-CoV-2 pseudovirus was generated according to a published protocol (Hoffmann et ah, Cell, 2020; PMID 32142651).
- the pseudotype virus bears the SARS-CoV-2 S protein, which mediates cell entry. Therefore, the pseudovirus can be inactivated by neutralizing antibodies that bind SARS-CoV-2 S. This inactivation can be analyzed via in vitro methods.
- 4xl0 4 Vero 76 cells (ATCC® CRL-1587TM) per well were seeded in a 96-well plate (Greiner Bio-One GmbH, Cat. No. 655160) in 150 pL/well DMEM (Thermo Fisher Scientific, Cat. No. 61965059) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich GmbH, Cat. No. F7524). Cells were incubated for 4 to 6 hours at 37°C and 7.5% CO2. Meanwhile, mouse serum samples were diluted 1:6 up to 1:768 in DMEM/10% FBS in two-fold dilution steps.
- FBS fetal bovine serum
- Diluted serum samples were combined with an equal volume of titrated and pre-diluted VSV/SARS CoV-2 pseudovirus supernatant, resulting in a serum dilution ranging from 1:12 up to 1 : 1536.
- the pseudovirus/semm dilution mix was incubated for 5 min at RT on a microplate shaker at 750 rpm with an additional 5 min incubation at RT without agitation.
- 50 pL/well pseudovims/serum dilution mix was added to the seeded Vero-76 cells with the applied pseudovims volume per well corresponding to 200 infectious units (IU). Each dilution of serum samples was tested in duplicate wells.
- Vero 76 cells incubated with pseudovirus in the absence of mouse sera were used as positive controls. Vero 76 cells incubated without pseudovirus were used as negative controls. After the incubation, the cell culture plates were removed from the incubator, placed in an IncuCyte Live Cell Analysis system (Essen Bioscience) and incubated for 30 min prior to the analysis. Whole well scanning for brightfield and GFP fluorescence was performed using a 4x objective. To calculate the neutralizing titer, infected GFP-positive cell number per well was compared with the pseudovims positive control. Mean values of the pseudovims positive control multiplied by 0.5 represent the pseudovims neutralization 50% (pVN50). Serum samples with mean values below this cut-off exhibit >50% vims neutralization activity, respectively. Attorney Docket No.: 2013237-0170
- mice were immunized IM once as outlined in Table 3. The immunogenicity of the RNA vaccine will be investigated by focusing on the antibody immune response.
- mice were immunized IM once as outlined in Table 3. The immunogenicity of the RNA vaccine will be investigated by focusing on the antibody immune response.
- ELISA data 7, 14, 21 and 28 d after the first immunization show an early, dose-dependent immune activation against the SI protein and the receptor binding domain (Figure 6).
- Sera obtained 14, 21, and 28 d after immunization show high SARS-CoV-2 pseudovirus neutralization, especially sera from mice immunized with 1 or 5 pg BNT162M and correlating with the strong increase of IgG antibody titers ( Figure 7).
- RNA vaccine coding for BNT162cl B ALB/c mice were immunized IM once as outlined in Table 3. The immunogenicity of the RNA vaccine will be investigated by focusing on the antibody immune response.
- mice were immunized IM once as outlined in Table 3.
- the Attorney Docket No.: 2013237-0170 immunogenicity of the RNA vaccine will be investigated by focusing on the antibody immune response.
- mice were immunized IM once as outlined in Table 3. The immunogenicity of the RNA vaccine will be investigated by focusing on the antibody immune response.
- the induction of an antibody response using a very low immunization dose of 0.2 pg/mouse when using the modRNA platform (BNT162bl, BNT162b2) as well as the saRNA platform (BNT162cl) indicates a high potency of the vaccine candidates.
- mice BNT162b2 induced a higher antigen- specific titer compared to BNT162bl encoded with the identical RNA platform.
- the immunogenicity in mice against the antigens differs between the RNA platforms.
- the most immunogenic platform based on antigen- specific antibody induction is the modRNA followed by saRNA.
- the uRNA platform induces the lowest antigen- specific antibody titer.
- An exemplary LNP delivery system was developed to effectively and safely deliver therapeutic nucleic acids into the cytosol of various cell types after local administration in vivo.
- the early formulation work was performed with several promising LNP formulations and surrogate RNA coding for luciferase.
- the aim of the experiments was to correlate the effect of different ionizable cationic lipids on the efficacy of RNA delivery by LNPs in vivo.
- Formulations were compared in terms of RNA encapsulation efficiency, apparent pKa, LNP size and polydispersity.
- ALC-0315 exhibited suitable physical characteristics regarding particle size, homogeneity, and RNA encapsulation efficiency.
- ALC-0315/DSPC/CHOL/ALC-0159 prototype was submitted for in vivo screening.
- the results presented in Figure 16 summarize the in vivo testing of two independent pilot batches using luciferase (Luc) RNA.
- the results demonstrate improved potency of the ALC-0315 prototype as compared to an internal benchmark (ALC-0218).
- ALC-0315 was identified as a highly potent cationic lipid and brought forward for further product development studies.
- the formulation screening procedure described above involves intravenous administration resulting in delivery primarily to the liver.
- the mechanism of LNP uptake into hepatocytes is driven by binding of endogenous apolipoproteins to the LNP followed by receptor-mediated endocytosis e.g. through low density lipoprotein receptors.
- Luc RNA containing LNPs comprising ALC-0315 were injected intravenously (0.3 mg/kg) and intramuscularly (0.2 mg/kg) into ApoE knockout mice in the presence or absence of recombinant human ApoE3.
- wild-type C57B1/6 mice were also treated by the different routes of administration.
- RNA-LNP were pre-incubated with recombinant human ApoE3 (1 mg encapsulated mRNA with 1 mg ApoE3) for 1 hour at room temperature (RT) prior to administration. Luc expression was monitored at 4, 24, 72 and 96 hours post administration ( Figure 17).
- mice When mice were administered intravenously, Luc expression was detected in the wild- type C57B1/6 mice. In the ApoE knockout mice Luc expression was significantly reduced however when preincubated with exogenous ApoE the expression of Luc was recovered to similar expression levels as wild-type mice ( Figure 18).
- RNA-LNP in vivo Luc expression experiments using mouse models showed, that similar mechanisms are involved in the uptake of RNA-LNP in case of intramuscular administration as for intravenous administration, and this is not only true for hepatocytes but also for the cells local to the administration site.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021260099A AU2021260099A1 (en) | 2020-04-22 | 2021-04-22 | RNA constructs and uses thereof |
MX2022013255A MX2022013255A (en) | 2020-04-22 | 2021-04-22 | Rna constructs and uses thereof. |
JP2022563994A JP2023522246A (en) | 2020-04-22 | 2021-04-22 | RNA constructs and uses thereof |
CN202310385622.XA CN116585464A (en) | 2020-04-22 | 2021-04-22 | RNA constructs and uses thereof |
CN202180041726.8A CN115867654A (en) | 2020-04-22 | 2021-04-22 | RNA constructs and uses thereof |
IL297417A IL297417A (en) | 2020-04-22 | 2021-04-22 | Rna constructs and uses thereof |
EP21720748.9A EP4139452A1 (en) | 2020-04-22 | 2021-04-22 | Rna constructs and uses thereof |
BR112022019782A BR112022019782A2 (en) | 2020-04-22 | 2021-04-22 | ANN CONSTRUCTS AND THEIR USES |
KR1020227040675A KR20230004735A (en) | 2020-04-22 | 2021-04-22 | RNA constructs and uses thereof |
CA3173922A CA3173922A1 (en) | 2020-04-22 | 2021-04-22 | Rna constructs and uses thereof |
US17/565,842 US11779659B2 (en) | 2020-04-22 | 2021-12-30 | RNA constructs and uses thereof |
US17/565,921 US11951185B2 (en) | 2020-04-22 | 2021-12-30 | RNA constructs and uses thereof |
Applications Claiming Priority (48)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2020061239 | 2020-04-22 | ||
EPPCT/EP2020/061239 | 2020-04-22 | ||
EPPCT/EP2020/066968 | 2020-06-18 | ||
EP2020066968 | 2020-06-18 | ||
EPPCT/EP2020/068174 | 2020-06-26 | ||
EP2020068174 | 2020-06-26 | ||
EPPCT/EP2020/069805 | 2020-07-13 | ||
EP2020069805 | 2020-07-13 | ||
EPPCT/EP2020/071733 | 2020-07-31 | ||
EP2020071733 | 2020-07-31 | ||
EP2020071839 | 2020-08-03 | ||
EPPCT/EP2020/071839 | 2020-08-03 | ||
EPPCT/EP2020/073668 | 2020-08-24 | ||
EP2020073668 | 2020-08-24 | ||
EPPCT/EP2020/081544 | 2020-11-09 | ||
EP2020081544 | 2020-11-09 | ||
EPPCT/EP2020/081981 | 2020-11-12 | ||
EP2020081981 | 2020-11-12 | ||
EPPCT/EP2020/082601 | 2020-11-18 | ||
EP2020082601 | 2020-11-18 | ||
EPPCT/EP2020/082989 | 2020-11-20 | ||
EP2020082989 | 2020-11-20 | ||
EPPCT/EP2020/083435 | 2020-11-25 | ||
EP2020083435 | 2020-11-25 | ||
EPPCT/EP2020/084342 | 2020-12-02 | ||
EP2020084342 | 2020-12-02 | ||
EPPCT/EP2020/085145 | 2020-12-08 | ||
EP2020085145 | 2020-12-08 | ||
EP2020085653 | 2020-12-10 | ||
EPPCT/EP2020/085653 | 2020-12-10 | ||
EPPCT/EP2020/087844 | 2020-12-23 | ||
EP2020087844 | 2020-12-23 | ||
EP2021050027 | 2021-01-04 | ||
EPPCT/EP2021/050027 | 2021-01-04 | ||
EPPCT/EP2021/050875 | 2021-01-15 | ||
EP2021050874 | 2021-01-15 | ||
EP2021050875 | 2021-01-15 | ||
EPPCT/EP2021/050874 | 2021-01-15 | ||
EP2021051772 | 2021-01-26 | ||
EPPCT/EP2021/051772 | 2021-01-26 | ||
EPPCT/EP2021/052572 | 2021-02-03 | ||
EP2021052572 | 2021-02-03 | ||
EP2021052716 | 2021-02-04 | ||
EPPCT/EP2021/052716 | 2021-02-04 | ||
EP2021054622 | 2021-02-24 | ||
EPPCT/EP2021/054622 | 2021-02-24 | ||
EPPCT/EP2021/059947 | 2021-04-16 | ||
PCT/EP2021/059947 WO2021213924A1 (en) | 2020-04-22 | 2021-04-16 | Coronavirus vaccine |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/565,842 Continuation US11779659B2 (en) | 2020-04-22 | 2021-12-30 | RNA constructs and uses thereof |
US17/565,921 Continuation US11951185B2 (en) | 2020-04-22 | 2021-12-30 | RNA constructs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021214204A1 true WO2021214204A1 (en) | 2021-10-28 |
Family
ID=75438688
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/059947 WO2021213924A1 (en) | 2020-04-22 | 2021-04-16 | Coronavirus vaccine |
PCT/EP2021/060508 WO2021214204A1 (en) | 2020-04-22 | 2021-04-22 | Rna constructs and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/059947 WO2021213924A1 (en) | 2020-04-22 | 2021-04-16 | Coronavirus vaccine |
Country Status (13)
Country | Link |
---|---|
US (6) | US11547673B1 (en) |
EP (4) | EP3901260A1 (en) |
JP (4) | JP2021191743A (en) |
KR (2) | KR20230015350A (en) |
CN (5) | CN113521268A (en) |
AU (2) | AU2021261471A1 (en) |
BR (2) | BR112022019781A2 (en) |
CA (2) | CA3174215A1 (en) |
GB (3) | GB202307565D0 (en) |
IL (2) | IL297419A (en) |
MX (2) | MX2022013254A (en) |
TW (1) | TW202206096A (en) |
WO (2) | WO2021213924A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11414453B2 (en) | 2015-09-21 | 2022-08-16 | Trilink Biotechnologies, Llc | Compositions and methods for synthesizing 5′-capped RNAs |
US11471525B2 (en) | 2020-02-04 | 2022-10-18 | Curevac Ag | Coronavirus vaccine |
WO2022162027A3 (en) * | 2021-01-27 | 2022-11-03 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022235847A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Technologies for early detection of variants of interest |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
WO2023228116A1 (en) * | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
US11865190B2 (en) | 2018-10-09 | 2024-01-09 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
US11872280B2 (en) | 2020-12-22 | 2024-01-16 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
RU2814020C2 (en) * | 2022-02-15 | 2024-02-21 | Федеральное государственное бюджетное учреждение "Центр стратегического планирования и управления медико-биологическими рисками здоровью" Федерального медико-биологического агентства | Set of conservative epitopes of viral proteins, method of their identification and selection, vaccine composition and method of vaccination |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112029781B (en) * | 2020-08-14 | 2023-01-03 | 中山大学 | Novel coronavirus SARS-CoV-2 safety replicon system and application thereof |
GB202017649D0 (en) * | 2020-11-09 | 2020-12-23 | Autolus Ltd | Polypeptide |
WO2023066496A1 (en) * | 2021-10-21 | 2023-04-27 | BioNTech SE | Coronavirus vaccine |
CN116200403A (en) * | 2021-11-30 | 2023-06-02 | 石药集团巨石生物制药有限公司 | Novel coronavirus mRNA vaccine for preventing mutant strain |
WO2023110422A1 (en) | 2021-12-16 | 2023-06-22 | Stefan Grabuschnig | Vaccine preparation |
WO2023121264A1 (en) * | 2021-12-20 | 2023-06-29 | 아이진 주식회사 | Vaccine composition for sars-cov-2 variant, and use thereof |
CN114031675B (en) * | 2022-01-10 | 2022-06-07 | 广州市锐博生物科技有限公司 | Vaccines and compositions based on the S protein of SARS-CoV-2 |
WO2023154818A1 (en) * | 2022-02-09 | 2023-08-17 | Modernatx, Inc. | Mucosal administration methods and formulations |
WO2023152188A1 (en) * | 2022-02-11 | 2023-08-17 | Attana Ab | Analytical method |
CN116768987A (en) * | 2022-03-09 | 2023-09-19 | 中生复诺健生物科技(上海)有限公司 | mRNA vaccine encoding novel coronavirus S protein |
WO2023172547A1 (en) * | 2022-03-11 | 2023-09-14 | National Health Research Institutes | Nucleic acid-lipid nanoparticle and method using the same |
WO2023180394A1 (en) * | 2022-03-22 | 2023-09-28 | Osivax | Mrna vaccine compositions and their use |
WO2023202711A1 (en) * | 2022-04-22 | 2023-10-26 | 仁景(苏州)生物科技有限公司 | Mrna vaccine based on novel coronavirus |
CN114989308B (en) * | 2022-05-12 | 2023-04-04 | 中国科学院微生物研究所 | Novel coronavirus chimeric nucleic acid vaccine and use thereof |
WO2023220693A1 (en) * | 2022-05-12 | 2023-11-16 | SunVax mRNA Therapeutics Inc. | Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator |
WO2023220842A1 (en) * | 2022-05-19 | 2023-11-23 | Shenzhen Genius Biotech Service Co.,Ltd. | A fusion protein as a subunit vaccine immunogen against sars-cov-2 and the preparation thereof |
US11654121B1 (en) | 2022-06-22 | 2023-05-23 | Flagship Pioneering Innovations Vi, Llc | Combination therapies for the treatment of viral infections |
WO2023250111A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Combination therapies for the treatment of viral infections |
CN114934056B (en) * | 2022-06-24 | 2023-10-20 | 仁景(苏州)生物科技有限公司 | mRNA vaccine based on novel coronavirus Omikovia mutant strain |
WO2024014770A1 (en) * | 2022-07-14 | 2024-01-18 | 엠큐렉스 주식회사 | Modified rna for preparing mrna vaccine and therapeutic agent |
CN117414418A (en) * | 2022-07-19 | 2024-01-19 | 深圳深信生物科技有限公司 | mRNA vaccine of novel coronavirus variant strain and application thereof |
WO2024017253A1 (en) * | 2022-07-19 | 2024-01-25 | 深圳深信生物科技有限公司 | Mrna for sars-cov-2 s protein and use thereof |
CN115716866A (en) * | 2022-09-30 | 2023-02-28 | 珠海丽凡达生物技术有限公司 | Novel coronavirus vaccine and preparation method and application thereof |
WO2024057237A1 (en) | 2022-09-16 | 2024-03-21 | Pfizer Inc. | Lipid nanoparticles |
CN115869332A (en) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | mRNA drug with low expression in liver after delivery into body and preparation method thereof |
CN115998714B (en) * | 2023-03-20 | 2023-06-30 | 威瑞生物科技(昆明)有限责任公司 | Lipid nanoparticle, delivery system and preparation method of delivery system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008157688A2 (en) * | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
WO2013143683A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
WO2016005324A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
Family Cites Families (344)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898278A (en) | 1986-12-05 | 1990-02-06 | Nalge Company | Storage container |
JPH10113117A (en) | 1996-10-11 | 1998-05-06 | Tomoji Tanaka | Insulated box |
AU733310C (en) | 1997-05-14 | 2001-11-29 | University Of British Columbia, The | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
US6381981B1 (en) | 2001-05-02 | 2002-05-07 | Advanced Tissue Sciences, Inc. | Container for shipping and storing frozen products |
EP1800697B1 (en) | 2001-06-05 | 2010-04-14 | CureVac GmbH | Stabilised mRNA with increased G/C-content for use in gene therapy |
US20030082357A1 (en) | 2001-09-05 | 2003-05-01 | Cem Gokay | Multi-layer core for vacuum insulation panel and insulated container including vacuum insulation panel |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
WO2004002415A2 (en) | 2002-06-27 | 2004-01-08 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
WO2004002453A1 (en) | 2002-06-28 | 2004-01-08 | Protiva Biotherapeutics Ltd. | Method and apparatus for producing liposomes |
DE10229872A1 (en) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immune stimulation through chemically modified RNA |
ATE371437T1 (en) * | 2003-02-17 | 2007-09-15 | Peter Burkhard | PEPTIDIC NANOPARTICLES AS DRUG DELIVERY AND ANTIGEN DISPLAY SYSTEMS |
US7897744B2 (en) | 2003-04-28 | 2011-03-01 | The Public Health Agency Of Canada | SARS virus nucleotide and amino acid sequences and uses thereof |
US20050002953A1 (en) | 2003-05-06 | 2005-01-06 | Jens Herold | SARS-coronavirus virus-like particles and methods of use |
EP1632094A4 (en) | 2003-06-10 | 2010-06-23 | Nokia Corp | Method and apparatus for switching mobile station between autonomous and scheduled transmissions |
CA2532196A1 (en) | 2003-06-18 | 2005-01-20 | Chinese National Human Genome Center At Shanghai | Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof |
WO2005012337A2 (en) | 2003-07-15 | 2005-02-10 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
WO2005012360A2 (en) | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
WO2005013904A2 (en) | 2003-08-04 | 2005-02-17 | University Of Massachusetts | Sars nucleic acids, proteins, vaccines, and uses thereof |
TW200515917A (en) * | 2003-09-15 | 2005-05-16 | Us Government | Methods and compositions for the generation of a protective immune response against SARS-COV |
US7129042B2 (en) | 2003-11-03 | 2006-10-31 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus |
ES2396127T3 (en) | 2003-12-02 | 2013-02-19 | Institut Pasteur | Use of proteins and peptides encoded by the genome of a new strain of coronavirus associated with SARS |
US20050178142A1 (en) | 2004-02-17 | 2005-08-18 | Perry Ralph J. | 96 hour duration insulated cryo-pack for maintaining -40 degree fahrenheit |
US7870748B2 (en) | 2005-02-25 | 2011-01-18 | Byrne Kathleen H | Method for controlled rate freezing and long term cryogenic storage |
EP2478760A1 (en) | 2005-05-10 | 2012-07-25 | Monsanto Technology LLC | Genes and uses for plant improvement |
AU2006259415B2 (en) | 2005-06-15 | 2012-08-30 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
ES2937245T3 (en) | 2005-08-23 | 2023-03-27 | Univ Pennsylvania | RNA containing modified nucleosides and methods of using the same |
DE102005046490A1 (en) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency |
JP2009544754A (en) | 2006-07-28 | 2009-12-17 | アプライド バイオシステムズ, エルエルシー | Dinucleotide MRNA cap analog |
US8865398B2 (en) | 2006-09-01 | 2014-10-21 | Abbott Laboratories | Combination hepatitis C virus antigen and antibody detection method |
DE102006051516A1 (en) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Base) modified RNA to increase the expression of a protein |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
PL215513B1 (en) | 2008-06-06 | 2013-12-31 | Univ Warszawski | New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein |
AU2015210364B2 (en) | 2008-10-09 | 2017-03-09 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
EP2370099B1 (en) | 2008-12-09 | 2016-04-20 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
AU2010208035B2 (en) | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
AU2015210336B2 (en) | 2010-08-17 | 2017-05-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CN103687957A (en) | 2011-05-17 | 2014-03-26 | 现代治疗公司 | Engineered nucleic acids and methods of use thereof for non-human vertebrates |
PL2717893T3 (en) | 2011-06-08 | 2019-12-31 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
EP2755693A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG10201602654SA (en) | 2011-10-03 | 2016-05-30 | Moderna Therapeutics Inc | Modified nucleosides,nucleotides,and nucleic acids,and uses thereof |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
EP2791364A4 (en) | 2011-12-14 | 2015-11-11 | Moderna Therapeutics Inc | Methods of responding to a biothreat |
CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
CN104968354A (en) | 2011-12-21 | 2015-10-07 | 现代治疗公司 | Methods of increasing the viability or longevity of an organ or organ explant |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
ES2654205T3 (en) | 2012-03-27 | 2018-02-12 | Curevac Ag | Artificial nucleic acid molecules for enhanced protein or peptide expression |
DK3260541T3 (en) | 2012-03-27 | 2019-08-12 | Curevac Ag | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PREPTIDE EXPRESSION |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243950A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
PT2922554T (en) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Terminally modified rna |
WO2014089239A1 (en) | 2012-12-07 | 2014-06-12 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
EP2931914A4 (en) | 2012-12-13 | 2016-08-17 | Moderna Therapeutics Inc | Modified polynucleotides for altering cell phenotype |
SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
EP3578200A1 (en) | 2013-02-22 | 2019-12-11 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
DK2970955T3 (en) | 2013-03-14 | 2019-02-11 | Translate Bio Inc | METHODS FOR CLEANING MESSENGER RNA |
DK2971102T3 (en) | 2013-03-14 | 2018-08-27 | Translate Bio Inc | QUANTITATIVE DETERMINATION FOR CAPPING EFFECTIVENESS OF MESSENGER RNA |
EP2971013B1 (en) | 2013-03-15 | 2020-08-19 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | Removal of dna fragments in mrna production process |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
EP3578652B1 (en) | 2013-03-15 | 2023-07-12 | ModernaTX, Inc. | Ribonucleic acid purification |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
TW201534578A (en) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | Novel lipid |
EP3036330B1 (en) | 2013-08-21 | 2018-09-12 | CureVac AG | Method for increasing expression of rna-encoded proteins |
ES2702466T3 (en) | 2013-08-21 | 2019-03-01 | Curevac Ag | Procedure to increase the expression of proteins encoded by RNA |
EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
AU2014337156A1 (en) | 2013-10-18 | 2016-05-12 | Modernatx, Inc. | Compositions and methods for tolerizing cellular systems |
ES2806575T3 (en) | 2013-11-01 | 2021-02-18 | Curevac Ag | Modified RNA with decreased immunostimulatory properties |
EP3062798B1 (en) | 2013-11-01 | 2020-05-06 | CureVac AG | Modified rna with decreased immunostimulatory properties |
SG10201805660WA (en) | 2013-12-30 | 2018-08-30 | Curevac Ag | Methods for rna analysis |
EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
HRP20220070T1 (en) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Nucleic acid vaccines |
CN117402871A (en) | 2014-04-25 | 2024-01-16 | 川斯勒佰尔公司 | Method for purifying messenger RNA |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
CA3179824A1 (en) | 2014-06-25 | 2015-12-30 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
WO2016011306A2 (en) | 2014-07-17 | 2016-01-21 | Moderna Therapeutics, Inc. | Terminal modifications of polynucleotides |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
EP3218508A4 (en) | 2014-11-10 | 2018-04-18 | Modernatx, Inc. | Multiparametric nucleic acid optimization |
DE202015009961U1 (en) | 2014-12-12 | 2022-01-25 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
US20180000953A1 (en) | 2015-01-21 | 2018-01-04 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
EP4026568A1 (en) | 2015-04-17 | 2022-07-13 | CureVac Real Estate GmbH | Lyophilization of rna |
AU2016253972B2 (en) | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
SG11201708541QA (en) | 2015-05-20 | 2017-12-28 | Curevac Ag | Dry powder composition comprising long-chain rna |
EP3298142B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
DK3303583T3 (en) | 2015-05-29 | 2020-07-13 | Curevac Real Estate Gmbh | METHOD FOR PREPARATION AND PURIFICATION OF RNA, INCLUDING AT LEAST ONE STEP FOR TANGENTIAL FLOW FILTRATION |
EP3307305A4 (en) | 2015-06-10 | 2019-05-22 | Modernatx, Inc. | Targeted adaptive vaccines |
WO2017015457A1 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Ebola vaccine |
EP3324979B1 (en) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Infectious disease vaccines |
US20190008887A1 (en) | 2015-07-30 | 2019-01-10 | ModernaTX Inc. | Multimeric mrna |
MA42543A (en) | 2015-07-30 | 2018-06-06 | Modernatx Inc | CONCATEMERIC PEPTIDIC EPITOPE RNA |
DE22195354T1 (en) | 2015-08-10 | 2023-05-25 | CureVac Manufacturing GmbH | METHOD OF INCREASING REPLICATION OF A CIRCULAR DNA MOLECULE |
WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
US20180237849A1 (en) | 2015-08-17 | 2018-08-23 | Modernatx, Inc. | Rna mapping/fingerprinting |
AU2016315444B2 (en) | 2015-08-28 | 2023-02-23 | BioNTech SE | Method for reducing immunogenicity of RNA |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
WO2017049245A2 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
DK3350333T3 (en) | 2015-09-17 | 2022-01-31 | Modernatx Inc | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION |
CN113584020A (en) | 2015-09-21 | 2021-11-02 | 垂林克生物技术公司 | Compositions and methods for synthesizing 5' -capped RNA |
US10849920B2 (en) | 2015-10-05 | 2020-12-01 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
SI3362461T1 (en) | 2015-10-16 | 2022-05-31 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
AU2016340183A1 (en) | 2015-10-16 | 2018-04-19 | Modernatx, Inc. | mRNA cap analogs and methods of mRNA capping |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
PE20181530A1 (en) | 2015-10-22 | 2018-09-26 | Modernatx Inc | RESPIRATORY SYNCITIAL VIRUS VACCINE |
US20180289792A1 (en) | 2015-10-22 | 2018-10-11 | ModernaTX. Inc. | Sexually transmitted disease vaccines |
MX2018004918A (en) | 2015-10-22 | 2019-04-01 | Modernatx Inc | Herpes simplex virus vaccine. |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
HRP20220872T1 (en) | 2015-10-22 | 2022-12-23 | Modernatx, Inc. | Respiratory virus vaccines |
CN114404581A (en) | 2015-10-22 | 2022-04-29 | 摩登纳特斯有限公司 | Cancer vaccine |
JP6921833B2 (en) | 2015-10-22 | 2021-08-18 | モデルナティーエックス, インコーポレイテッド | Human cytomegalovirus vaccine |
TW201729838A (en) | 2015-10-22 | 2017-09-01 | 現代公司 | Nucleic acid vaccines for varicella zoster virus (VZV) |
MX2018004916A (en) | 2015-10-22 | 2019-07-04 | Modernatx Inc | Broad spectrum influenza virus vaccine. |
PL3368507T3 (en) | 2015-10-28 | 2023-03-27 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2017100551A1 (en) | 2015-12-09 | 2017-06-15 | Alexion Pharmaceuticals, Inc. | HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION |
LT3386484T (en) | 2015-12-10 | 2022-06-10 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
CA3007108A1 (en) | 2015-12-17 | 2017-06-22 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
RS63051B1 (en) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Compounds and compositions for intracellular delivery of agents |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
GB2546257A (en) | 2016-01-08 | 2017-07-19 | The Wool Packaging Company Ltd | Temperature controlled packaging and transportation method |
EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2017162266A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
US20190167811A1 (en) | 2016-04-13 | 2019-06-06 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
WO2017201348A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
AU2017268396B2 (en) | 2016-05-18 | 2023-05-18 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
JP7114485B2 (en) | 2016-05-18 | 2022-08-08 | モデルナティエックス インコーポレイテッド | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease |
MA45050A (en) | 2016-05-18 | 2019-03-27 | Modernatx Inc | LIPOPROTEIN LIPASE CODING POLYNUCLEOTIDES FOR THE TREATMENT OF HYPERLIPIDEMIA |
US20190275170A1 (en) | 2016-05-18 | 2019-09-12 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
KR102533456B1 (en) | 2016-05-18 | 2023-05-17 | 모더나티엑스, 인크. | Polynucleotides encoding relaxin |
US20190382774A1 (en) | 2016-05-18 | 2019-12-19 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
WO2017201347A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
MA45032A (en) | 2016-05-18 | 2019-03-27 | Fundacion Para La Investig Medica Aplicada | POLYNUCLEOTIDES CODING FOR PORPHOBILINOGEN DESAMINASE FOR THE TREATMENT OF ACUTE INTERMITTEN PORPHYRIA |
EP3458092A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
AU2017286606A1 (en) | 2016-06-14 | 2018-12-13 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
GB201611050D0 (en) | 2016-06-24 | 2016-08-10 | Softbox Systems Ltd | A passive temperature control system for transport and storage containers |
CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
EP3529255A1 (en) * | 2016-10-19 | 2019-08-28 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
MA46584A (en) | 2016-10-21 | 2019-08-28 | Modernatx Inc | HUMAN CYTOMEGALOVIRUS VACCINE |
WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
EP3532103A1 (en) * | 2016-10-26 | 2019-09-04 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
MX2019004810A (en) | 2016-10-26 | 2019-10-15 | Modernatx Inc | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof. |
WO2018081462A1 (en) | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Methods and compositions for rna mapping |
CN110352071A (en) | 2016-10-26 | 2019-10-18 | 库瑞瓦格股份公司 | Lipidic nanoparticles mRNA vaccine |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
MA46766A (en) | 2016-11-11 | 2019-09-18 | Modernatx Inc | INFLUENZA VACCINE |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
US20180243225A1 (en) | 2017-01-25 | 2018-08-30 | Modernatx, Inc. | Ebola/marburg vaccines |
CA3052255A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Rna cancer vaccines |
WO2018144775A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
US20200032274A1 (en) | 2017-02-01 | 2020-01-30 | Moderna TX, Inc. | Polynucleotide secondary structure |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | High potency immunogenic compositions |
US20200368162A1 (en) | 2017-02-24 | 2020-11-26 | Modernatx, Inc. | Nucleic Acid-Based Therapy of Muscular Dystrophies |
CR20190444A (en) | 2017-02-28 | 2019-12-17 | Sanofi Sa | Therapeutic rna |
KR102619015B1 (en) | 2017-03-15 | 2023-12-28 | 큐 바이오파마, 인크. | How to Regulate Your Immune Response |
DK3596042T3 (en) | 2017-03-15 | 2022-04-11 | Modernatx Inc | CRYSTAL FORMS OF AMINOLIPIDS |
EP3595727A1 (en) | 2017-03-15 | 2020-01-22 | ModernaTX, Inc. | Lipid nanoparticle formulation |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
MA47787A (en) | 2017-03-15 | 2020-01-22 | Modernatx Inc | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
IL298380A (en) | 2017-03-15 | 2023-01-01 | Modernatx Inc | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
MA52262A (en) | 2017-03-15 | 2020-02-19 | Modernatx Inc | BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS |
WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
WO2018175783A1 (en) | 2017-03-22 | 2018-09-27 | Modernatx, Inc. | Rna bacterial vaccines |
US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
US20200054737A1 (en) | 2017-04-26 | 2020-02-20 | Modema TX, Inc. | Herpes simplex virus vaccine |
EP4253544A3 (en) | 2017-05-18 | 2023-12-20 | ModernaTX, Inc. | Modified messenger rna comprising functional rna elements |
CN107033250B (en) | 2017-05-23 | 2020-01-21 | 山东省农业科学院奶牛研究中心 | Bovine coronavirus recombinant multi-epitope antigen and application thereof |
WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
WO2018232355A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna antibodies |
WO2019035998A1 (en) | 2017-08-17 | 2019-02-21 | Modernatx, Inc. | Systems with fluid path control and regulation |
EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | Analytical hplc methods |
US20200254086A1 (en) | 2017-08-18 | 2020-08-13 | Moderna TX, Inc. | Efficacious mrna vaccines |
JP7408098B2 (en) | 2017-08-18 | 2024-01-05 | モデルナティエックス インコーポレイテッド | RNA polymerase variants |
MA49922A (en) | 2017-08-18 | 2021-06-02 | Modernatx Inc | PROCESSES FOR HPLC ANALYSIS |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Zika virus rna vaccines |
US20190192646A1 (en) | 2017-11-03 | 2019-06-27 | Modernatx, Inc. | Salmonella vaccines |
WO2019092002A1 (en) | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
GB201718660D0 (en) | 2017-11-10 | 2017-12-27 | Ucl Business Plc | Improved liposome for mRNA delivery to cells |
EP3713601A4 (en) | 2017-11-21 | 2022-03-09 | Modernatx, Inc. | Epstein-barr virus vaccines |
MA54676A (en) | 2018-01-29 | 2021-11-17 | Modernatx Inc | RSV RNA VACCINES |
CA3089117A1 (en) | 2018-01-30 | 2019-08-08 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
JP2021521855A (en) | 2018-04-27 | 2021-08-30 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | Design and delivery of homologous recombination repair templates for editing hemoglobin-related mutations |
EP3801627A1 (en) | 2018-05-30 | 2021-04-14 | Translate Bio, Inc. | Phosphoester cationic lipids |
EP3813848A4 (en) | 2018-06-27 | 2022-07-20 | ModernaTX, Inc. | Personalized cancer vaccine epitope selection |
TW202019955A (en) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods |
AU2019338557A1 (en) | 2018-09-13 | 2021-03-25 | Modernatx, Inc. | Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders |
JP2022500543A (en) | 2018-09-19 | 2022-01-04 | モデルナティーエックス, インコーポレイテッド | High-purity PEG lipids and their use |
EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
MA53650A (en) | 2018-09-19 | 2021-07-28 | Modernatx Inc | PEG LIPIDS AND THEIR USES |
CA3113651A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
KR20210093871A (en) | 2018-10-02 | 2021-07-28 | 인텔리아 테라퓨틱스, 인크. | Ionizable amine lipids |
AU2019374818A1 (en) | 2018-11-07 | 2021-05-27 | Modernatx, Inc. | RNA cancer vaccines |
CN111200358B (en) | 2018-11-19 | 2021-09-03 | 广东美的白色家电技术创新中心有限公司 | System for restraining electromagnetic interference of refrigerant radiator and household appliance |
CN115120716A (en) | 2019-01-14 | 2022-09-30 | 健泰科生物技术公司 | Methods of treating cancer with PD-1 axis binding antagonists and RNA vaccines |
WO2020160397A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
KR20210142636A (en) | 2019-02-20 | 2021-11-25 | 모더나티엑스, 인크. | RNA polymerase variants for co-transcriptional capping |
CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
US20220241399A1 (en) | 2019-03-15 | 2022-08-04 | Moderna TX, Inc. | Hiv rna vaccines |
WO2020198337A1 (en) * | 2019-03-25 | 2020-10-01 | Ohio State Innovation Foundation | Engineered mrna sequences and uses thereof |
JP2022535006A (en) | 2019-05-31 | 2022-08-04 | モデルナティエックス インコーポレイテッド | Proliferating T cell assay |
MA56517A (en) | 2019-06-24 | 2022-04-27 | Modernatx Inc | MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS AND THEIR USES |
CN110378000B (en) | 2019-07-11 | 2020-11-24 | 上海理工大学 | Structural static strength design method based on strength field |
US20230097090A1 (en) | 2019-08-14 | 2023-03-30 | Acuitas Therapeutics, Inc. | Improved lipid nanoparticles for delivery of nucleic acids |
EP4013865A4 (en) | 2019-08-14 | 2023-08-23 | ModernaTX, Inc. | Processes for purifying downstream products of in vitro transcription |
WO2021050864A1 (en) | 2019-09-11 | 2021-03-18 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US20220349006A1 (en) | 2019-09-19 | 2022-11-03 | Moderna TX, Inc. | Cap guides and methods of use thereof for rna mapping |
GB201915905D0 (en) | 2019-11-01 | 2019-12-18 | Spybiotech Ltd | Viruses with modified capsid proteins |
IL294290A (en) | 2019-12-31 | 2022-08-01 | Elixirgen Therapeutics Inc | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
US20210217484A1 (en) | 2020-01-10 | 2021-07-15 | Modernatx, Inc. | Variational autoencoder for biological sequence generation |
WO2021147025A1 (en) | 2020-01-22 | 2021-07-29 | The University Of Hong Kong-Shenzhen Hospital | Anti 2019-ncov vaccine |
KR20220141302A (en) | 2020-01-27 | 2022-10-19 | 노바백스, 인코포레이티드 | coronavirus vaccine formulation |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
US20210228707A1 (en) | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
KR20220133224A (en) * | 2020-01-28 | 2022-10-04 | 모더나티엑스, 인크. | coronavirus RNA vaccine |
BR112022015053A2 (en) | 2020-01-30 | 2022-09-20 | Modernatx Inc | IMMUNIZING COMPOSITIONS AGAINST RESPIRATORY VIRUS |
WO2021155323A1 (en) | 2020-01-31 | 2021-08-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines |
WO2021155760A1 (en) | 2020-02-03 | 2021-08-12 | 康希诺生物股份公司 | Mrna vaccine for 2019-ncov coronavirus, preparation method and application thereof |
IL293571A (en) | 2020-02-04 | 2022-08-01 | Curevac Ag | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
KR20220123294A (en) | 2020-02-05 | 2022-09-06 | 샨시 진보 바이오-파르마시우티컬 씨오., 엘티디. | Polypeptides, methods for their preparation and uses |
AU2021216443A1 (en) | 2020-02-07 | 2022-09-08 | RNAimmune, Inc. | Composition and method of mRNA vaccines against novel coronavirus infection |
EP4100052A2 (en) | 2020-02-07 | 2022-12-14 | ModernaTX, Inc. | Sars-cov-2 mrna domain vaccines |
AU2020429019B2 (en) | 2020-02-10 | 2023-02-02 | Institute Of Microbiology, Chinese Academy Of Sciences | Beta-coronavirus antigen, preparation method therefor and use thereof |
KR20220140586A (en) * | 2020-02-11 | 2022-10-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | SARS-CoV-2 vaccine |
EP4103584A1 (en) | 2020-02-12 | 2022-12-21 | La Jolla Institute for Immunology | Coronavirus t cell epitopes and uses thereof |
CN113186203B (en) | 2020-02-13 | 2022-12-30 | 斯微(上海)生物科技股份有限公司 | Vaccine agent for treating or preventing coronavirus diseases |
CA3167611A1 (en) | 2020-02-13 | 2021-08-19 | Etienne Simon-Loriere | Nucleic acid vaccine against the sars-cov-2 coronavirus |
CA3166811A1 (en) | 2020-02-13 | 2021-08-19 | Nicolas Robert Xavier Escriou | Measles-vectored covid-19 immunogenic compositions and vaccines |
JP2023515387A (en) | 2020-02-14 | 2023-04-13 | エピバックス・インコーポレーテッド | T cell epitope clusters and related compositions useful for prevention, diagnosis and treatment of COVID-19 |
GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
CN111303254A (en) | 2020-02-20 | 2020-06-19 | 北京新创生物工程有限公司 | Novel coronavirus (SARS-CoV-2) antigen detection kit |
CN110951756B (en) | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | Nucleic acid sequence for expressing SARS-CoV-2 virus antigen peptide and its application |
WO2021000969A2 (en) | 2020-02-23 | 2021-01-07 | 广州恩宝生物医药科技有限公司 | Nucleic acid sequence expressing sars-cov-2 virus antigen peptide and use thereof |
CN110974950B (en) | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | Adenovirus vector vaccine for preventing SARS-CoV-2 infection |
CN111218458B (en) | 2020-02-27 | 2020-11-20 | 珠海丽凡达生物技术有限公司 | mRNAs encoding SARS-CoV-2 virus antigen and vaccine and preparation method of vaccine |
WO2021178306A1 (en) | 2020-03-01 | 2021-09-10 | Dynavax Technologies Corporation | Coronavirus vaccines comprising a tlr9 agonist |
US20210332085A1 (en) | 2020-03-05 | 2021-10-28 | Swey-Shen Chen | CoV-2 (CoV-n) antibody neutralizing and CTL vaccines using protein scaffolds and molecular evolution |
US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
EP4117720A1 (en) | 2020-03-09 | 2023-01-18 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
US20220016234A1 (en) | 2020-03-11 | 2022-01-20 | Immunitybio, Inc. | Anti covid-19 therapies using nucleocapsid and spike proteins |
IL295630A (en) | 2020-03-13 | 2022-10-01 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
CN111218459B (en) | 2020-03-18 | 2020-09-11 | 中国人民解放军军事科学院军事医学研究院 | Recombinant novel coronavirus vaccine taking human replication-defective adenovirus as vector |
WO2021188906A1 (en) | 2020-03-19 | 2021-09-23 | Nature's Toolbox, Inc. | Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same |
IL296617A (en) | 2020-03-20 | 2022-11-01 | Biontech Us Inc | Coronavirus vaccines and methods of use |
CN111088283B (en) | 2020-03-20 | 2020-06-23 | 苏州奥特铭医药科技有限公司 | mVSV viral vector, viral vector vaccine thereof and mVSV-mediated novel coronary pneumonia vaccine |
WO2021194826A2 (en) | 2020-03-24 | 2021-09-30 | Icahn School Of Medicine At Mount Sinai | Recombinant sars-cov-2 spike protein and uses thereof |
GB202004493D0 (en) | 2020-03-27 | 2020-05-13 | Imp College Innovations Ltd | Coronavirus vaccine |
TW202144574A (en) | 2020-03-30 | 2021-12-01 | 國立大學法人大阪大學 | Prophylactic or therapeutic vaccine for coronavirus infection or symptoms associated with coronavirus infection |
US11559577B2 (en) | 2020-03-31 | 2023-01-24 | Engimata, Inc. | Immunogenic composition forming a vaccine, and a method for its manufacture |
US11278617B2 (en) | 2020-03-31 | 2022-03-22 | Engimata, Inc | Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture |
WO2021201612A1 (en) | 2020-03-31 | 2021-10-07 | 주식회사 에스엘백시젠 | Novel vaccine composition for prevention and treatment of coronavirus |
CN116113431A (en) | 2020-04-01 | 2023-05-12 | 迪奥辛瓦克斯有限公司 | Coronavirus vaccine |
WO2021202599A2 (en) | 2020-04-01 | 2021-10-07 | Valiant Biosciences, Llc | Adeno-associated virus based compositions and related methods for inducing humoral immunity |
AU2021247163A1 (en) | 2020-04-01 | 2022-10-20 | University Of Florida Research Foundation, Incorporated | Multilamellar RNA nanoparticle vaccine against SARS-CoV-2 |
TW202202169A (en) | 2020-04-02 | 2022-01-16 | 中央研究院 | Biodegradable nanocomplex vaccines, methods for prevention of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection |
WO2021203044A2 (en) | 2020-04-03 | 2021-10-07 | Icahn School Of Medicine At Mount Sinai | High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2 |
CN111876419B (en) | 2020-04-03 | 2022-03-11 | 苏州吉玛基因股份有限公司 | Small interfering nucleic acid for inhibiting novel coronavirus, composition and application |
CN115715199A (en) | 2020-04-03 | 2023-02-24 | 帕普泰克疫苗有限公司 | Coronavirus vaccine |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
RU2747762C1 (en) | 2020-04-05 | 2021-05-13 | Илья Владимирович Духовлинов | Vaccine for the prevention or treatment of coronavirus infection based on a genetic construct |
EP4132949A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Sars-cov2 coronavirus reconstituted rbm and uses thereof |
CN112023035A (en) | 2020-04-07 | 2020-12-04 | 中国医学科学院医学生物学研究所 | Nano vaccine taking S protein RBD region of SARS-CoV-2 virus as antigen and preparation thereof |
CN113874507A (en) | 2020-04-09 | 2021-12-31 | 苏州艾博生物科技有限公司 | Nucleic acid vaccine for coronavirus |
WO2021211760A1 (en) | 2020-04-14 | 2021-10-21 | The Regents Of The University Of California | Large sequence pan-coronavirus vaccine compositions |
US20230310582A1 (en) | 2020-04-14 | 2023-10-05 | Duke University | Sars-2 spike protein designs, compositions and methods for their use |
US20210322541A1 (en) | 2020-04-17 | 2021-10-21 | Vlp Therapeutics, Inc. | Coronavirus vaccine |
WO2021209824A1 (en) | 2020-04-17 | 2021-10-21 | Institut Pasteur | Methods and products for serological analysis of sars-cov-2 infection |
WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
CA3176320A1 (en) | 2020-04-20 | 2021-10-28 | Richard STRATFORD | Sars-cov-2 vaccines |
WO2021212568A1 (en) | 2020-04-21 | 2021-10-28 | 苏州方科生物科技有限公司 | Novel coronavirus specific antigen peptide and use thereof |
WO2021216738A2 (en) | 2020-04-21 | 2021-10-28 | Intima Bioscience, Inc. | Compositions and methods of generating an immune response |
US20230143228A1 (en) | 2020-04-21 | 2023-05-11 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
AU2021259612A1 (en) | 2020-04-21 | 2022-11-10 | Intima Bioscience, Inc. | Cellular vaccine platform and methods of use |
EP4139616A1 (en) | 2020-04-22 | 2023-03-01 | Pfizer Inc. | Coronavirus vaccine |
GB202307565D0 (en) | 2020-04-22 | 2023-07-05 | BioNTech SE | Coronavirus vaccine |
WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
KR102482994B1 (en) | 2020-04-29 | 2022-12-29 | 에스케이바이오사이언스(주) | Vaccine composition for preventing or treating infection of SARS-CoV-2 |
IT202000009625A1 (en) | 2020-04-30 | 2021-10-30 | Takis S R L | SARS-COV-2 ANTIGEN CODING POLYNUCLEOTIDES AND RELATED USE IN THE MEDICAL FIELD AS VACCINES. |
WO2021223647A1 (en) | 2020-05-06 | 2021-11-11 | The University Of Hong Kong | Compositions and methods for making and using vaccines against covid-19 |
WO2021224946A1 (en) | 2020-05-07 | 2021-11-11 | Bharat Biotech International Limited | Coronavirus vaccine through nasal immunization |
CA3177940A1 (en) | 2020-05-07 | 2021-11-11 | Anusha DIAS | Optimized nucleotide sequences encoding sars-cov-2 antigens |
CN111518175B (en) | 2020-05-11 | 2021-02-26 | 广东珩达生物医药科技有限公司 | SARS-COV-2 antigen polypeptide and its recombinant adeno-associated virus and application in preparing vaccine |
EP4105228A4 (en) | 2020-05-11 | 2023-10-11 | Hengda Biomedical Technology Co., Ltd. | Sars-cov-2 antigen polypeptide, recombinant adeno-associated virus thereof, and application in preparation of vaccine |
WO2021231560A1 (en) | 2020-05-12 | 2021-11-18 | Greffex, Inc. | Engineering coronavirus spike proteins as vaccine antigens, their design and uses |
EP4149484A1 (en) | 2020-05-15 | 2023-03-22 | ModernaTX, Inc. | Rna formulations for high volume distribution |
WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
US20210355170A1 (en) | 2020-05-18 | 2021-11-18 | The Regents Of The University Of Colorado, A Body Corporate | Stabilizing Mutants of Prefusion Sars-Cov-2 (Covid-19) Spike Protein And Improved Yeast Surface Display Engineering Platform For The Same |
CN111363858B (en) | 2020-05-26 | 2020-09-29 | 南京黎明生物制品有限公司 | 2019-nCoV S gene detection nucleic acid composition, kit and production method |
KR20230053008A (en) | 2020-05-29 | 2023-04-20 | 큐어백 에스이 | Nucleic Acid-Based Combination Vaccines |
WO2021253172A1 (en) | 2020-06-15 | 2021-12-23 | 上海市公共卫生临床中心 | Method for inducing anti-novel coronavirus neutralizing antibody using receptor recognition domain |
US10906944B2 (en) | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
WO2022003119A1 (en) | 2020-07-01 | 2022-01-06 | CEBINA GmbH | Cross-reactive coronavirus vaccine |
GB2596820A (en) | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
US20230248818A1 (en) | 2020-07-08 | 2023-08-10 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified RNA for Inducing an Immune Response Against SARS-CoV-2 |
CN111978377B (en) | 2020-07-09 | 2022-05-31 | 苏州和锐生物科技有限公司 | COVID-19 antigen, preparation method and application |
WO2022011332A2 (en) | 2020-07-10 | 2022-01-13 | Engimata, Inc | Immunogenic composition forming a vaccine, and a method for its manufacture |
CN112043825B (en) | 2020-07-13 | 2023-12-05 | 中国医学科学院医学生物学研究所 | Subunit vaccine for preventing novel coronavirus infection based on novel coronavirus spike protein S1 region |
CN111848753B (en) | 2020-07-20 | 2022-03-15 | 中国科学院过程工程研究所 | Novel coronavirus epitope and application thereof |
RU2733834C1 (en) | 2020-07-28 | 2020-10-07 | Федеральное бюджетное учреждение науки Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Artificial ectos_sc2 gene encoding an ectodomain of the sars-cov-2 coronavirus s glycoprotein with a c-terminal trimerization domain, a recombinant plasmid pstem-rvsv-ectos_sc2, which provides expression of the artificial gene, and a recombinant strain of vesicular stomatitis virus rvsv-ectos_sc2, used to create a vaccine against sars-cov-2 coronavirus |
CN112028976A (en) | 2020-08-05 | 2020-12-04 | 上海裕隆生物科技有限公司 | 2019 novel coronavirus spike protein receptor binding domain protein and application |
CN111939250B (en) | 2020-08-17 | 2022-07-29 | 郑州大学 | Vaccine for preventing COVID-19 and preparation method thereof |
RU2731342C9 (en) | 2020-08-22 | 2021-10-05 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Pharmaceutical agent and method for use thereof for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments) |
RU2731356C9 (en) | 2020-08-22 | 2021-10-05 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Expression vector for creating immunobiological agent for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments) |
CN112048005B (en) | 2020-09-04 | 2022-09-09 | 江苏省中国科学院植物研究所 | Novel coronavirus S protein fragment polyploid, preparation method thereof, detection kit, vaccine and medicament |
CN112266411B (en) | 2020-09-25 | 2022-06-24 | 北京诺思兰德生物技术股份有限公司 | Novel coronavirus vaccine and application thereof |
CN112094327A (en) | 2020-09-25 | 2020-12-18 | 军事科学院军事医学研究院军事兽医研究所 | Truncation body based on novel coronavirus RBD-SD1 protein and application thereof |
CN112226445B (en) | 2020-10-20 | 2021-05-11 | 成都欧林生物科技股份有限公司 | Nucleic acid for coding spike protein of SARS-CoV-2 virus and its application |
CN112220920B (en) | 2020-10-30 | 2023-06-13 | 上海泽润生物科技有限公司 | Recombinant novel coronavirus vaccine composition |
CN112358533B (en) | 2020-10-30 | 2023-07-14 | 上海泽润生物科技有限公司 | Recombinant spike protein and preparation method and application thereof |
US20240041785A1 (en) | 2020-11-16 | 2024-02-08 | BioNTech SE | Compositions and methods for stabilization of lipid nanoparticle mrna vaccines |
CN112480217B (en) | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | Vaccines and compositions based on S antigen protein of SARS-CoV-2 |
CN112626089B (en) | 2020-12-08 | 2022-03-11 | 杭州百凌生物科技有限公司 | SARS-CoV-2 virus S protein receptor binding region coding gene, antibody and application |
CA3205569A1 (en) | 2020-12-22 | 2022-06-30 | CureVac SE | Rna vaccine against sars-cov-2 variants |
CN112794884B (en) | 2020-12-28 | 2022-02-18 | 中国科学院微生物研究所 | Novel coronavirus protein, preparation method and neutralizing antibody detection kit |
CN112321688B (en) | 2021-01-06 | 2021-03-26 | 广东华南疫苗股份有限公司 | Stable coronavirus recombinant protein dimer and expression vector thereof |
-
2021
- 2021-04-16 GB GBGB2307565.8A patent/GB202307565D0/en not_active Ceased
- 2021-04-16 EP EP21168938.5A patent/EP3901260A1/en active Pending
- 2021-04-16 CN CN202110413326.7A patent/CN113521268A/en active Pending
- 2021-04-16 JP JP2021069705A patent/JP2021191743A/en active Pending
- 2021-04-16 WO PCT/EP2021/059947 patent/WO2021213924A1/en unknown
- 2021-04-16 IL IL297419A patent/IL297419A/en unknown
- 2021-04-16 GB GB2105481.2A patent/GB2594365B/en active Active
- 2021-04-16 US US17/233,396 patent/US11547673B1/en active Active
- 2021-04-16 CN CN202110414349.XA patent/CN113521269A/en active Pending
- 2021-04-16 GB GB2105465.5A patent/GB2594364A/en active Pending
- 2021-04-16 JP JP2021069840A patent/JP2021185136A/en active Pending
- 2021-04-16 JP JP2022564006A patent/JP2023522249A/en active Pending
- 2021-04-16 AU AU2021261471A patent/AU2021261471A1/en active Pending
- 2021-04-16 KR KR1020227040676A patent/KR20230015350A/en active Search and Examination
- 2021-04-16 MX MX2022013254A patent/MX2022013254A/en unknown
- 2021-04-16 TW TW110113684A patent/TW202206096A/en unknown
- 2021-04-16 EP EP21168950.0A patent/EP3901261A1/en active Pending
- 2021-04-16 EP EP21720413.0A patent/EP4138897A1/en active Pending
- 2021-04-16 CN CN202180029692.0A patent/CN115811986A/en active Pending
- 2021-04-16 CA CA3174215A patent/CA3174215A1/en active Pending
- 2021-04-16 BR BR112022019781A patent/BR112022019781A2/en unknown
- 2021-04-22 CN CN202310385622.XA patent/CN116585464A/en active Pending
- 2021-04-22 CN CN202180041726.8A patent/CN115867654A/en active Pending
- 2021-04-22 IL IL297417A patent/IL297417A/en unknown
- 2021-04-22 WO PCT/EP2021/060508 patent/WO2021214204A1/en unknown
- 2021-04-22 EP EP21720748.9A patent/EP4139452A1/en active Pending
- 2021-04-22 JP JP2022563994A patent/JP2023522246A/en active Pending
- 2021-04-22 AU AU2021260099A patent/AU2021260099A1/en active Pending
- 2021-04-22 KR KR1020227040675A patent/KR20230004735A/en unknown
- 2021-04-22 MX MX2022013255A patent/MX2022013255A/en unknown
- 2021-04-22 CA CA3173922A patent/CA3173922A1/en active Pending
- 2021-04-22 BR BR112022019782A patent/BR112022019782A2/en unknown
- 2021-12-30 US US17/565,921 patent/US11951185B2/en active Active
- 2021-12-30 US US17/565,842 patent/US11779659B2/en active Active
-
2022
- 2022-03-18 US US17/698,829 patent/US11925694B2/en active Active
- 2022-03-18 US US17/699,035 patent/US20230073461A1/en not_active Abandoned
- 2022-11-16 US US17/988,742 patent/US20240075165A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008157688A2 (en) * | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
WO2013143683A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
WO2016005324A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
Non-Patent Citations (23)
Title |
---|
"Helvetica Chimica Acta", 1995, article "A multilingual glossary of biotechnological terms: (IUPAC Recommendations" |
"Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING CO. |
ANAND RAMANATHAN ET AL.: "mRNA capping: biological functions and applications", NUCLEIC ACIDS RESEARCH, vol. 44, no. 16, 17 June 2016 (2016-06-17), GB, pages 7511 - 7526, XP055388045, ISSN: 0305-1048, DOI: 10.1093/nar/gkw551 * |
BAIERSDORFER M. ET AL., MOL THER NUCLEIC ACIDS, vol. 15, no. 15, 2019, pages 26 - 35 |
BOULOY M. ET AL.: "Both the 7-methyl and the 2'-O-methyl groups in the CAP of mRNA strongly influence its ability to act as primer for influenza virus RNA transcription", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, NEW YORK, NY, US, vol. 77, no. 7, 1 July 1980 (1980-07-01), pages 3952 - 3956, XP000607007 * |
DECROLY E ET AL., NATURE REVIEWS, vol. 10, 2012, pages 51 - 65 |
GOULD ET AL., ANTIVIRAL RES., vol. 87, 2010, pages 111 - 124 |
HABJAN ET AL.: "figure S1", 1 June 1980 (1980-06-01), XP055826456, Retrieved from the Internet <URL:https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003663#s5> [retrieved on 20210721] * |
HABJAN MATTHIAS ET AL.: "Sequestration by IFIT1 impairs translation of 2'O-unmethylated capped RNA", PLOS PATHOGENS, vol. 9, no. 10, 3 October 2013 (2013-10-03), pages e1003663, XP055826325, Retrieved from the Internet <URL:https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.ppat.1003663/1/ppat.1003663.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa@plos-prod.iam.gserviceaccount.com/20210721/auto/storage/goog4_request&X-Goog-Date=20210721T091441Z&X-Goog-Expires=86400&X-Goog-SignedHeaders=h> DOI: 10.1371/journal.ppat.1003663 * |
HOFFMANN ET AL., CELL, 2020 |
HOLTKAMP ET AL., BLOOD, vol. 108, 2006, pages 4009 - 4017 |
HYDE J.L. ET AL.: "A viral RNA structural element alters host recognition of nonself RNA", SCIENCE, vol. 343, no. 6172, 30 January 2014 (2014-01-30), US, pages 783 - 787, XP055826832, ISSN: 0036-8075, DOI: 10.1126/science.1248465 * |
HYDE J.L. ET AL: "supplementary information", SCIENCE, vol. 343, no. 6172, 30 January 2014 (2014-01-30), US, pages 783 - 787, XP055826833, ISSN: 0036-8075, DOI: 10.1126/science.1248465 * |
JOSE ET AL., FUTURE MICROBIOL., vol. 4, 2009, pages 837 - 856 |
KACZMAREK, J. C. ET AL., GENOME MEDICINE, vol. 9, 2017, pages 60 |
KARIKO K ET AL., MOL. THER., vol. 20, 2012, pages 948 - 953 |
KOPPEL, D., J. CHEM. PHYS., vol. 57, 1972, pages 4814 - 4820 |
MAHIN AJ ET AL., METHODS MOL BIOL, vol. 1428, 2016, pages 297 - 306 |
MASEK T ET AL., ANAL BIOCHEM, vol. 336, 2005, pages 46 - 50 |
RAMANATHAN A. ET AL., NUCLEIC ACIDS RES, vol. 44, no. 16, 2016, pages 7511 - 7526 |
ZENG CHUNXI ET AL.: "Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo", BIORXIV, 5 April 2020 (2020-04-05), XP055826383, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.01.019877v1.full.pdf> [retrieved on 20210721], DOI: 10.1101/2020.04.01.019877 * |
ZENG CHUNXI ET AL.: "Supplementary Information", 5 April 2020 (2020-04-05), XP055826382, Retrieved from the Internet <URL:file:///C:/Users/GM03048/Downloads/media-1.pdf> [retrieved on 20210721] * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11578095B2 (en) | 2015-09-21 | 2023-02-14 | Trilink Biotechnologies, Llc | Compositions and methods for synthesizing 5'-Capped RNAs |
US11878991B2 (en) | 2015-09-21 | 2024-01-23 | Trilink Biotechnologies, Llc | Compositions and methods for synthesizing 5′-Capped RNAs |
US11414453B2 (en) | 2015-09-21 | 2022-08-16 | Trilink Biotechnologies, Llc | Compositions and methods for synthesizing 5′-capped RNAs |
US11865190B2 (en) | 2018-10-09 | 2024-01-09 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
US11596686B2 (en) | 2020-02-04 | 2023-03-07 | CureVac SE | Coronavirus vaccine |
US11471525B2 (en) | 2020-02-04 | 2022-10-18 | Curevac Ag | Coronavirus vaccine |
US11964011B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11964012B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
US11779659B2 (en) | 2020-04-22 | 2023-10-10 | BioNTech SE | RNA constructs and uses thereof |
US11951185B2 (en) | 2020-04-22 | 2024-04-09 | BioNTech SE | RNA constructs and uses thereof |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11925694B2 (en) | 2020-04-22 | 2024-03-12 | BioNTech SE | Coronavirus vaccine |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
US11872280B2 (en) | 2020-12-22 | 2024-01-16 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
WO2022162027A3 (en) * | 2021-01-27 | 2022-11-03 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022235847A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Technologies for early detection of variants of interest |
RU2814020C2 (en) * | 2022-02-15 | 2024-02-21 | Федеральное государственное бюджетное учреждение "Центр стратегического планирования и управления медико-биологическими рисками здоровью" Федерального медико-биологического агентства | Set of conservative epitopes of viral proteins, method of their identification and selection, vaccine composition and method of vaccination |
WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
WO2023228116A1 (en) * | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11951185B2 (en) | RNA constructs and uses thereof | |
WO2019232103A1 (en) | Messenger rna vaccines and uses thereof | |
CN112867509A (en) | RNA particles comprising polymyosine | |
CN115335084A (en) | RNA particles comprising polymyosine | |
US20230414747A1 (en) | Lnp compositions comprising rna and methods for preparing, storing and using the same | |
WO2023073190A1 (en) | Rna constructs and uses thereof | |
WO2022218503A1 (en) | Lnp compositions comprising rna and methods for preparing, storing and using the same | |
US20230099898A1 (en) | Composite rna particles | |
AU2022336160B2 (en) | Potency assay for therapeutic potential of coding nucleic acid | |
WO2024075022A2 (en) | Rna constructs and uses thereof | |
WO2023148277A1 (en) | Agents and methods for targeted delivery of nucleic acids to cells | |
AU2022256732A1 (en) | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same | |
WO2024028445A1 (en) | Rna for preventing or treating tuberculosis | |
WO2024027910A1 (en) | Rna for preventing or treating tuberculosis | |
WO2023036960A1 (en) | Lipid-based rna formulations suitable for therapy | |
WO2023051926A1 (en) | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists | |
WO2023126404A1 (en) | Lipid-based formulations for administration of rna | |
JP2024517642A (en) | Viral vaccines | |
CN116829134A (en) | LNP compositions comprising RNA and methods of making, storing, and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21720748 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3173922 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022019782 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022563994 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227040675 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021260099 Country of ref document: AU Date of ref document: 20210422 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021720748 Country of ref document: EP Effective date: 20221122 |
|
ENP | Entry into the national phase |
Ref document number: 112022019782 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220930 |